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ABSTRACT  
 
We contribute in saving the lives of cancer patients through early detection and diagnosis,  
since one of the major challenges in cancer treatment is that patients are diagnosed at very late 
stages when appropriate medical interventions become less effective and full curative treatment 
is no longer achievable. Cancer classification using gene expressions is extremely challenging 
given the complexity and high dimensionality of the data. Current classification methods 
typically rely on samples collected from a single tissue type and perform a prerequisite of gene 
feature selection to avoid processing the full set of genes. These methods fall short in taking 
advantage of genome-wide next generation sequencing technologies which provide a snapshot 
of the whole transcriptome rather than a predetermined subset of genes. We propose a Deep 
Learning framework for cancer diagnosis by developing a multi-tissue cancer classifier based 
on whole-transcriptome gene expressions collected from multiple tumor types covering 
multiple organ sites. We introduce a new Convolutional Neural Network architecture called 
Gene eXpression Network (GeneXNet), which is specifically designed to address the complex 
nature of gene expressions. Our proposed GeneXNet provides capabilities of detecting genetic 
alterations driving cancer progression by learning genomic signatures across multiple tissue 
types without requiring the prerequisite of gene feature selection. We design an end-to-end 
Deep Reinforcement Learning framework that automatically learns the optimal network 
architecture together with the associated optimal hyperparameters that maximizes the 
performance of our multi-tissue cancer classifier. Our framework eliminates the manual 
process of handcrafting the design of deep network architectures and the manual process of 
hyperparameter optimization on the target dataset. Our model achieves 98.9% classification 
accuracy on human samples representing 33 different cancer tumor types across 26 organ sites. 
We demonstrate how our model can be used for transfer learning to build classifiers for tumors 
lacking sufficient samples to be trained independently. We contribute in providing medical 
professionals with more confidence in using Deep Learning for medical diagnosis by 
introducing visualization procedures to provide biological insight on how our network is 
performing classification across multiple tumors. To our knowledge, this is the first effort to 
develop a multi-tissue cancer classifier based on a full set of whole-transcriptome gene 
expressions collected from tumors across different tissue types without requiring a prerequisite 
process of gene feature selection.   
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CHAPTER 1   
 INTRODUCTION 
 
“This research is about saving lives of Cancer Patients”  
 
 The Global Burden of Cancer 
 The World Health Organization reports that cancer is an incurable 
disease which is considered one of the leading causes of death 
worldwide accounting for an estimated 9.6 million deaths in 2018 [1]. 
The cumulative risk of incidence indicates that 1 in 8 men and 1 in 10 
women will develop the disease in a lifetime [2]. Lung cancer is the 
most commonly diagnosed cancer and the leading cause of cancer 
death, followed by breast, prostate, colorectal, stomach, and liver 
cancer [2]. 
Cancer is a generic term for a large group of diseases that can affect any part of the body. 
Other terms used are malignant tumors and neoplasms. One defining feature of cancer is the 
rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then 
invade adjoining parts of the body and spread to other organs, the latter process is referred to 
as metastasizing. Metastases are a major cause of death from cancer [3]. 
 
 
 
 
9.6 million Cancer deaths in 2018 worldwide  
Squamous cell carcinoma Lung caner [1] 
Figure 1.1  Estimated world cancer mortality in 2018 [1], [2] 
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 Challenges in Early Diagnosis and Treatment of Cancer  
Despite the dramatic impact of Cancer and high mortality rates, many of these deaths can 
be avoided. It is reported by the World Health Organization that between 30-50% of cancer 
death cases can be prevented through early detection and treatment [3]. A major challenge is 
that the disease is not diagnosed early enough to allow for appropriate and effective treatment. 
When Cancer patients are diagnosed at very late stages, appropriate treatment interventions 
become less effective and full curative treatment is no longer achievable [1]. 
The increasing complexity of the disease and its molecular biology has made it extremely 
difficult for medical experts to use traditional patient diagnosis and laboratory screening 
techniques to detect early signs and symptoms of cancer.  In absence of any early detection or 
screening and treatment intervention, patients are diagnosed at very late stages when curative 
treatment is no longer an option [4]. 
One of the major challenges of Cancer treatment, especially when using Chemotherapy, is 
to maximize the drug efficiency but at the same time minimize the toxic effects on healthy 
cells. As a result, accurate classification and diagnosis of the Cancer tumor is crucial to 
successful treatment. Conventional laboratory screening techniques for Cancer classification 
usually rely on the biological insights of the medical experts and have primarily focused on the 
morphological appearance of the tumor. This has serious limitations, since tumors with similar 
histopathological appearance can follow significantly different clinical courses and show 
different responses to therapy [1].  
Accordingly, advancements in cancer classification and prediction play an important role in 
early detection since a major challenge in cancer treatment is that patients are diagnosed at very 
late stages where appropriate interventions become less effective and full curative treatment is 
no longer achievable [4]. Cancer classification can be divided into two categories which are 
class discovery and class prediction. The task of class discovery is to identify a new tumor 
which was previously unrecognized. Class prediction is the task of diagnosing a tumor sample 
and assigning it to the correct predefined class [4]. 
 
 Cancer Genomics 
Technological advances in structural genomics have allowed studying the full set of DNAs 
in the human genome [4], [25]. DNA is a molecule in the cell nucleus that contains instructions 
for making proteins. A segment of DNA that contains information for making a protein is called 
a gene [4]. During the transcription process, DNA that makes up a gene is copied into a 
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complementary molecule called messenger RNA (mRNA). The mRNA moves from the 
nucleus to the cytoplasm where it interacts with ribosomes which are the protein factories of 
the cell [4]. DNA alterations can affect the structure, function and amount of corresponding 
proteins leading to a change in a cell’s behavior from normal to cancerous [24]. Next generation 
sequencing (NGS) methods such as whole-genome DNA sequencing and Total RNA 
sequencing are considered revolutionary technologies for studying genetic changes in Cancer 
[22], [27]. These technologies provide great potential for cancer classification and better 
understanding of tumor progression given their ability to sequence thousands of genes at one 
time and detect multiple types of genomic and transcriptome gene expression alterations [20], 
[21], [25]. They provide capabilities for comparing the sequence of DNA and RNA in cancer 
cells with that in normal cells, such as blood or saliva to identify genetic changes that may be 
driving the growth of a tumor in addition to measuring the activity of genes to understand which 
proteins are abnormally active in cancer cells leading to uncontrolled growth [26]. Gene 
expression analysis using total RNA sequencing provides a snapshot of the whole 
transcriptome rather than a predetermined subset of genes, enables testing multiple genes 
simultaneously and can detect both coding plus multiple forms of noncoding RNA [22]. These 
methods have eliminated many limitations involved in microarray based experiments that were 
previously used for measuring gene expressions [22], [25], [27].  
 
 
 Early Cancer Diagnosis using Gene Expressions 
Gene expressions have been extensively used in biological research and cancer 
classification [5], [6], [7], [8], [9], [10], [13], [11], [17]. Individual proteins determine the cell 
function and at the same time the protein synthesis is dependent on which genes are expressed 
by the cell. Accordingly, the expression pattern of a gene provides indirect information about 
a cell function [1]. Gene expression refers to the process of translating information in DNA 
into functional products including proteins and non-coding RNA [4]. While Microarrays have 
traditionally been used for gene expression analysis, they have shown many limitations since 
the snapshot of the transcriptome they provide is incomplete and they cannot detect previously 
unidentified genes or transcripts [21], [22], [25]. 
Gene expression quantification can be used to identify which genes are preferentially 
expressed in various tissues. Transcription produces what is referred to as precursor messenger 
RNA (pre-mRNA) which undergoes further modifications leading to mature mRNA [4].  
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By collecting mRNA samples for tumors of known classes, supervised learning can be used 
to build discriminative models which can learn the gene patterns of the underlying disease and 
then be used to predict the tumor class of new patient samples which were not previously 
diagnosed [1]. This is considered a great achievement as there are many Microarray 
experiments which demonstrate how it was possible to classify and distinguish between certain 
cancer types using data classification even though they are clinically indistinguishable [1], [72], 
[73].  
For example, Figure 1.2 shows the classification between two types of Leukemia Cancer 
(AML and ALL) which are clinically indistinguishable [73]. The figure shows how Clustering 
of microarray gene expression data was used to distinguish between Acute Myeloid Leukemia 
(AML) and Acute Lymphoblastic leukemia (ALL) using only data classification. Rows 
correspond to genes and columns correspond to human samples [73].  
Another example of a microarray experiment is shown in Figure 1.3 which was used to 
analyse a total of 78 Breast Cancer patients to develop what is known as the PAM50 Breast 
Cancer Intrinsic Classifier which predicts the breast cancer type out of several classes [74]. 
This classifier predicts the Breast Cancer type out of several classes which are: Luminal A, 
Luminal B, Basal-like, Human Epidermal Growth Factor receptor 2 (HER2)+ [74]. 
Figure 1.2  Classification of AML and ALL Leukemia  using Gene Expression Data [73] 
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 Complexity in Cancer Classification using Gene Expression Data 
Despite all these potential capabilities, cancer classification using gene expressions 
produced from Total RNA sequencing is extremely challenging given the complexity and 
massive amount of genetic data that is produced [20], [21], [25], [26], [38]. The magnitude of 
variants obtained from RNA-Sequencing is exponential which makes it difficult for traditional 
bioinformatics and machine learning approaches to evaluate genetic variants for disease 
prediction [4], [22], [23]. Gene expression data is characterized by being very high in 
dimensionality in terms of having a very large number of features representing the genes, and 
a very small number of training data representing the patient samples [9], [22], [33]. 
Complexity is also due to the fact that only a small subset of genes might be influencing the 
cancer tumor being diagnosed [4], [29].  
Current cancer classification methods avoid processing the full set of genes to overcome 
these complexities and are mainly based on performing a process of gene feature selection as 
a prerequisite to the classifier learning process [28], [29], [30], [31].  
Figure 1.3  PAM50 Classifier for Classification of Breast Cancer using Gene Expression Data [74] 
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Gene feature selection is the process of selecting a small subset of informative genes which 
are discriminative among the full set of genes collected from the tumor samples [32], [33]. 
Gene feature selection will allow the learning process to proceed, but the resulting classifier 
will not have the opportunity to learn the molecular signatures of genes which have been 
excluded and their influence on the underlying cancer tumor [34], [35].  
Current methods for cancer classification follow the approach of feature engineering and 
are based on applying innovative gene feature selection techniques as a prerequisite to the 
classifier learning process to discover a small subset of informative genes which are 
discriminative among the tumor being analysed [28], [29], [31]. Gene selection methods can 
be generally classified into filtering, wrapping and embedded methods [32], [33]. The accuracy 
of such a classifier depends heavily on the successful identification of these discriminative 
features [34], [35]. Furthermore, the same classification method might not succeed in achieving 
the same accuracy if applied on a tumor for a different tissue type which will most likely have 
a different subset of informative genes [1]. 
Substantial work has been done for cancer classification by performing gene feature 
selection and building on traditional machine learning methods such as Support Vector 
Machines [15], [18], [30], Random Forests [14], Decision Trees [16], AdaBoost [11], K-
Nearest Neighbor [14] and Genetic algorithms [9], [11]. Current classification methods which 
are based on gene feature selection are not optimal for early cancer diagnosis. This is because 
these methods will fall short in taking the full advantage of DNA and RNA sequencing 
technologies to discover the correlated patterns between genes across the full set of DNAs in 
the human genome and to detect multiple types of genetic alterations that may be driving the 
growth of a tumor across the whole transcriptome rather than a predetermined subset of genes 
[5], [6]. Another limitation of current methods is that they typically rely on gene expressions 
collected mainly from a single cancer tissue type based on the same anatomical site of origin.  
This approach does not utilize the full potential of the recent emerging whole-genome 
sequencing technologies and data produced by large-scale genomic projects which are 
producing detailed molecular characterizations of thousands of tumors using genome-wide 
platforms [38]. Recent studies which have performed an integrated multiplatform analysis 
across multiple cancer types have revealed molecular classification within and across tissues 
of origin [5], [7]. The results of these studies have recommended that the traditional approach 
of anatomic cancer classification should be supplemented by classification based on molecular 
alterations shared by tumors across different tissue types [5]. 
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 Deep Learning for Early Cancer Diagnosis 
This has motivated our research for early diagnosis of cancer by leveraging the latest deep 
learning methods to develop a comprehensive multi-tissue cancer classifier. Our proposed 
classifier is based on molecular signatures of whole-transcriptome wide gene expressions, that 
are collected from human samples representing multiple cancer tissue types covering multiple 
organ sites of origin. Our approach using deep learning eliminates the need for discovering a 
predefined subset of genes by combining the process of gene feature selection and classification 
into one end-to-end learning system.  We propose a new Convolutional Neural Network 
architecture called “Gene eXpression Network” (GeneXNet) which is specifically designed to 
learn the complex nature of whole-transcriptome gene expressions and which gives the 
opportunity to design cancer classifiers with capabilities of detecting more complex types of 
genetic alterations by learning the genomic signatures shared across multiple cancer tissue 
types. To our knowledge, this is the first effort to develop a multi-tissue cancer classifier based 
on a full set of whole-transcriptome wide gene expressions collected from tumors across 
different tissue types without requiring a prerequisite process of gene feature selection. We 
demonstrate how our model can perform transfer learning to build classifiers for other types of 
cancer tumors which are lacking sufficient patient samples to be trained independently. We 
design an end-to-end Deep Reinforcement Learning framework to automatically learn the 
optimal Deep Neural Network architecture together with the associated optimal 
hyperparameters that maximizes the performance of our multi-tissue cancer classifier. We 
introduce visualization procedures to provide more biological insight on how our model is 
performing cancer classification across multiple tumor types. We visualize gene localization 
maps highlighting the important regions in the gene expressions influencing the tumor class 
prediction. We also visualize the molecular clusters formed by intermediate gene expression 
feature maps learned by the network which helps in revealing the genomic relationships of 
gene expressions that are influential in the tumor progression. 
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CHAPTER 2   
 LITERATURE SURVEY 
 
 Cancer Genomics 
DNA is a molecule in the cell nucleus that contains instructions for making proteins. A segment 
of DNA that contains information for making a protein is called a gene [4]. During the 
transcription process, DNA that makes up a gene is copied into a complementary molecule 
called messenger RNA (mRNA). The mRNA moves from the nucleus to the cytoplasm where 
it interacts with ribosomes which are the protein factories of the cell [4]. DNA alterations can 
affect the structure, function and amount of corresponding proteins leading to a change in a 
cell’s behaviour from normal to cancerous [24].  
 
 
Figure 2.1  Genetic Changes and Cancer [4] 
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 Next Generation Sequencing (NGS) 
Technological advances in structural genomics have allowed studying the full set of DNAs in 
the human genome [4], [25]. Next generation sequencing (NGS) methods such as whole-
genome DNA sequencing and Total RNA sequencing are considered revolutionary 
technologies for studying genetic changes in Cancer [22], [27]. These technologies provide 
great potential for cancer classification and better understanding of tumor progression given 
their ability to sequence thousands of genes at one time and detect multiple types of genomic 
and transcriptome gene expression alterations [20], [21], [25]. They provide capabilities for 
comparing the sequence of DNA and RNA in cancer cells with that in normal cells, such as 
blood or saliva to identify genetic changes that may be driving the growth of a tumor in addition 
to measuring the activity of genes to understand which proteins are abnormally active in cancer 
cells leading to uncontrolled growth [26]. Gene expression analysis using total RNA 
sequencing provides a snapshot of the whole transcriptome rather than a predetermined subset 
of genes, enables testing multiple genes simultaneously and can detect both coding plus 
multiple forms of noncoding RNA [22]. These methods have eliminated many limitations 
involved in microarray based experiments that were previously used for measuring gene 
expressions [22], [25], [27].  
 
 
 Gene Expression Analysis 
The advances in Next generation sequencing (NGS) and DNA microarray technologies have 
provided the capabilities to measure the expression levels of thousands of genes during various 
biological processes, collected from different experimental samples and conditions [22], [27].  
Gene expression refers to the process of translating information in DNA into functional 
products including proteins and non-coding RNA. Only a fraction of genes in a cell are 
expressed at a given time where a distinct set of regulators determine the expression profiles 
of each cell. Transcription produces what is referred to as precursor messenger RNA (pre-
mRNA) which undergoes further modifications leading to mature mRNA. The formation of a 
malignant tumor is typically a transformation characterized by distribution of genetic 
information and irregular expression of multiple genes [1]. 
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Figure 2.2  Schematic overview of protein-coding gene expression pathways [1] 
 
During a Next Generation Sequencing experiment, DNA sequences under multiple 
conditions are captured for analysis where the collective data samples are commonly referred 
to as gene expression data [21]. The variations in conditions of the data samples could represent 
different time intervals in a specific biological process or they could represent different samples 
from different organs or tissues [25]. For example, the gene expressions could represent the 
DNA sequence progression of infected cancer cells at different stages, or they could represent 
samples from different tissues of healthy and infected patients [27]. 
Medical procedures for early cancer diagnosis and screening still depend heavily on clinical 
and histological analysis, which is the study of the microscopic anatomy of cells and tissues. 
But despite this common practice, there are many well-known research experiments which 
have proven that clinical and histological analysis are insufficient to distinguish between 
subclasses in several types of cancer [1], [4].  
Analysis of Cancer gene expression data can have many objectives, but among the most 
common are class prediction and class discovery [1]. Class prediction is based on collecting 
mRNA samples for Cancer tumors of known classes, then using supervised learning and 
classification techniques to build discriminative models which can be used to learn the 
molecular signatures of the underlying tumor. These models can then be used to predict the 
tumor class of new patient samples which were previously unrecognized. Class discovery on 
the other hand is based on unsupervised learning to identify the molecular signature of a new 
subclass of a cancer tumor which was previously unknown [1], [4]. 
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 Cancer Classification using Gene Expressions 
Gene expressions have been extensively used in biological research and cancer classification 
[5], [6], [7], [8], [9], [10], [13], [11], [17]. By collecting mRNA samples for tumors of known 
classes, supervised learning can be used to build discriminative models which can learn the 
gene patterns of the underlying disease and then be used to predict the tumor class of new 
patient samples which were not previously diagnosed [1]. This is considered a great 
achievement as there are many Microarray experiments which demonstrate how it was possible 
to classify and distinguish between certain cancer types using data classification even though 
they are clinically indistinguishable [1], [72], [73]. For example the classification between two 
types of Leukemia Cancer (AML and ALL) which are clinically indistinguishable [70]. 
Another example is the microarray experiment used to analyze a total of 78 Breast Cancer 
patients to develop what is known as the PAM50 Breast Cancer Intrinsic Classifier which 
predicts the breast cancer type out of several classes [71]. 
 
 Gene Feature Selection 
Current methods for cancer classification follow the approach of feature engineering and are 
based on applying innovative gene feature selection techniques as a prerequisite to the classifier 
learning process to discover a small subset of informative genes which are discriminative 
among the tumor being analysed [28], [29], [31]. Gene selection methods can be generally 
classified into filtering, wrapping and embedded methods [32], [33]. The accuracy of such a 
classifier depends heavily on the successful identification of these discriminative features [34], 
[35]. Furthermore, the same classification method might not succeed in achieving the same 
accuracy if applied on a tumor for a different tissue type which will most likely have a different 
subset of informative genes [1]. 
It is very common that the gene expression data produced from Next Generation Sequencing 
or microarray experiments will contain many data anomalies such as noise and missing values 
which are expected in any biological experimental procedure. Accordingly, preprocessing the 
gene expression data is a crucial step before attempting any analysis for disease diagnosis to 
ensure the quality and accuracy of the results. One of the biggest challenges in analyses of gene 
expression data is that only a small subset of the genes could be influencing the tumor being 
monitored and also it is possible that interesting features of the disease are only present in a 
subset of the data. Accordingly gene feature selection is an important preprocessing step. Other 
preprocessing tasks include data normalization and estimating missing values [32]. 
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Gene expression data can be represented in a 2D matrix representation as shown in Figure 
2.3. The matrix stores real values where each row represents the expression patterns of genes 
and each column represents the expression profiles of tumor samples such that the value in cell 
𝑋𝑖𝑗 represents the expression level measured for gene (i) in the patient sample(j).  
 
 Gene Filtering  
Gene filtering is the process of selecting a small subset of genes which are discriminative 
among the full range of genes underlying the tumor being analyzed [32]. These genes are called 
informative genes, biomarkers or differentially expressed genes. Filter methods rely on pre-
processing techniques which analyze potential overall gain of the selected features while 
ignoring performance of the learning algorithm [34]. Examples Principle component analysis 
(PCA) and Singular Value Decomposition SVD [30]. In general, there are two common 
filtering techniques which are widely used which are ranking methods and space search 
methods. In a ranking method, a scoring function is used to choose the top ranking genes. While 
in a space search method, the genes are selected by optimizing a certain cost function to provide 
a tradeoff between maximizing the information gain and minimizing the redundancy among 
the selected genes [32], [33]. 
 
 Gene Wrapping 
A drawback in filtering the gene expression data before building the classifier is that it produces 
a dataset where the genes might have a high level of correlation within the same class. This 
correlation might be resulting from shared upstream signaling of molecules which might result 
in misclassification. [34]. The process of Wrapping as opposed to filtering, attempts to solve 
this problem by embedding the feature selection step directly into the classifier. Gene wrapping 
relies on selecting a subset of features according to the performance gain they provide to the 
learning algorithm [32], [33]. 
Figure 2.3  Gene Expression 2D Matrix Representation (G x N) 
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 Gene Filtering using Ranking 
In a ranking method, a scoring function is used to choose the top ranking genes. The following 
is a summary of the steps used to filter the genes using ranking [37]: 
 
1) Define a scoring function to measure the expression level differences between the 
various gene samples and rank the features based on the obtained scores. 
2) Estimate the statistical significance of the obtained scores. 
3) Select the top ranking genes which are statistically significant. 
4) Validate the subset of selected genes. 
 
Score Functions 
 
There are a wide variety of ranking score functions available in the literature which is 
summarized in the tables below [33]. The first table describes the notations used for the 
definitions. The ranking score functions can be divided into the following groups : 
 
▪ Rank Score Functions 
▪ T-Test Functions 
▪ Bayesian Functions 
▪ Information Theory Functions 
▪ Functions based on Probability Density Function (PDF-Based) 
▪ Correlation Gene Class Label Functions 
 
Estimating Statistical Significance 
Calculating a score function is not enough for gene selection, but the statistical significance 
has to be estimated as a form of probability measure that a good score ranking has not been 
obtained by chance [33]. Statistical significance tests typically consist of running permutations 
of multiple tests which are identical with the distinction that the features or the class label can 
be chosen differently on each test [37]. 
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The following is a summary of the most widely used score functions for Gene Filtering 
Ranking methods and their corresponding notations [32], [33], [37]. 
 
 
 
 
  
Score Function for Gene Filtering Ranking Methods [FS1] 
Figure 2.4 Score Functions for Gene Filtering Ranking Methods [32], [33], [37] 
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 Cancer Classification Methods using Gene Expressions 
Cancer classification is based on collecting samples for tumors of known classes and using 
supervised learning to build discriminative models which can learn the gene patterns of the 
underlying disease and then be used to predict the tumor class of new patient samples which 
were not previously diagnosed [1]. Current methods for cancer classification follow the 
approach of feature engineering and are based on applying innovative gene feature selection 
techniques as a prerequisite to the classifier learning process to discover a small subset of 
informative genes which are discriminative among the tumor being analysed [28], [29], [31]. 
The accuracy of such a classifier depends heavily on the successful identification of these 
discriminative features [34], [35].  
Substantial work has been done for cancer classification by performing gene feature 
selection and building on traditional machine learning methods such as Support Vector 
Machines [15], [18], [30], Random Forests [14], Decision Trees [16], AdaBoost [11], K-
Nearest Neighbor [15] and Genetic algorithms [9], [11]. Many other techniques which combine 
gene feature selection and classification have also been proposed, for example: a hybrid method 
which integrates genetic programming and particle swarm optimization was used to build a 
scale-free complex network classifier using an ensemble of different gene feature sets [8]. A 
self-training subspace clustering algorithm was proposed by first applying a low-rank 
representation to extract discriminative features from gene expressions [13]. A deep neural 
forest model was used with a combination of fisher ratio and neighborhood rough set for 
dimensionality reduction of gene expressions [12]. An ensemble classifier was developed using 
a combination of k-means clustering, t-test, self-organizing maps and hierarchical clustering 
[10]. A classifier was developed using a multilayer recursive feature elimination method based 
on an embedded integer-coded genetic algorithm [9]. A gene expression graph structure was 
proposed for using the weight of graph edges to filter and determine significance of genes 
before classification [17]. A one-class logistic regression machine learning algorithm was used 
to identify stemness features extracted from transcriptomic and epigenetic data from cancer 
tumors to reveal clinical insight and potential drug targets for anti-cancer therapies [6]. 
The following sections present a survey of the state-of-the-art cancer classification methods 
using gene expression data. 
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 Support Vector Machines (SVM) 
Many studies have been proposed for Cancer classification using Support Vector Machines 
(SVM) and gene feature selection as a prerequisite to the learning process [15], [18], [30]. 
One of the proposed examples is based on robust principle component analysis (RPCA) and 
SVM to classify tumor samples of gene expressions [18]. First RPCA is used to extract the 
characteristic genes from gene expression data. In the second stage, Linear Discriminant 
Analysis (LDA) is then used to refine the subset of characteristic genes. Finally, SVM is then 
applied to classify the tumor samples of gene expressions based on the identified features [18]. 
 
 K-Nearest Neighbors  
A comparative study was performed for applying different feature selection methods on the 
classification performance of cancer using DNA microarrays of leukemia, prostate and colon 
cancer data [15]. Feature selection of gene expressions was applied using the methods of 
Fisher, T-Statistics, SNR and ReliefF. Classification was then performed using K-Nearest 
Neighbors and Support vector machines. The study showed that the combination between SNR 
feature selection and SVM produced the highest accuracy for cancer classification [15]. 
Figure 2.5  RPCA and LDA to extract characteristic genes from gene expressions before applying SVM. The 
gene expression matrices D, A, and S represent the observation matrix, low-rank matrix and sparse perturbation 
signals to decompose the gene expression data [18] 
D
eGene Expressions 
Observation Matrix 
A
eGene Expressions 
Low Rank Matrix 
S
eGene Expressions       
Sparse Perturbation Matrix 
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 Fuzzy Decision Trees (DT) 
A Fuzzy decision tree algorithm was proposed for the classification of gene expressions since 
they have shown to outperform classical decision tree algorithms [16]. Classical decision trees 
have shown some disadvantages in that their performance tends to deteriorate with the increase 
of features and emergence of complex interactions as in gene expression data. Since most 
decision trees depend on dividing the search space into mutually exclusive regions, the 
resulting tree must include several copies of the same subtree to accurately represent complex 
data like gene expressions. This greedy approach is prone to overfitting on the training set in 
addition to irrelevant features and noise. On the other hand, Fuzzy decision trees do not require 
assigning a data instance with a single branch and can simultaneously assign more branches to 
the same instance with a gradual certainty. Using this approach, Fuzzy decision trees retain the 
symbolic tree structure and are able to represent concepts by producing continuous 
classification outputs with gradual transitions between classes [16]. 
 
 AdaBoost 
A hybrid ensemble algorithm combining AdaBoost and genetic algorithm (GA) was 
proposed for cancer classification with gene expression data [11]. A decision group is proposed 
to improve the diversity of base classifiers in the ensemble system and GA is used to optimize 
the weight of Adaboost's base classifier. In a traditional Adaboost algorithm, a single classifier 
is used as the base classifier and cannot be changed after selection. The introduction of a 
decision group as the base classifier of the Adaboost algorithm was used to improve the 
diversity of the base classifiers [11]. 
 
Figure 2.6  Fuzzy Decision Tree Classifier for Ovarian Cancer Gene Expressions [16] 
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 Particle Swarm Optimization 
A hybrid method which integrates genetic programming and particle swarm optimization was 
used to build a scale-free complex network classifier using an ensemble of different gene 
feature sets [8]. A Complex Network (CN) classifier was used to implement the classification 
task. A Complex Network is different from a Neural Network in terms of topological structure. 
A CN has an uneven distribution of nodes, while a NN has an even distribution. CN models 
are used to simulate structural properties of many real-world networks like social networks and 
bibliographical index networks. An algorithm was used to initialize the structure, which 
allowed input variables to be selected over layered connections and different activation 
functions for different nodes. Then a hybrid method integrated Genetic Programming and 
Particle Swarm Optimization was used to identify an optimal structure with the parameters 
encoded in the classifier. The ensemble classifiers were constructed using different feature sets 
including Pearson’s correlation, Spearman’s correlation, euclidean distance, Cosine 
coefficient, and the Fisher-ratio [8]. 
 
 
 Random Forests (RF) 
A method was proposed using Random Forest for cancer classification of miRNA gene 
expression data [14]. The method was used to overcome challenges in existing techniques 
caused by the extremely low miRNA count in body fluids and also problems related to cross 
contamination between cells and exosomes in sample preparation steps. The proposed system 
was able to successfully identify miRNA markers responsible for classification of cancer [14]. 
Figure 2.7  Topology of a Cancer Classifier implementing a scale-free Complex Network [8] 
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 Deep Neural Forest Models (DFN) 
A Deep Neural Forest (DFN) model was proposed for cancer classification with a combination 
of fisher ratio and neighborhood rough set for dimensionality reduction of gene expressions 
[12]. The motivation in using a DFN is to transform a multi-class classification problem into 
many binary classification problems in each forest. The cascade structure of the DFN is used 
to deepen the traditional Flexible Neural Tree (FNT) model so that the depth of the model is 
increased without introducing additional parameters. FNT is a special neural network with the 
advantage of automatic optimization of structure and parameters. Gene feature selection was 
first performed using a fisher ratio in combination with neighborhood rough set to select the 
most informative genes among the gene expression data. The fisher ratio was used to eliminate 
invalid genes and then neighborhood rough set is applied to reduce redundant genes. The fisher 
ratio method can effectively deal with noise in the gene expression data as it filters the noisy 
genes according to its contribution to classification. The neighborhood rough set has the 
characteristics of not requiring discretization of continuous data and avoids information loss 
caused by data discretization, which can eliminate redundant genes [12].  
 
 
Figure 2.8  Deep Neural Forest Structure used for Cancer Classification [12]  
Flexible Neural Tree (FNT) 
Representation 
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 Self-training Subspace Clustering 
A self-training subspace clustering algorithm under low-rank representation (SSC-LRR) was 
proposed for cancer classification of gene expressions [13]. First, a Low-rank representation 
(LRR) is applied to extract discriminative features from the high-dimensional gene expression 
data. The self-training subspace clustering (SSC) method is then used to generate the cancer 
classification predictions. The advantage of combining these two methods is that the  Low-
rank representation is able to perform subspace segmentation which can reduce the dimension 
of the gene expression data, and then the enhanced semi-supervised self-training subspace 
clustering algorithm can effectively utilize both the labeled and unlabeled data. To analyse the 
results, the study performed a decomposition of the gene expression data matrix into a low-
rank representation matrix and a sparse matrix and then visualized the results. It was shown 
that cancer samples belonging to the same class often have the same subspace structure. This 
means that the low-rank representation can unveil the intrinsic structure of data much better 
than the original data matrix and therefore the low-rank representation can provide more useful 
discriminative information leading to a better classification performance. From a biological 
point of view, different types of cancers are often associated with some specific genes and 
therefore the corresponding gene expression data may fall into specific feature subspaces, 
which can be unveiled by using LRR [13]. The proposed SSC-LRR method was tested on two 
separate cancer benchmark datasets in control with four state-of-the-art classification methods. 
The method showed that several genes (RNF114, HLA-DRB5, USP9Y, and PTPN20) were 
identified as new cancer identifiers that deserve further clinical investigation [13].  
 
  
Figure 2.9  Illustration of Cancer Classification of Gene Expressions using Self-training Subspace Clustering and 
Low-Rank representation (SSC-LRR). (a) shows the original gene expression data matrix, (b) shows the 
decomposed low-rank representation and (c) shows the decomposed sparse representation [13]. 
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 One-Class Logistic Regression 
A one-class logistic regression machine learning algorithm was used to identify stemness 
features extracted from transcriptomic and epigenetic data from cancer tumors to reveal clinical 
insight and potential drug targets for anti-cancer therapies [6]. Stemness is defined as the 
potential for self-renewal and differentiation from the cell of origin. Cancer progression 
involves gradual loss of a differentiated phenotype and acquisition of progenitor-like, stem-
cell-like features [4]. The proposed study was based on an integrated analysis of cancer 
stemness in human tumors of different cancer types including gene expression data of mRNA 
and miRNA. By applying one-class logistic regression to molecular datasets from normal stem 
cells and their progeny, the method developed two different molecular metrics of stemness and 
then used them to classify epigenomic and transcriptomic features of the cancer tumors [6].  
  
Figure 2.10  Results of One-class Logistic Regression used to identify biological processes associated with 
Cancer Stemness. (A) Correlation between mRNAsi and mRNA expression for published hallmarks of 
stemness. (B) Correlation between mRNAsi and selected oncogenic processes [6]. 
A B 
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 Multilayer Recursive Feature Elimination 
A Multilayer Recursive Feature Elimination (MGRFE) method was proposed for cancer 
classification based on an embedded integer-coded genetic algorithm [11]. The feature 
elimination was aimed at selecting the gene combination with minimal size and maximal 
information. The method uses the filtering algorithms t-test and Maximal Information 
Coefficient (MIC) to reduce the feature range and generate a candidate feature set. MGRFE 
combines the advantages of both evolution calculation of genetic algorithms and the explicit 
Recursive Feature Elimination (RFE) to achieve the minimum discriminative gene subset with 
optimal classification ability. The experiments of the study showed that MGRFE outperforms 
state-of-the-art feature selection algorithms with better cancer classification accuracy and a 
smaller selected gene number on 19 benchmark microarray datasets including multiclass and 
imbalanced datasets [11]. 
Figure 2.11  Cancer Classification  using Multilayer Recursive Feature Elimination (MGRFE) based on 
an embedded integer-coded Genetic Algorithm (GA) [11]. 
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 Graph Structure Algorithms 
A gene expression graph structure was proposed for cancer classification by using the weight 
of graph edges to filter and determine the significance of genes before classification [17]. The 
informative genes were selected by filtering the weight values between genes such that greater 
weights indicate a stronger relationship between two genes. The method was also able to detect 
out-of-class samples that do not belong to any trained class.  
 
 Genetic Algorithms (GA) 
Genetic algorithms (GA) have been frequently used for cancer classification of gene 
expressions by combining gene feature selection and other machine learning methods. For 
example, an embedded integer-coded genetic algorithm was used for cancer classification of 
19 benchmark microarray datasets [9]. The approach relied on first applying a multilayer 
recursive feature elimination method based on the embedded integer-coded genetic algorithm 
with the aim of selecting the gene combination with minimal size and maximal information. 
Another example is the use of a hybrid ensemble algorithm combining genetic algorithms and 
AdaBoost for cancer classification with gene expression data [11]. A hybrid method was also 
used which integrates genetic programming and particle swarm optimization to build a scale-
free complex network classifier using an ensemble of different gene feature sets [8]. 
 
 Ensemble Classifiers  
One of the common approaches in classification is to use an Ensemble of multiple classifiers 
to improve Classification accuracy. An Ensemble classifier was developed for classification of 
Lung Adenocarcinoma cancer (LUAD) into molecular subtypes using a combination of k-
means clustering, t-test, Self-organizing Maps (SOM) and Hierarchical Clustering [10]. The 
method determined 24 differentially expressed genes which could be used as therapeutic 
targets, and five genes (RTKN2, ADAM6, SPINK1, COL3A1, and COL1A2) which could be 
potential novel markers for Lung cancer (LUAD). 
Figure 2.12  Cancer Classification using a Weighted Gene Expression Graph Structure [17]. 
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 Deep Learning 
Traditional machine learning techniques have shown limitations in processing high 
dimensional data [59]. Recent neuroscience findings have provided additional insight into the 
principles governing information representation in the brain. The discovery motivated the 
emergence of deep machine learning which has since revolutionized the capabilities of 
processing high dimensional data [59]. Deep learning methods rely on building complex multi-
layer network architectures capable of processing huge amounts of high dimensional data with 
minimal preprocessing requirements [46], [58]. Deep learning leverages spatial relationships 
among data to reduce the number of dimensions to be learned which dramatically improves the 
learning process in comparison to traditional machine learning methods [59], [67].  
 
 Learning using Deep Multilayer Architectures   
Traditional shallow architectures such as 2-layer neural networks, SVMs and kernel machines 
have been shown to be universal learning machines. But deep multilayer architectures have the 
capability of representing more complex functions [59]. The approach using Deep Learning is 
through building architectures with multiple layers each with a non-linear function. Each layer 
transforms the input to increase the level of accuracy and invariance of the selected features. 
As the Deep Learning architectures increase in depth and layers, the learning procedure is 
capable of representing complex functions which are very sensitive to the slightest details in 
the input objects and which are also insensitive to any irrelevant variations [59], [67].  
  
 Feature Extraction using Representation Learning  
Deep learning is commonly referred to as Representation Learning which is a technique based 
on using raw data as input with no feature extraction as a prerequisite. Deep learning relies on 
building architectures with multiple levels of representation by combining non-linear building 
blocks. Each level in the architecture transforms the input into a representation at a higher more 
abstract level which provides the capability of learning complex non-linear functions [59]. 
Figure 2.13  Visualization of Extracted Features from Deep Learning Networks [65] 
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 Training Deep Architectures using Gradient Descent & Backpropagation  
Supervised learning is used to train deep multilayer architectures. Training is performed by 
collecting a large amount of labelled data and presenting it to the network to produce an output 
score for each labelled category. By defining the appropriate objective function that measures 
the error between the network output and the desired output, we can adjust the network weights 
using Gradient descent optimization to reduce the classification error [59], [66].  
Gradient descent optimization can be illustrated by considering the cost function, averaged 
over all the training data, as a very high dimensional landscape full of hills in the network 
weight space. The negative gradients represent the direction of steepest descent in this 
landscape which can be used to iteratively determine the local minimum [62]. 
 
By training deep multilayer networks using Gradient descent and Backpropagation, the 
network learns to map an input of fixed size, such as an image, to an output which could 
represent probability scores of the classification categories [66]. A non-linear activation 
function is applied before passing the weighted sum of the inputs from one layer to the next. 
The hidden layers are considered to be performing a non-linear transformation of the input so 
that the classification of the output categories can become linearly separable [46].  
Figure 2.14  Training Multilayer Neural Networks using Backpropagation [59] 
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Deep network architectures can be trained by means of stochastic gradient descent using 
backpropagation by application of the chain rule for derivatives. To adjust the network weights, 
we need to calculate the gradient of the error function with respect to all the weight parameters 
in the network.  Backpropagation calculations can be used to propagate the gradients from the 
output layer back to the input by passing through the multiple layers [67]. 
 
 
 
 
 Convolutional Neural Networks  
 CNN Overview 
Convolutional Neural Networks (CNNs) are similar to traditional Neural Networks in having 
neurons with learnable weights and biases but differ greatly in the architecture and connectivity 
between the various layers. CNNs are made of multiple layers where each layer is arranged in 
the form of a 3D volume of neurons that has a specific width, depth and height. Each layer 
transforms the input 3D volume to an output 3D volume using a non-linear transformation 
function. The notion of depth is different from the number of layers of the network which was 
typically referred to as depth in traditional neural networks, but the depth in this context refers 
to the depth of the activation volume of neurons in a particular layer [59]. CNNs also differ in 
that the neurons in a particular layer will only be connected to a small region in the previous 
layer instead of the traditional fully connected networks, [66]. The following sections provide 
a survey of some of the current state-of-the-art convolutional neural networks used in computer 
vision and natural language processing applications. 
Figure 2.15 Computing Gradients for Deep Networks using Backpropagation [67] 
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 (ALEX-Net) ImageNet Classification with Deep Networks 
 
ALEX-Net was among the first Convolutional Neural Networks that drew great attention to the 
capabilities of deep learning and managed to outperform some of the existing classification 
benchmarks with a relatively high margin [66]. It won the first place in the ImageNet 2012 
competition. It was used to classify 1.2 million high resolution images covering 1000 different 
classes. The network had 5 convolutional layers followed by max pooling layers in some of 
them and then followed by 3 fully connected layers and a final 1000-way softmax for 
classification. The network had 60 million parameters and 650,000 neurons. A dropout 
regularization was used on the fully connected layers to reduce over fitting [66].    
Figure 2.16  ALEX-NET Convolutional Neural Network [66] 
Figure 2.18  Examples of Convolutional Kernels learned by ALEX-NET in the first layer [66] 
Figure 2.17  Classification of ImageNet 2012 Images using ALEX-NET [66] 
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Figure 2.20  Visualization of layer 3 features for a fully trained ZF-NET network [65]. 
 (ZF-Net) Visualizing and Understanding Convolutional Networks 
The ZF-Net network architecture provided a visualization technique to gain more insight on 
the functions of the intermediate feature layers of a Convolutional Neural Network and how it 
performs its classification [65]. This insight was used to further enhance the design of the 
network and enhance its classification performance and was able to achieve better performance 
in the ImageNet competition compared to ALEXNET. By using what is referred to as a De-
convolutional Neural Network, it was possible to visualize the intermediate feature maps 
extracted by the intermediate layers of a Convolutional Neural Network which has provided 
more insight on the functions of the intermediate layers and their role in feature extraction [65].  
 
 
Using the ZF-NET, it was possible to visualize the top activation for any feature map projected 
back to the image pixel space. This visualization made it possible to reveal the different 
structures that excite the activation map and demonstrated how it is invariant to any input 
deformations. The visualization of features also demonstrated through experimental trials that 
the features extracted by CNNs are not just random patterns, but they have significant 
interpretations in how the class discrimination is performed. It also demonstrates how the 
network is able to extract features with desirable properties such as compositionality and 
increasing variance as the data is moved deeper into the network layers [65]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19  ZF-NET Convolutional Neural Network [65]. 
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Figure 2.21  VGG-NET Convolutional Neural Network configurations [64] 
 (VGG-Net) Very Deep Convolutional Networks for Image Recognition 
The VGG-Net network attempts to further improve the architecture of CNNs by studying the 
variations of design in terms of the depth of the network. Experiments are performed to 
gradually increase the depth of the network by adding more convolutional layers while fixing 
other network parameters and using a very small 3x3 filter [64]. Variations in CNN depth 
configuration included networks starting from 11 weight layers (8 Conv. and 3 FC layers) up-
to networks with 19 weight layers (16 Conv. And 3 FC layers). At the same time variations are 
applied to the width of the network by changing the number of filters used from 64 in the first 
layer and up-to 512. Changing the number of filters determines the volume width or number 
of channels of the stacked activation maps after convolution. These variations in network depth 
demonstrated that the representation depth is beneficial for the accuracy of the classification 
and that state-of-the-art performance can be achieved by a conventional CNN architecture with 
substantially increased depth [64]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38   
  
 
AUC SID:  800-09-0336                                                                       Name: Tarek Khorshed 
 Inception Model Architectures 
It has been shown that if a large sparse Deep Neural Network architecture can be used to 
represent the probability distribution of a dataset, then the optimal network architecture can be 
constructed on a layer by layer basis by analysis of the correlation statistics of the activations 
of the last layer and clustering neurons with highly correlated outputs [63]. 
The Inception model architecture attempts to find an optimal approximation for a local 
sparse structure that is covered by readily available dense components. Construction proceeds 
layer by layer by analyzing the correlation statistics of the last layer and clustering them into 
groups of units with high correlation [63]. The resulting clusters will form the units of the next 
layer and are connected to the units in the previous layer. This model is based on the assumption 
that each unit from the earlier layer will correspond to some region of the input and that these 
units will be grouped into filter banks. This process will result in the early layers which are 
closer to the input, to build up many clusters which are concentrated in a single region which 
can then be covered by a layer of 1x1 convolutions in the following layer. To avoid the 
overhead of expensive computations resulting from merging of the output of the pooling layer 
with that of the convolutional layer, a dimension reduction is applied to preserve the sparse 
representations in the network [63]. 
 
 
  
Figure 2.22  Inception Module Architectures [63] 
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 (Google-Net) Going Deeper with Convolutions 
Google-NET was able to outperform previous designs and win the ImageNet contest in 2014 
ILSVCR14. The main advantage of this network architecture is the improvement in utilization 
of the computing resources inside the network. The implementation relied on designs which 
allowed increasing depth and width of the network while keeping the computational budget 
constant. The architecture decisions were based on the Hebbian principle and the use of multi-
scale processing to optimize quality [63].  
Google-NET has demonstrated that using dense building 
blocks for approximating the expected optimal sparse 
structure is a successful technique for improving the 
performance of Neural Networks. The experimental 
results of this network have shown that moving to sparser 
architectures is feasible and achieves comparable 
performance when compared to more expensive networks 
of similar depth and width [63]. 
 
 
 
 
 
  
Figure 2.23  Google-NET Convolutional Neural Network Architecture [63] 
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 Deep Residual Learning Framework 
Challenge in Training Deeper Networks 
State-of-the-art CNNs have shown that better classification performance can be achieved by 
architectures with substantially increased depth [64]. But at the same time, with depth being a 
significant factor, creating more deeper networks is not as simple as stacking more network 
layers into the network architecture [58].  
One of the major problems that arises with training deeper networks is referred to as the 
Degradation problem [58]. Degradation occurs with the increase in network depth where the 
training accuracy gets saturated and then at a certain point it starts to rapidly degrade. 
Experiments have shown that the degradation is not caused by overfitting but rather due to the 
increase of network layers. The example below illustrates the training of the CIFAR-10 dataset 
where increase in number of layers has resulted in in higher training and test error [58]. 
Residual learning was introduced to overcome degradation in learning performance with 
deep networks. If we assume that a series of stacked non-linear layers in a CNN can 
asymptotically approximate complex non-linear functions and that these layers can be 
represented by a mapping 𝐻(𝑥), where x is the input to the first layer, then we can equivalently 
assume that these stacked layers can also asymptotically approximate the residual function 
𝐻(𝑥) − 𝑥, given that both input and out have the same dimension.  
The idea of residual learning is that instead of expecting the deep layers to approximate 
𝐻(𝑥) we let them approximate a residual function 𝑓(𝑥) = 𝐻(𝑥) − 𝑥 so that the original 
function becomes 𝑓(𝑥) + 𝑥. If the added layers can be constructed as an identity mapping then 
the training error of the deep network should not exceed the shallow model of the same 
network. Residual learning has proved that it is easier to optimize the residual mapping than to 
optimize the original mapping. In the case that the identity mapping was optimal then it would 
be easier to drive the residual to zero than to approximate the identity mapping by a stack of 
non-linear layers [58].  
 
  
Figure 2.24  Deep Residual Learning Framework [58] 
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 (ResNet) Deep Residual Learning Networks for Image Recognition 
ResNet is a CNN architecture built on the residual learning framework [58]. The network was 
able to outperform previous designs and win the ImageNet contest in 2015 ILSVCR15. The 
architecture of this network is provides the capability to train networks which are relatively 
deeper than previous network designs. The idea is based on reformulating the layers as learning 
residual functions with reference to the layer inputs, instead of learning unreferenced functions. 
The experiments performed using this network demonstrated that Residual networks are easier 
to optimize and can achieve more accuracy when the depth of the network is increased [58]. 
  
Figure 2.25  Comparison between Plain and Residual Convolutional Neural Network Architectures [58]. 
Deep Network with Plain Layers
 
 Deep Network with Residual [DL3] 
Layers 
Deep Network with Residual Layers 
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 (Inception-ResNet) Impact of Residual Connections on Learning 
The idea behind the architecture of the Inception-ResNet [57] Convolutional Neural Network 
was to build a very deep network by combining the successful models used for Inception 
architectures together with the learning technique of Residual connections. The motivation is 
that Inception architectures have been shown to achieve very good performance at relatively 
low computational cost and at the same time the use of residual connections have produced the 
best performance results in 2015 ImageNet challenge ILSVCR15 [57].  
  
Inception-C Block 
Inception-B Block 
Inception-A Block 
Figure 2.26  Inception-ResNet Convolutional Neural Network Architecture [57] 
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 (DenseNet) Densely Connected Convolutional Networks 
Dense Convolutional Networks attempt to ensure maximum information flow between layers 
in a deep network by connecting all layers, with matching feature-map sizes, directly with each 
other [41]. Recent studies have shown that convolutional networks can be substantially deeper, 
more accurate, and efficient to train if they contain shorter connections between layers close to 
the input and those close to the output. DenseNets build on this observation by connecting each 
layer to every other layer in a feed-forward fashion. Traditional convolutional networks with L 
layers have L connections, one between each layer and its subsequent layer. On the other hand,  
a DenseNet only has L(L+1)/2 direct connections [41]. For each layer, the feature-maps of all 
preceding layers are used as inputs and its own feature-maps are used as inputs into all 
subsequent layers. DenseNets have several advantages as they overcome the vanishing-
gradient problem, strengthen feature propagation and substantially reduce the number of 
parameters. DenseNets obtained significant improvements over the state-of-the-art CNNs on 
four benchmark datasets used in object recognition (CIFAR-10, CIFAR-100, SVHN, and 
ImageNet) [41]. 
  
Figure 2.27  DenseNet Convolutional Neural Network Architecture [41] 
44   
  
 
AUC SID:  800-09-0336                                                                       Name: Tarek Khorshed 
 (NasNet) Learning Transferable Architectures for Image Recognition 
The framework of learning transferable architectures is based on searching for an architectural 
building block on a small dataset and then transferring the block to a larger dataset [40]. The 
NasNet experiments search for the best convolutional layer or “cell” on a proxy dataset, such 
as the CIFAR-10 dataset, and then apply this cell to the ImageNet dataset by stacking together 
more copies of this cell, each with their own parameters to design the NasNet convolutional 
architecture. Searching for the best cell structure is much faster than searching for an entire 
network architecture and the cell itself is more likely to generalize to other problems. For 
experiments on ImageNet, a NASNet constructed from the best cell achieves accuracy of 
82.7% top-1 and 96.2% top-5. The NasNet model is 1.2% better in top-1 accuracy than the best 
human-invented architectures while having 28% less FLOPS in computational demand from 
the previous state-of-the-art model. [40] 
  
Figure 2.28  NasNet Convolutional Neural Network Architecture [40] 
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 (MobileNet) Efficient CNNs for Mobile Vision Applications 
MobileNet represents a class of efficient models designed for mobile and embedded vision 
applications. MobileNets are based on a streamlined architecture that uses depthwise separable 
convolutions to build light weight deep neural networks [39], [43]. The MobileNet architecture 
is based on depthwise separable convolutions which is a form of factorized convolutions which 
factorize a standard convolution into a depthwise convolution and a 1x1 convolution called a 
pointwise convolution. The depthwise convolution applies a single filter to each input channel 
while the pointwise convolution then applies a 1x1 convolution to combine the outputs of the 
depthwise convolution. This factorization has the effect of drastically reducing computation 
and model size [43]. Experiments have demonstrated the effectiveness of MobileNets across a 
wide range of applications and use cases including object detection, finegrain classification, 
face attributes and large scale geo-localization [43]. 
MobileNet V2 improve on the original design by introducing a novel layer called the 
inverted residual with linear bottleneck [39]. This module takes as an input a low-dimensional 
compressed representation which is first expanded to high dimension and filtered with a 
lightweight depthwise convolution and then features are subsequently projected back to a low-
dimensional representation with a linear convolution. Experiments demonstrated that 
MobileNet V2 improves the state of the art performance of mobile models on multiple tasks 
and benchmarks as well as across a spectrum of different model sizes [39]. 
  
Figure 2.29  Architecture of Separable Convolution Blocks in MobileNet Convolutional 
Neural Network Architecture [39]. 
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Figure 2.30  Confusion Matrix Performance Metrics [66] 
 ROC Analysis for Evaluation of Classification Performance 
The receiver operating characteristics (ROC) curves [68] will be used for evaluation of the 
classification performance of our proposed Convolutional Neural Network models as 
compared to the existing benchmarks for state-of-the-art classification methods. A confusion 
matrix is constructed by analysis of the four common possible outcomes which are defined for 
classification evaluation as shown in the figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROC Curve 
 
The ROC curve is a 2-dimensional graph where the true positive rate (TP) is plotted on the Y 
axis and false positive rate (FP) is plotted on the X axis. The ROC describes relative tradeoffs 
between benefits (true positives) and costs (false positives). The lower left point (0, 0) 
represents a classifier which commits no false positive errors but also gains no true positives. 
The opposite of unconditionally issuing positive classifications is represented by the upper 
right point (1, 1). The point (0, 1) represents perfect classification. A point in ROC space is 
better than another if it is to the northwest, which means the true positive rate is higher or the 
false positive rate is lower or both [68]. 
 
  
Figure 2.31  ROC Curve [68] 
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Applying a Threshold for ROC Curve 
 
When using a layer such as Softmax for the Classification decision in a Convolutional Neural 
Network, the decision is a set of probabilities describing our confidence in each of the 
decisions. In this case a threshold can be used to produce a discrete classifier where each 
threshold value produces a different point in ROC graph. The figure shows an example of ROC 
curve where the instances have been sorted by their scores, and each point is labeled by the 
score threshold that produces it [68]. 
 
Avoiding Performance Evaluation Skews caused by Gene Expression Class Distribution  
 
ROC curves have an advantage of insensitivity in changes to class distribution. If the proportion 
of positive to negative instances changes in a test set, the ROC curves will not change. The 
class distribution is the relationship of the positive column on the left to the negative column 
on the right. Any performance metric that uses values from both columns will be inherently 
sensitive to class skews. For example, Precision-Recall curves are sensitive to changes in class 
distribution as compared to ROC curves as demonstrated in the figure below [68].  
  
Figure 2.32  Comparison between ROC and Precision-Recall curves under 
skews in Class data Distribution [68] 
 
 
(a) ROC curves 1:1;   
(b) Precision-recall curves 1:1  
(c) ROC curves 1:10 
(d) (d) Precision-recall curves 1:10 
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CHAPTER 3   
 RESEARCH METHODOLOGY 
 
 Problem Definition 
The World Health Organization reports that cancer is a leading cause of death worldwide 
accounting for an estimated 9.6 million deaths in 2018 [1]. Despite this dramatic impact, 
between 30-50% of cancer death cases can be prevented through early detection and treatment 
[3]. Advancements in cancer classification and prediction play an important role in saving the 
lives of cancer patients, since a major challenge in cancer treatment is that patients are 
diagnosed at very late stages where appropriate interventions become less effective and full 
curative treatment is no longer achievable [4].  
Machine learning for medical diagnosis using genomics is very difficult given the high 
dimensionality of the data and lack of sufficient patient samples for training [1], [4].  
Technological advances in structural genomics have allowed studying the full set of DNAs in 
the human genome [25]. Next generation sequencing (NGS) methods such as whole-genome 
DNA sequencing and Total RNA sequencing are considered revolutionary technologies for 
studying genetic changes in Cancer [22], [27]. These technologies provide great potential for 
cancer classification and better understanding of tumor progression given their ability to 
sequence thousands of genes at one time and detect multiple types of genomic alterations [20], 
[21], [25]. They provide capabilities for comparing the sequence of DNA and RNA in cancer 
cells with that in normal cells to identify genetic changes that may be driving the growth of a 
tumor [26]. Gene expression analysis using total RNA sequencing provides a snapshot of the 
whole transcriptome rather than a predetermined subset of genes and can detect both coding 
plus multiple forms of noncoding RNA [22]. These methods have eliminated many limitations 
involved in microarray based experiments that were previously used for measuring gene 
expressions [22], [25], [27].  
Cancer classification using gene expressions produced from Total RNA sequencing is 
extremely challenging given the complexity and massive amount of genetic data that is 
produced [20], [21], [25], [26], [38]. The magnitude of variants obtained from RNA-
Sequencing is exponential which makes it difficult for traditional machine learning approaches 
to evaluate genetic variants for disease prediction [4], [22], [23]. Gene expression data is 
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characterized by being very high in dimensionality in terms of having a very large number of 
features representing the genes, and a very small number of training data representing the 
patient samples [9], [22], [33]. Complexity is also due to the fact that only a small subset of 
genes might be influencing the cancer tumor being diagnosed [4], [29].  
Current cancer classification methods avoid processing the full set of genes to overcome 
these complexities and are mainly based on performing a process of gene feature selection as 
a prerequisite to the classifier learning process [28], [29], [30], [31]. Gene feature selection will 
allow the learning process to proceed, but the resulting classifier will not have the opportunity 
to learn the molecular signatures of genes which have been excluded and their influence on the 
underlying cancer tumor [34], [35]. Current classification methods which are based on gene 
feature selection are not optimal for early cancer diagnosis. This is because these methods will 
fall short in taking the full advantage of DNA and RNA sequencing technologies to discover 
the correlated patterns between genes across the full set of DNAs in the human genome and to 
detect multiple types of genetic alterations that may be driving the growth of a tumor across 
the whole transcriptome rather than a predetermined subset of genes [5], [6]. Another limitation 
of current methods is that they typically rely on gene expressions collected mainly from a single 
cancer tissue type based on the same anatomical site of origin.  This approach does not utilize 
the full potential of the recent emerging whole-genome sequencing technologies and data 
produced by large-scale genomic projects which are producing detailed molecular 
characterizations of thousands of tumors using genome-wide platforms [38]. Recent studies 
which have performed an integrated multiplatform analysis across multiple cancer types have 
revealed molecular classification within and across tissues of origin [5], [7]. The results of 
these studies have recommended that the traditional approach of anatomic cancer classification 
should be supplemented by classification based on molecular alterations shared by tumors 
across different tissue types [5]. 
Deep Machine Learning continues to be an active research area [59] and therefore provides 
great potential for early disease detection and diagnosis. Among the great challenges in using 
deep learning for disease classification is the absence of a systematic approach to discover 
optimal model architectures. Deep learning is dependent on manually designing and 
configuring deep network architectures, where the optimal design configuration is achieved by 
training and experimentation on huge benchmark datasets [39], [41], [46], [57], [58], [42], [43]. 
Another challenge in using deep machine learning for disease diagnosis, is that deep networks 
are conceived as “black boxes” without much interpretation on how these complex models 
make their decisions [53]. Existing visualization techniques for deep networks used for 
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computer vision tasks [52], [53], [65] can be interpreted by non-experts when studied in 
conjunction with image or video datasets because they are visually comprehensible. These 
methods are not directly applicable to genomic datasets such as gene expressions, since they 
cannot be visually rendered in a human-friendly form that allows easy interpretations. 
 
 Research Objectives  
To address the above problems, this has motivated our research for early cancer diagnosis by 
targeting the following research objectives: 
Objective 1:  
Leveraging the latest Deep Learning methods to design a comprehensive Multi-Tissue 
cancer classifier based on molecular signatures of whole-transcriptome wide gene 
expressions, that are collected from human samples representing multiple cancer tissue 
types and covering multiple organ sites.  
Research Questions: Will the performance of disease prediction improve by learning the 
molecular signatures of whole-transcriptome wide gene expressions? Does a cancer 
classifier have to be limited to learning the molecular signatures of tumors from a single 
tissue type? Is there any value to learn the molecular signatures of tumors across multiple 
tissues and organ sites? 
Method: Developing cancer classifiers with the capabilities of detecting more complex 
types of genetic alterations driving cancer progression, by learning the genomic signatures 
of whole-transcriptome gene expressions shared across multiple cancer tissue types and 
measuring the improvement in comparison to traditional single tissue classification. 
 
Objective 2:  
Design a Deep Learning framework for early cancer diagnosis by combining the process 
of gene feature selection and classification into one end-to-end learning system.  
Research Questions: Can deep learning be used to overcome the limitations of traditional 
machine learning methods in processing complex high dimensional genomic data? Can we 
design a cancer classifier using genes across the full set of DNAs in the human genome 
without performing a prerequisite process of gene feature selection? 
Method: Eliminating the dependency on the prerequisite process of gene feature selection 
which is performed by current state-of-the-art cancer classification methods for discovering 
a predefined subset of informative genes to be used in the learning process. 
 
51   
  
 
AUC SID:  800-09-0336                                                                       Name: Tarek Khorshed 
Objective 3:  
Design a new Deep Neural Network architecture which is specifically designed to address 
the complex nature of whole-transcriptome gene expressions. The new model architecture 
should have the capabilities of learning the sequence of DNA and RNA in cancer cells and 
identifying genetic changes that alter cell behavior and cause uncontrollable growth and 
malignancy. The new architecture should also have the capabilities of learning the genomic 
signatures across multiple tissue types without requiring the prerequisite of gene feature 
selection.  
Research Questions: Can we improve the performance of current cancer classifiers for 
early disease prediction by taking better advantage of Next Generation Sequencing methods 
such as whole-genome DNA sequencing and Total RNA sequencing that can provide a 
snapshot of the whole transcriptome? Can the existing state-of-the-art deep learning models 
that have been designed specifically for computer vision tasks, also be successfully applied 
for cancer classification using genomic data? Can we improve the performance of current 
cancer classifiers by designing a deep learning model architecture specifically designed for 
the complex nature of genomic data and whole-transcriptome gene expressions across 
multiple tissue types? 
Method: Developing cancer classifiers with the capabilities of taking full advantage of 
genome-wide Next Generation Sequencing technologies to discover the correlated patterns 
of genes across the full set of DNAs in the human genome and across multiple cancer tissue 
types. To our knowledge, this is the first effort to develop a Multi-Tissue cancer classifier 
based on a full set of whole-transcriptome wide gene expressions collected from tumors 
across different tissue types without requiring a prerequisite process of gene feature 
selection. 
 
Objective 4:  
Design a Deep Transfer Learning model that can effectively function as a generic Multi-
Tissue cancer classifier by learning genomic signatures collected from multiple cancer 
tissue types and using Transfer Learning to build classifiers for tumor types that are lacking 
sufficient patient samples to be trained independently.  
Research Questions: Do we need a huge amount of human patient samples to train deep 
learning models with genomic data? Can we benefit from deep learning model architectures 
to efficiently build and train cancer classifiers despite the lack of huge amounts of cancer 
patient samples? 
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Method: Eliminating the dependency on huge amounts of patient data and contributing to 
solving one of the biggest challenges in cancer classification which is lack of patient 
samples. Comparing the classification performance between applying transfer learning 
using the genomic signatures of a pre-trained model versus performing a full training 
procedure using the available patient samples. 
 
Objective 5:  
Design an end-to-end Deep Reinforcement Learning framework that would automatically 
learn the optimal Deep Neural Network architecture together with the associated optimal 
hyperparameters that would maximize the performance of our multi-tissue cancer classifier.  
Research Questions: Can we avoid the process of manually designing and handcrafting a 
deep model architecture and avoid the process of manually performing hyperparameter 
optimization to improve the performance of our cancer classifier? 
Method: Developing a comprehensive multi-tissue cancer classifier that would eliminate 
the manual process of handcrafting the network architecture and eliminate the manual 
process of hyperparameter optimization and fine-tuning on the target dataset. 
 
Objective 6:  
Design visualization procedures to provide more biological insight on how the proposed 
network model is learning genomic signatures of whole-transcriptome gene expressions 
and accurately performing classification across multiple cancer tumors. Design the 
capability to visualize gene localization maps highlighting the important regions in the gene 
expressions influencing the tumor class prediction. Design the capability to visualize the 
molecular clusters formed by intermediate gene expression feature maps learned by the 
network which helps in revealing the genomic relationships of gene expressions that are 
influential in the tumor progression.  
Research Questions: If we manage to successfully use deep learning models to improve 
the performance of cancer classifiers for early cancer diagnosis, can we provide medical 
professionals with any form of biological interpretation on how these complex models are 
making their predictions?  
Method: Contribute to providing medical professionals with more confidence in using 
deep learning for medical diagnosis by providing interpretation on how these complex deep 
learning models are making their predictions. 
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 Approach 
The following sections outline our approach for achieving our research objectives and 
answering the research questions. We describe the motivation in using deep learning to design 
a multi-tissue cancer classifier and overcome the complexity in feature extraction in 
comparison to traditional machine learning methods. We outline our approach for using 
transfer learning to solve one of the biggest challenges in cancer classification which is lack of 
patient samples. We describe our approach to discover and learn the optimal deep network 
architecture that would maximize the performance of our classifier by designing an end-to-end 
Deep Reinforcement Learning framework. Finally, we introduce our approach using 
visualizations to provide more biological insight on how our deep learning framework is 
performing multi-tissue cancer classification. The detailed methods are presented in chapter 4. 
 Using Deep Learning to Design a Multi-Tissue Cancer Classifier 
Deep Machine learning and Computational Intelligence are concerned with designing 
intelligent systems that can independently learn from data and make complex predictions and 
decisions in dynamically changing real world environments. Deep learning has had a major 
impact in many research and business applications such as Autonomous Self-driving Cars, 
Computer Vision, Medical Diagnosis, Biometric Identification, eCommerce, Banking and 
Cybersecurity. It has become a key element in many military defense applications and 
government intelligence and law enforcement agencies [40], [59], [60].  
Traditional machine learning techniques have shown limitations in processing high 
dimensional data [66]. Recent neuroscience findings have provided additional insight into the 
principles governing information representation in the brain. The discovery motivated the 
emergence of deep machine learning which has since revolutionized the capabilities of 
processing high dimensional data [59]. Deep learning methods rely on building complex multi-
layer network architectures capable of processing huge amounts of high dimensional data with 
minimal data preprocessing requirements, [42], [46], [58], Deep learning leverages spatial 
relationships among data to reduce the number of dimensions to be learned which dramatically 
improves the learning process in comparison to traditional machine learning techniques [67].  
 
 Overcoming Complexity in Feature Extraction of Gene Expression Data 
Traditional machine learning methods are dependent on a prerequisite which requires domain 
experts to handcraft the relevant set of features to be used in the learning algorithm [59]. The 
design of a classification system required careful engineering and continuous fine-tuning to 
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design a feature extractor which would be capable of capturing the characteristics of the data 
being analyzed and transform it into a suitable feature vector to be fed as an input to the learning 
algorithm [67]. The performance of the learning system in terms of prediction and classification 
depended heavily on the successful identification of these features [59]. Deep learning on the 
other hand, is commonly referred to as Representation Learning since it is based on using raw 
data as input with no feature extraction as a prerequisite. Deep learning relies on building 
architectures with multiple levels of representation by combining non-linear building blocks, 
each level in the architecture transforms the input data into a representation at a higher more 
abstract level which provides the capability of learning complex non-linear functions [59].  
For the problem of early cancer diagnosis using whole-transcriptome gene expression data, 
deep learning would provide the capabilities of automatically learning the molecular patterns 
of expressed genes which are influencing the cancer tumor being diagnosed and using that to 
amplify the discrimination score for classification. The major advantage is that the genetic 
features of the cancer tumors will not require to be pre-identified by medical professionals, but 
rather they will be automatically discovered through the deep learning process. 
 
 Deep Learning Architecture for Multi-Tissue Cancer Classification 
Current methods for cancer classification are based on gene feature selection as a prerequisite 
to the classifier learning process. Our approach using deep learning provides an alternative 
solution to feature engineering and eliminates the dependency on huge amounts of training data 
and the prerequisite gene feature selection. This is achieved by combining the process of gene 
feature selection and classification into one end-to-end learning system using the whole set of 
transcriptome wide gene expressions collected from tumors across different tissue types. We 
propose a new Convolutional Neural Network (CNN) architecture called “Gene eXpression 
Network” (GeneXNet) that combines multiple layers of non-linear building blocks which 
transform the gene expression data into a representation at a higher more abstract level. This 
allows the network to automatically learn the molecular patterns of expressed genes which are 
influencing the tumors and use that to amplify the discrimination score for classification. The 
advantage is that the classifier will not be limited to learning the molecular characterization of 
a single tissue type but will have the capability of detecting more complex types of genomic 
alterations by learning the genetic signatures collected from multiple tumors and across 
multiple cancer tissue types. Another major advantage of our approach is that it allows 
performing very efficient transfer learning by reusing the molecular signatures learned by the 
trained networks. The weights of the pretrained networks can be used as feature extractors to 
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build and finetune classifiers for other different types of cancer tumors which might be lacking 
sufficient patient samples to be trained independently. This helps in solving one of the biggest 
challenges in building discriminative classifiers based on gene expressions which are 
characterized by having a very large number of genes versus a very small number of patient 
samples [1], [22]. 
 
 Transfer Learning using Genomic Signatures of Multiple Tumors to Overcome 
Lack of Patient Samples 
Our approach for building a comprehensive multi-tissue cancer classifier is by designing a new 
Convolutional Neural Network (CNN) architecture with the capability of learning the genomic 
signatures of whole-transcriptome wide gene expressions shared across multiple cancer tumor 
types. By training the model with samples from multiple tissue types collected from multiple 
organ sites, the classifier is able to learn and extract complex patterns from the gene expression 
data that represent genomic and transcriptomic alterations such as mutations, rearrangements, 
deletions, amplifications and the addition or removal of chemical marks. This allows the 
classifier to more accurately classify cancer tumors which are resulting from DNA or RNA 
changes that alter cell behavior across multiple tissues and cause uncontrollable growth and 
malignancy. 
A major advantage is that we are able to reuse the genomic signatures learned by the trained 
model to perform very efficient transfer learning to solve one of the biggest challenges in 
cancer classification which is lack of patient samples. We demonstrate how transfer learning 
can be used to build and finetune classifiers for other different types of cancer tumors not 
included in the underlying dataset, which might be lacking sufficient patient samples to be 
trained independently. By reusing the weights of the pretrained network model, we demonstrate 
how the same network or an extended version of it can be used for feature extraction on a 
different cancer tumor type. The intuition behind transfer learning comes from recent studies 
which have performed an integrated multiplatform analysis across multiple cancer types that 
have revealed similar molecular classification within and across tissues of origin [5], [7]. This 
means that the discriminative molecular features for one cancer classifier will most likely be 
relevant for other cancer types. Our pretrained model will have already learned the complex 
types of genetic alterations and genomic signatures collected from multiple cancer tissue types 
originating from different organs and can effectively function as a generic model for cancer 
classification. 
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 Deep Reinforcement Learning Framework to Discover the Optimal Deep Network 
Architecture 
Our objective is to design an end-to-end learning framework that would enable us to 
automatically learn the optimal deep network architecture together with the associated optimal 
hyperparameters that would maximize the multi-tissue classification performance on our 
cancer tumor dataset.  
The development of deep neural network architectures to improve accuracy and 
performance continues to be an active research area [39], [41], [46], [57], [58], [42], [43]. The 
drawback in using similar design approaches for building a comprehensive multi-tissue cancer 
classifier is that they rely on manually designing and configuring the network architecture [86], 
where the optimal design configuration is achieved by experimentation on benchmark  datasets 
such as ImageNet [48]. One of the great challenges in using deep networks is the absence of a 
systematic approach to search within the huge network architecture space which is exponential 
in size to discover the optimal architecture [87]. Since our objective is to build a comprehensive 
multi-tissue cancer classifier based on molecular signatures of whole-transcriptome gene 
expressions, we would like to design our end-to-end deep learning framework without 
manually configuring the optimal network architecture. We would like to eliminate the manual 
process of handcrafting the network architecture which typically depends on carefully 
engineering and fine-tuning the design to achieve optimal performance on the target dataset.  
To solve this problem, we propose a different approach by designing an end-to-end Deep 
Reinforcement Learning (DRL) framework. The objective of the DRL framework is to discover 
and learn the optimal Deep Network architecture that would maximize the performance of our 
multi-tissue cancer classifier on any potential gene expression dataset. In our proposed DRL 
framework, we use a Recurrent Neural Network (RNN) to generate different network 
architectures and we train the RNN using Reinforcement Learning to find an optimal 
architecture that would maximize the expected classification performance on our underlying 
multi-tissue cancer dataset. Our methods are motivated from the work done in the areas of 
Robotics and Optimal Control of Autonomous Vehicles using Deep Reinforcement Learning 
[89], [90], [91], [92], [93] and also the work done in Adversarial Game Playing using 
Reinforcement Learning and Deep Neural Networks [100], [101].  We build on the Policy 
Gradient optimization methods which use Reinforcement Learning and Trajectory 
optimization to learn complex nonlinear policies used in controlling high dimensional robotics 
systems using deep neural networks [94], [95], [96]. We also build on the gradient based 
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optimization methods using Recurrent Neural Networks which have been used for image 
classification [40], [81]. 
 
 Visualizing Genomic Relationships of Gene Expressions Across Multiple Tumors 
One of the challenges in using deep learning for disease diagnosis, is that deep networks are 
conceived as “black boxes” without much interpretation on how these complex models make 
their decisions [53]. Extensive work has been done to introduce novel visualization techniques 
for deep networks to help understand and interpret their record breaking performance in 
computer vision tasks [52], [53], [65]. The output from these techniques can be interpreted by 
non-experts when studied in conjunction with image or video datasets because they are visually 
comprehensible. Unfortunately, these methods are not directly applicable to genomic datasets 
such as gene expressions, since they cannot be visually rendered in a human-friendly form that 
allows easy interpretations. Our approach is to design a learning system architecture that can 
contribute in solving this problem by taking full potential of next generation sequencing 
technologies that produce datasets with detailed molecular characterizations of thousands of 
tumors using genome-wide platforms. 
We introduce visualization procedures to provide more biological insight on how our model 
is performing cancer classification across multiple tumor types. We visualize gene localization 
maps highlighting the important regions in the gene expressions influencing the tumor class 
prediction. We also visualize the molecular clusters formed by intermediate gene expression 
feature maps learned by the network which helps in revealing the genomic relationships of 
gene expressions that are influential in the tumor progression. 
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CHAPTER 4   
 METHODS 
The following sections present our detailed methods for achieving our research objectives. We 
describe our Deep Learning framework and formulate the details of our Gene eXpression 
Network architecture. We present the details of using transfer learning using genomic 
signatures across multiple cancer tumors. We formulate our network training and optimization 
using stochastic gradient descent and adaptive learning optimization. We describe and 
formulate the details of our end-to-end Deep Reinforcement Learning framework to discover 
and learn the optimal deep network architecture that maximizes the performance of our cancer 
classifier. Finally, we describe the details of our visualization procedures to provide more 
biological insight on how our framework is performing multi-tissue cancer classification. 
 Deep Learning System Architecture  
A schematic diagram of our end-to-end deep learning system architecture is shown in Figure 
4.1. The first section represents the data collection and preparation process. It depends on 
collecting human samples representing multiple types of cancer tumors collected from multiple 
tissues spanning different organs across the body. The next step performs the gene expression 
quantification using a Next Generation Sequencing procedure. Total RNA sequencing is 
performed for measuring gene expression quantification across the whole-transcriptome and 
extracting both coding mRNA and noncoding miRNA. The gene expression data is normalized 
and then converted into a representation which makes it suitable for feeding it as input data to 
our deep learning model. Details about the cancer tumors used in our experiments is explained 
in the datasets section of the experiments chapter.   
Human samples 
26 Organ Sites 
33 Tumor Types 
Gene Expression Network 
(GeneXNet) 
Tumor Class 
Prediction 
Tumor 
Classification 
Total RNA 
Sequencing 
mRNA 
Gene Expression 
 Quantification 
Input 
Gene Expression 
Figure 4.1  Deep Learning System Architecture 
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The second section of our learning system represents building and training a deep 
Convolutional Neural Network (CNN) to automatically learn the molecular signatures of the 
full set of whole-transcriptome gene expression data and produce a trained model which can 
be used for classification of cancer tumors. Our model, which we refer to as “Gene eXpression 
Network” (GeneXNet), relies on building an architecture with multiple layers of non-linear 
functions which transform the gene expression data into feature maps to increase the level of 
accuracy and invariance of the selected gene features [67]. As the model increases in depth, it 
becomes capable of representing complex genetic alterations shared by tumors across different 
tissue types, which are very sensitive to the slightest details in the input samples. The genetic 
signatures learned by the feature maps in the deep layers, eliminate the need for the traditional 
prerequisite process of gene feature selection. This is because the feature maps are insensitive 
to any insignificant genes or irrelevant variations in the gene expression data [59],  [67].  
We train the model using supervised learning by feeding the collected human samples as 
input and producing an output probability score for each labelled category of cancer tumors. 
We define a cross-entropy loss function suitable for gene expression data that measures the 
error between the network input and the desired output, then we use stochastic gradient descent 
optimization and backpropagation [62] to adjust the network weights and reduce the 
classification error to the optimal levels. Full training details are explained in the experiments.  
 Convolutional Neural Networks 
Convolutional Neural Networks (CNNs) have contributed to many record breaking 
achievements especially in the areas of computer vision and image recognition [39], [40], [41], 
[42], [46], [60]. The development of new CNN architectures to improve accuracy and 
performance continues to be an active research area such as AlexNet [66], VGGNet [64], 
GoogLeNet [63], InceptionNet [57], ResNet [46], [58], DenseNet [41], MobileNet [39], [43], 
SENet [42] and  NasNet [40]. CNNs are made of multiple layers where each layer is arranged 
in the form of a 3D volume of neurons that has a specific width, height and depth. Each layer 
transforms the input volume to an output volume using a non-linear transformation function. 
CNNs differ in that the neurons in a particular layer will only be connected to a small region 
in the previous layer instead of the traditional fully connected networks [59].  
The motivation in using CNNs for classification of cancer tumors using gene expressions is 
that the convolution operation is very suitable for the high dimensional and sparse nature of 
the data. Since the input data has a very high dimensionality, it is not practical to use traditional 
kernel learning methods and fully connected networks since the resulting models will have a 
huge number of parameters to be learned which makes the learning process infeasible [59].  
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 Gene Expression Data Representation for CNNs 
 
In order to train our Convolutional Neural Network model using the cancer tumor samples, we 
first have to represent the gene expression data in a format suitable for the network input. Figure 
4.2 shows an outline for the gene expression data representation we implement for one of the 
datasets used in our experiments for patient samples representing 26 different cancer organ 
sites [38]. Full details about the cancer tumors used in our experiments is explained in the 
experiments chapter. Figure 4.2(b) represents a clustering heatmap of the mRNA gene 
expressions. The column clusters represent the cancer tumor types grouped by organ site, where 
each column represents a patient sample, each row represents a single gene and the cell color 
legends reflect the mRNA expression level of genes. If we have a total of N cancer tumor 
samples, each sample will have a total of G features representing the full set of genes produced 
by the whole-transcriptome sequencing procedure. We then represent the gene expression data 
in an equivalent 2D matrix of real numbers with dimensions (G, N) as in Figure 4.2(c). The 
matrix stores real values of the normalized gene expressions such that the value in cell 𝑋𝑖𝑗 
represents the expression level measured for gene (i) in the patient sample (j). Each tumor 
sample can be represented by a (G, 1) dimensional vector of gene expressions which we convert 
into the equivalent 3D volume with dimensions (Width, Height, Depth) to make it suitable as 
an input vector to our CNN model. The volume dimensions can be reshaped with any arbitrary 
length which matches the correct number of total features. The depth dimension is taken from 
the CNN terminology used in image classification where the depth is usually set to 3 
representing the number of RGB color channels. For images, values represent the pixel 
intensity, while for our cancer tumor dataset the values represent gene expression 
quantification. The training data for all the N samples can then be represented by the 4D input 
matrix with dimensions (No. of Samples, Width, Height, Depth) as shown in Figure 4.2(d). 
Figure 4.2  Gene Expression Data Representation for CNNs 
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 Learning Genomic Signatures using Convolutions 
 
The intuition in using the convolution operation for learning genomic signatures of cancer 
tumors is to leverage several architectural characteristics which distinguish Convolutional 
Neural Networks from traditional machine learning methods. These characteristics include: 
Sparse Connectivity, Parameter Sharing, Pooling and Equivariant representations [59],  [67].  
Since the gene expression data is very high in dimensionality, it is not practical to use the 
traditional fully connected neural networks since the resulting network will have a huge number 
of parameters to be learned which makes the learning process infeasible. To overcome this 
problem, we make use of convolutional layers which implement small convolutional filters to 
represent the weight parameters of the model. Figure 4.3 shows a schematic diagram for the 
convolutional layer we implement for gene expression data. The objective of the convolution 
layers is to learn filters that will be activated when matched with specific patterns or features 
in the gene expressions. The convolution layers perform a convolution operation which is a dot 
product between a sliding filter and the input across the full depth of the input gene expression 
volume to produce an activation map. We implement the convolution operation as in [75] by 
defining the convolution for each 2D layer of the gene expression volume as: 
 𝐺𝐸𝑂𝑢𝑡(𝑖 , 𝑗) = (𝐹 ∗ 𝐺𝐸𝐼𝑛)(𝑖 , 𝑗) =  ∑ ∑ 𝐺𝐸𝐼𝑛(𝑖 − 𝑚 , 𝑗 − 𝑛) 𝐹(𝑚 , 𝑛)
𝑛𝑚
 (1) 
where 𝐺𝐸𝐼𝑛, 𝐺𝐸𝑂𝑢𝑡 represents the input and output gene expression feature maps and 𝐹 is the 
sliding convolutional filter. The output volume of each layer is created by stacking the 
activation maps for all filters.  
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Figure 4.3  Convolutional Layer for Gene Expression Data 
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 Each neuron in the convolutional layer is only connected to a local region in the input 
volume covering the full depth which is the receptive field of the neuron. The neurons still 
perform the standard operation of a neural network by calculating the dot product between the 
input and the weights then applying a non-linear function. The main difference is that the 
neuron is connected only with its receptive field in the input and at the same time shares the 
same weight parameters as other neurons in the same feature activation map. 
Since the gene expression feature maps are represented by a 3D volume, we then define the 
convolution across the full depth of feature maps as: 
 𝐺𝐸𝑂𝑢𝑡(𝑘, 𝑖, 𝑗) =  ∑ 𝐺𝐸𝐼𝑛(𝑙, 𝑖 + 𝑚 − 1, 𝑗 + 𝑛 − 1) 𝐹(𝑘, 𝑙, 𝑚, 𝑛)
𝑙,𝑚,𝑛
 (2) 
where 𝐺𝐸𝐼𝑛, 𝐺𝐸𝑂𝑢𝑡(𝑘, 𝑖, 𝑗) represents the input and output gene expression values for the 
feature map at depth 𝑘, row 𝑖 and column 𝑗 and 𝐹(𝑘, 𝑙, 𝑚, 𝑛) represents a 4D convolutional 
filter between the output feature map at depth 𝑘, and the input feature map at depth 𝑙 with an 
offset of 𝑚 rows and 𝑛 columns. 
In order to tackle the complexity and high dimensional nature of the gene expression data we 
also make use of downsampling as in [75] by defining a stride parameter 𝑆 to skip over some 
positions of the gene expression feature maps to reduce the computational cost: 
 𝐺𝐸𝑂𝑢𝑡(𝑘, 𝑖, 𝑗) = ∑ [𝐺𝐸𝐼𝑛(𝑙, (𝑖 − 1) ∗ 𝑆 + 𝑚, (𝑗 − 1) ∗ 𝑆 + 𝑛) 𝐹(𝑘, 𝑙, 𝑚, 𝑛)]
𝑙,𝑚,𝑛
 (3) 
Table 4.1 shows the formulas we use to calculate the dimensions of the output volume 
representing the gene expression feature maps after applying the convolution operation. 
Table 4.1  Calculating Volume of Gene Expression Feature Maps after Convolution 
Parameter Description 
𝑊1, 𝐻1, 𝐷1 Input volume width, height and depth 
𝐺  No. of genes = (𝑊1𝑥𝐻1𝑥𝐷1) 
𝐾  No. of Filters = No. of Hidden Neurons = No. of Activation Maps = 𝐷2 
𝐹  Filter size = (𝐹 𝑥 𝐹) 
𝑆  Stride applied when moving the filter across the input volume 
𝑃  Zero padding applied to input volume  
𝑊2 Output Volume Width = [(𝑊1 − 𝐹 + 2𝑃)/𝑆] + 1 
𝐻2 Output Volume Height = (𝐻1 − 𝐹 + 2𝑃)/𝑆] + 1 
𝐷2 Output Volume Depth = No. of Filters = 𝐾  
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By implementing local receptive fields using small sized filters, the network can learn and 
extract small meaningful relationships between the molecular signatures of the genes which in 
turn can describe the characteristic influencing the cancer tumor. The sparse network 
connectivity, parameter sharing and convolutions using small kernels have helped in tackling 
the very high dimensional nature of the gene expression data since it dramatically reduced the 
number of parameters that the network needs to learn which means the learning process is much 
more efficient in terms of computation and storage requirements. This also helped in 
overcoming problems related to lack of sufficient cancer patient samples since the learning 
process became less prone to overfitting. Figure 4.4 illustrates the reduction in complexity by 
using sparsely connected networks for gene expression data in comparison to fully connected 
networks. 
 
We also make use of a Pooling layer after the convolution layer which provides a very 
important characteristic for learning the genomic signatures of cancer tumors by performing 
subsampling of the gene expression data. Our network design incorporates a max pooling 
function which is based on replacing the output of the feature maps at certain locations with a 
summary statistic of the nearby output values [75]. This allows our network model to generate 
gene expression feature maps which are invariant to local translations in the molecular 
signatures of the cancer tumor. This is a very important feature which enables building a 
classifier that can make predictions across multiple tumor types with the capability of learning 
the complex types of genomic signatures collected from multiple cancer tissue types 
originating from different organs. The intuition in extracting features which are invariant to 
local translations is adapted from using convolutional neural networks for image recognition.  
Gene Expressions 
Feature Maps 
Gene Expressions 
Feature Maps 
Fully Connected Network 
Gene Expressions 
Feature Maps 
Gene Expressions 
Feature Maps 
Sparsely Connected Network 
x1 
 
y1 
 
x2 
 
y2 
 
x3 
 
y3 
 
x4 
 
y4 
 
x5 
 
y5 
 
x1 
 
y1 
 
x2 
 
y2 
 
x3 
 
y3 
 
x4 
 
y4 
 
x5 
 
y5 
 
Input Output Input Output 
Figure 4.4  Sparsely Connected Networks for Learning Gene Expressions 
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 Gene eXpression Network (GeneXNet) Architecture 
In this section we describe the detailed architecture of our proposed CNN model shown in 
Figure 4.5. Recent benchmark results obtained by deep CNNs for image recognition tasks have 
demonstrated that network depth is of great importance for feature extraction and have 
managed to achieve outstanding results by designing networks with deeper and more complex 
architectures [46], [58]. These models were able to exploit deep architectures because of the 
availability of large training datasets such as ImageNet which contains over 1 million training 
images [48]. Training deep models requires large amounts of training data to avoid common 
problems such as overfitting, vanishing gradients and degradation of accuracy [46], [58].  
Applying the same deep CNN architectures for classification of gene expression data is not 
an evident task since it faces two conflicting problems. On one hand, we need to benefit from 
deep network architectures to efficiently extract the molecular signatures of the large number 
of genes so that our classifier can accurately generalize when presented with tumor data from 
multiple tissue types. But on the other hand, the lack of sufficient human training samples, 
which could be in the range of only a few hundred samples, implies great challenges for training 
deep networks and results in overfitting during training which implies using smaller more 
compact networks.  
We attempted to build an end-to-end learning system for cancer classification without 
performing the prerequisite process of gene feature selection by using some of the available 
state-of-the-art CNN models which have been specifically designed for computer vision tasks. 
Our experimental results have shown that training these deep models suffered from severe 
Figure 4.5  Gene eXpression Network (GeneXNet) Architecture 
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overfitting when presented with the underlying dataset that includes the full set of 
transcriptome gene expressions collected from tumors across different tissue types. The dataset 
did not have sufficient training samples to train these deep models and achieve the required 
accuracy. Many regularization methods have been proposed to overcome overfitting by adding 
constraints on the learning model or including additional terms in the error function which can 
potentially help to decrease overfitting and improve performance [75]. Examples of 
regularization methods include L1, L2 regularization, early stopping, noise injection, data 
augmentation, bagging and dropout [51], [61], [75]. Our experiments have shown that these 
regularization methods could slightly help in reducing overfitting but are not sufficient to build 
a general multi-tissue cancer classifier given the large number of features in the whole-
transcriptome gene expressions and lack of sufficient cancer patient training samples.  
To solve these conflicting problems, we propose a new CNN architecture which we refer to 
as Gene eXpression Network (GeneXNet) shown in Figure 4.5. Our network is designed to 
specifically target the complex nature of gene expression data and also addresses the lack of 
training samples by incorporating multiple layers of building blocks which we refer to as 
GeneXNet blocks shown in Figure 4.6. These blocks are motivated from both deep residual 
learning networks [46], [58] and also densely connected convolutional networks [41] and are 
formed by merging together two different types of learning sub-blocks. 
 
 GeneXNet Building Block Formulation 
Our proposed Gene eXpression Network (GeneXNet) architecture combines multiple layers of 
non-linear building blocks which transform the gene expression data into a representation at a 
higher more abstract level allowing the network to automatically learn the molecular signatures 
influencing the cancer tumors. We refer to these blocks as GeneXNet blocks which are shown 
in Figure 4.6 and are formed by merging together two different types of learning sub-blocks.  
𝑥𝑙+1 
 
Dense Learning Block Residual Learning Block 
Input                    
Output                 𝑥𝑙 
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Figure 4.6 Gene eXpression Network (GeneXNet) Building Blocks 
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To formulate our building block, we define our network to have L layers of blocks where the 
non-linear transformation of Gene expressions can be denoted by 𝐺𝑙 and can be defined as: 
 𝑥𝑙+1 = 𝐺𝑙(𝑥𝑙, 𝑊𝑙) (4) 
 𝑊𝑙 =  {𝑤𝑙,𝑖| 1 ≤ 𝑖 ≤ 𝐾𝑙 } (5) 
where 𝑙 is the index of the block,  𝑊𝑙 represents the set of weights and biases of the 𝑙
𝑡ℎ block, 
𝑤𝑙,𝑖 represents the weights of the 𝑖
𝑡ℎ convolutional layer in the 𝑙𝑡ℎ block, 𝐾𝑙 represents the 
number of convolution layers in the 𝑙𝑡ℎ block and 𝑥𝑙, 𝑥𝑙+1 represent the input and output 
features of the 𝑙𝑡ℎ block. We apply “pre-activation” of weight layers as in [46] by defining the 
transformation at each layer as a sequence of multiple operations which are Batch 
Normalization (BN) [55], Rectified Linear Unit (ReLU) [49] and Convolution.  
If gene expression data flows through the network using only the transformation in (4), that 
would be following the traditional approach for CNN layers. Deep residual learning provides 
a framework for more efficiently training deep networks by reformulating the layers as learning 
residual functions with reference to the layer inputs [58]. Empirical results have shown that 
residual learning helps to avoid degradation in performance accuracy as the depth of the 
network increases [58]. Residual networks have achieved excellent performance in many 
image recognition and object detection tasks where networks with over 150 layers have been 
trained on ImageNet [66] and managed to achieve substantial accuracy gains in comparison to 
normal networks which simply stack consecutive layers [46]. To make use of residual learning 
we reformulate our building block by implementing the non-linear transformation of gene 
expressions 𝐺𝑙 as a residual function defined as:  
 𝑥𝑙+1 = 𝑓𝑙[ 𝐺𝑙(𝑥𝑙 , 𝑊𝑙)  +   𝑀(𝑥𝑙) ] (6) 
where 𝐺𝑙 is a residual function for the 𝑙
𝑡ℎ block, 𝑀(𝑥𝑙) is a mapping which bypasses the non-
linear transformation and 𝑓𝑙 represents a mapping function of the input and output features of 
the 𝑙𝑡ℎ block. The simplest form of residual learning can be realized by choosing 𝑓𝑙 to be a 
Rectified Linear Unit (ReLU) [49] and also introducing identity skip connections which are 
equivalent to choosing 𝑀(𝑥𝑙) as an identity mapping so that 𝑀(𝑥𝑙) =  𝑥𝑙. Another formulation 
can be realized by implementing both 𝑀(𝑥𝑙) and 𝑓𝑙 as identity mappings. We apply the later 
formulation which has shown to improve accuracy by creating a more direct path for 
information propagation and allowing the signal to propagate more directly from one unit to 
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any other unit in the forward and backward passes [46]. The resulting non-linear transformation 
of gene expressions and the gradient of the loss function can then be expressed recursively as:  
 𝑥𝐿 = 𝑥𝑙 + ∑  𝐺𝑖(𝑥𝑖, 𝑊𝑖)
𝐿−1
𝑖=𝑙
 (7) 
 
𝜕
𝜕𝑥𝑙
=  
𝜕
𝜕𝑥𝐿
𝜕𝑥𝐿
𝜕𝑥𝑙
=
𝜕
𝜕𝑥𝐿
[1 +
𝜕
𝜕𝑥𝑙
∑  𝐺𝑖(𝑥𝑖, 𝑊𝑖)
𝐿−1
𝑖=𝑙
] (8) 
where 𝑥𝐿 represents the output features of the network with L layers of blocks,  is the loss 
function and 𝜕 /𝜕𝑥𝑙 is the gradient obtained by applying the chain rule and backpropagation  
[46]. The residual function 𝐺𝑖 is implemented as in (4) by applying two or more weight layers 
each using pre-activation and the sequence of multiple operations BN, ReLU and convolution.  
 
 
The resulting block is shown in Figure 4.7 which we refer to as the Residual Learning block. 
We also experiment with applying a bottleneck architecture  [46], [58], by modifying the design 
of this block to have three layers instead of two in the form of (1x1), (3x3) and (1x1) 
convolutions. Since we are using the full set of whole-transcriptome genes, the role of the (1x1) 
convolution is to enhance computational efficiency by reducing the large dimensions of the 
intermediate feature maps before applying the convolution and then restore them back again. 
Despite the strong advantages of residual learning networks in allowing the gradient to flow 
directly through the skip connections, there have been other proposed approaches to use 
stochastic depth to improve the training of deep residual networks by dropping layers randomly 
during training [47]. This has led to different intuitions that there might be a great amount of 
redundancy in deep residual networks and that not all the layers are required [41]. Densely 
connected convolutional networks (DenseNets) [41] exploit the potential of the network 
through feature reuse as an alternative to deep or wide architectures by connecting all layers 
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Figure 4.7 Residual Learning Block of Gene eXpression Network. 
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with matching feature-map sizes directly with each other. This design consideration is very 
important for our task, since one of the biggest challenges in our work is to build a multi-tissue 
cancer classifier that can benefit from deep network architectures to efficiently extract the 
molecular signatures of large number of genes, without facing severe overfitting or degradation 
in performance due to the lack of sufficient human training samples. This has inspired us to 
further reformulate the design of our GeneXNet building block and augment its learning 
capability by introducing additional dense layers that precede the residual learning layers. The 
dense layers follow a similar approach as in DenseNets  [41]. The design of our dense layers 
is implemented by passing additional inputs into each layer from all preceding layers and 
passing the feature maps of each layer to all subsequent layers. Our aim from this design is to 
provide each layer with direct access to the gradients from the loss functions and the original 
input signal which can potentially improve flow of information throughout the network. Our 
additional dense layers are formulated as follows: 
 𝑥𝑙+1 = 𝐺𝑙( 𝐶𝑜𝑛𝑐𝑎𝑡[𝑥1 , 𝑥2 , 𝑥3 , … , 𝑥𝑙] ) (9) 
where 𝑥𝑙+1 represents the output of the 𝑙
𝑡ℎ block, 𝐶𝑜𝑛𝑐𝑎𝑡[𝑥1 , 𝑥2 , … , 𝑥𝑙] represents the 
concatenation of the gene expression feature maps resulting from all preceding layers and 𝐺𝑙 
represents the same transformation as in (4) which applies pre-activation of weights and the 
sequence of multiple operations BN, ReLU and convolution. The resulting block is shown in 
Figure 4.8 which we refer to as the Dense Learning block.  
 
Our proposed GeneXNet block is finally formed by merging together these two sub-blocks as 
shown in Figure 4.6, which represents a combination of dense learning and residual learning 
layers. We define several parameters in order to control the variation of the network design and 
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Figure 4.8 Dense Learning Block of Gene eXpression Network. 
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size across different gene expression data sets. The parameter 𝜃𝑘 controls the number of filters 
used in the convolution layers. The two parameters 𝜃𝐷 and 𝜃𝑅 define the percentage of dense 
and residual sub-blocks in the network, where 0 ≤ 𝜃𝐷 ≤ 1 and 0 ≤ 𝜃𝑅 ≤ 1. For example, 
when both 𝜃𝐷 and 𝜃𝑅  are set to 1, then all the network blocks include both a dense and a residual 
sub-block. When 𝜃𝐷 is set to 1 and 𝜃𝑅 to 0.5, then all the network blocks include dense sub-
blocks while only half of the blocks include residual sub-blocks.  
The full Gene eXpression Network (GeneXNet) architecture is shown in Figure 4.5. It is 
implemented by feeding the gene expression input matrix to multiple layers of GeneXNet 
blocks each containing a combination of dense and residual learning layers as described above. 
The network ends with a global average pooling [54] after the last GeneXNet block and a fully 
connected softmax layer for classification. We experiment with different network sizes having 
two to four GeneXNet blocks and with different 𝜃𝑘, 𝜃𝐷, 𝜃𝑅 configurations. A detailed 
architecture is shown in table 2 implementing a network with four GeneXNet blocks, 𝜃𝑘=32 
and both 𝜃𝐷, 𝜃𝑅 set to 1. 
 
Table 4.2  Gene eXpression Network detailed architecture.  
(Implementing a network with 4 blocks, 𝜃𝑘=32, 𝜃𝐷=1, 𝜃𝑅=1) 
 
  
GeneXNet 
Block 
(𝑙 ) 
Output Size 
Dense Sub-block Residual Sub-block 
 
Layer operations 
𝜃𝐷 = 1 
 
Filters 
𝜃𝑘 = 32 
Layer operations 
𝜃𝑅 = 1 
 
Filters 
𝜃𝑘 = 32 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(36,36,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
[
𝐶𝑜𝑛𝑣(1𝑥1 , 64 )
𝐶𝑜𝑛𝑣(3𝑥3 , 64 )
   𝐶𝑜𝑛𝑣(1𝑥1 , 256 )
 ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 2 
 
 
(18,18,512) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 12 
 
 
4𝜃𝑘 
𝜃𝑘  
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128)
   𝐶𝑜𝑛𝑣(3𝑥3 , 128)
   𝐶𝑜𝑛𝑣(1𝑥1 , 512)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 3 
 
 
(9,9,1024) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 24 
 
 
4𝜃𝑘 
𝜃𝑘  
[
 𝐶𝑜𝑛𝑣(1𝑥1 , 256)
 𝐶𝑜𝑛𝑣(3𝑥3 , 256)
    𝐶𝑜𝑛𝑣(1𝑥1 , 1024)
] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 4 
 
 
(5,5,2048) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 16 
 
 
4𝜃𝑘 
𝜃𝑘  
[
 𝐶𝑜𝑛𝑣(1𝑥1 , 512)
 𝐶𝑜𝑛𝑣(3𝑥3 , 512)
   𝐶𝑜𝑛𝑣(1𝑥1 ,2048)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,2048) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
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Our results have demonstrated that our proposed network which combines both dense and 
residual learning layers, has allowed training deeper network architectures with complex data 
such as gene expressions, despite the large number of genes. The dense layers allow the 
network to efficiently extract the genetic signatures from multiple tumors and across multiple 
cancer types. This is achieved by means of re-using the gene expression feature maps learned 
by different layers, which increases the variation of input signals fed to subsequent layers since 
it represents the collective knowledge of the network [41]. The residual layers with identity 
mappings contribute to providing a direct path for information propagation in the forward and 
backward passes [58] while the connectivity of the dense layers provide each layer with more 
direct access to the gradients from the loss function and the original input signal [41]. Our 
results have also shown that the combination of dense connections augmented with residual 
layers performs a regularizing effect which allows the network to achieve high accuracy in 
tumor classification while avoiding problems related to overfitting due to lack of human 
samples. 
 
 Transfer Learning using Genomic Signatures Across Multiple Cancer 
Tumor Types 
Our approach for building a comprehensive multi-tissue cancer classifier is by designing the 
Gene eXpression Network (GeneXNet) with the capability of learning the genomic signatures 
of whole-transcriptome wide gene expressions shared across multiple cancer tumor types. By 
training the model with samples from multiple tissue types collected from multiple sites of 
origin, the classifier is able to learn and extract complex patterns from the gene expression data 
that represent genomic and transcriptomic alterations such as mutations, rearrangements, 
deletions, amplifications and the addition or removal of chemical marks. This allows the 
classifier to more accurately classify cancer tumors which are resulting from DNA or RNA 
changes that alter cell behavior across multiple tissues and cause uncontrollable growth and 
malignancy. 
A major advantage is that we are able to reuse the genomic signatures learned by the trained 
model to perform very efficient transfer learning to solve one of the biggest challenges in 
cancer classification which is lack of patient samples. We demonstrate how transfer learning 
can be used to build and finetune classifiers for other different types of cancer tumors not 
included in the underlying dataset, which might be lacking sufficient patient samples to be 
trained independently. By reusing the weights of the pretrained GeneXNet model, we 
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demonstrate how the same network or an extended version of it can be used for feature 
extraction on a different cancer tumor type.  
The intuition behind transfer learning comes from recent studies which have performed an 
integrated multiplatform analysis across multiple cancer types that have revealed similar 
molecular classification within and across tissues of origin [5], [7]. This means that the 
discriminative molecular features for one cancer classifier will most likely be relevant for other 
cancer types. Our pretrained model will have already learned the complex types of genetic 
alterations and genomic signatures collected from multiple cancer tissue types originating from 
different organs and can effectively function as a generic model for cancer classification. 
Transfer learning using our GeneXNet model provides the capability to learn abstract 
feature representations from gene expressions of a specific multi-tumor cancer dataset and then 
transfer these representations to classify another type of cancer tumor. Our work is motivated 
from One-shot learning and Zero-shot learning  methods used in Computer Vision which 
attempt to learn visual models of object categories using very little training data or even no 
training data at all in the case of unseen object categories [105], [106]. This is achieved by 
using deep learning models to learn abstract feature representations and then transferring the 
knowledge from previously learned categories and using it for detection of new categories 
without the need to learn the representations of new object categories from scratch [107]. 
 
Our proposed approach for performing transfer learning can be summarized as follows: 
1) We build a multi-tissue multi-class classifier by training our GeneXNet model using ALL 
the underlying cancer tumor dataset which includes multiple organ sites covering multiple 
tumor types. 
 
Figure 4.9  Transfer Learning – Training GeneXNet Model 
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2) We create a GeneXNet Base block by freezing the weights of the trained GeneXNet model 
and then removing the classification layers at the end of the network. The GeneXNet Base 
block will function as a feature extractor inside a new extended network model. 
 
 
3) We create a new extended GeneXNet model by stacking the pre-trained GeneXNet Base 
block and adding a new randomly initialized classification layer. 
4) We Re-train and Finetune the new extended network using a new cancer tumor dataset 
which might be lacking sufficient patient samples to be trained independently. The training 
is performed while freezing the original network layers that have already been pre-trained. 
We perform Finetuning by Un-Freezing some of the last layers in the GeneXNet Base 
Block and Re-training these layers again together with the new classification layers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.10  Transfer Learning – Freezing GeneXNet Weights 
Figure 4.11  Transfer Learning – ReTraining and Finetuning Extended GeneXNet Model 
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 Gene eXpression Network Training and Optimization 
Training a deep multi-layer Convolutional Neural Network architecture like our Gene 
eXpression Network is a very complex optimization problem as it involves non-convex loss 
functions [67]. Adjusting the weights of the network to reduce the classification error requires 
an optimization algorithm capable of adapting the learning rate and leveraging information in 
the Hessian matrix of the loss function [62]. Among the challenges we faced in model 
optimization is the very high dimensional landscape of the network weight space resulting from 
training the network with whole-transcriptome gene expressions for every tumor sample. To 
overcome these problems, we define a multi-class cross-entropy loss function suitable for gene 
expression data and we train our model using mini-batch Stochastic Gradient Descent (SDG) 
with an adaptive learning rate optimization algorithm  [62]. We implement  several different 
optimization algorithms including Momentum [77], [78], AdaGrad [51], RMSprop [62] and 
Adam [50]. The following sections describe details of our network training and optimization 
for building a multi-tissue cancer classifier using whole-transcriptome gene expressions. 
 
 Optimization Objective and Loss Function 
The objective of training our Gene eXpression Network is to find an optimal mapping 
function 𝑦 =  𝑓∗(𝑥, 𝑊) by learning the network parameters 𝑊 that would correctly classify 
our input gene expression data 𝑥, which represents the cancer tumor sample, to the correct 
output 𝑦, which represents the class of the cancer tumor type. Our network architecture as 
described in the previous sections, represents this complex mapping function and we need to 
train and optimize the network to learn the network parameters 𝑊 that would result in the 
optimal classification performance. To learn the network parameters we follow the approach 
of learning conditional probability distributions using maximum likelihood [75]. In this 
approach, our network model represents a probability distribution 𝑃(𝑦 | 𝑥, 𝑊) which is the 
conditional probability of predicting the correct tumor class given the tumor sample and the 
network parameters. We define the loss function as the Negative Log Likelihood (NLL) or 
Cross Entropy Loss between the training data and the network’s class predictions since it 
represents the conditional probability of the tumor classes given the gene expression input. We 
define an overall optimization objective by defining an Error function 𝐸(𝑊) and then use 
gradient descent optimization to learn the parameters 𝑊 that would reduce the error 𝐸 to the 
optimal level when presented with the entire training data. Since the training data only 
represents a limited sample of the real cancer tumor distribution, our optimization objective is 
to minimize the expected loss on the training data. 
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We define the Error objective function 𝐸(𝑊) as the average over the training data given by: 
 𝐸(𝑊) =  
1
𝑁
 ∑ 𝐸𝑖[𝑓(𝑥𝑖 , 𝑊),   𝑦𝑖]
𝑁
𝑖=1
 (10) 
where 𝑥𝑖 is the 𝑖
𝑡ℎ training sample, 𝑊 represents the network’s parameters to be learned, 𝑦𝑖 is 
the target output,  𝑓(𝑥𝑖 , 𝑊) represents the predicted output by the network and  𝐸𝑖 represents 
the loss function for the 𝑖𝑡ℎ training sample.  
Since our target is to build a Multi-Tissue classifier then we need to choose both the 
prediction function 𝑓 and the loss function 𝐸𝑖 which are suitable for a multiclass classification 
problem. We therefore define the output prediction function 𝑓𝑘 using the softmax function as: 
 𝑓𝑘 = 𝑠𝑜𝑓𝑡𝑚𝑎𝑥(𝑧)𝑘 =  𝑃(𝐶𝑙𝑎𝑠𝑠𝑘 | 𝑥𝑖 , 𝑊) =  
𝑒𝑧𝑘
∑ 𝑒𝑧𝑗𝐶𝑗
 (11) 
 𝑧𝑘 = log 𝑃(𝑦 = 𝑘 |  𝑥𝑖 , 𝑊) (12) 
where 𝑓𝑘 represents the output prediction for the 𝑘
𝑡ℎ tumor class, C represents the number of 
tumor classes, 𝑧𝑘 is the 𝑘
𝑡ℎ element in the output vector which represents the unnormalized log 
probability of the 𝑘𝑡ℎ class. The output of the softmax is a vector with each element having the 
normalized class probability. The advantage of the softmax is that it is a form of multiclass 
logistic regression and produces the output predictions in the form of a valid probability 
distribution over the number of classes.  
We then define loss function 𝐸𝑖 using the cross-entropy loss as:   
 𝐸𝑖 =  − ∑ 𝑡𝑘 . 𝑙𝑜𝑔(𝑓𝑘)
𝐶
𝑗=1
 (13) 
where 𝑡𝑘 represents the 𝑘
𝑡ℎ element of the target output vector for class 𝑘 using a 1-of-C coding 
scheme such that all elements of the vector are zeros except for the 𝑘𝑡ℎ element which equals 
one.  Since only a single term equals one, then the cross-entropy loss can be written as:  
 𝐸𝑖 =  −log (
𝑒𝑧𝑘
∑ 𝑒𝑧𝑗𝐶𝑗
) (14) 
where 𝐸𝑖 represents the cross-entropy loss for the 𝑖
𝑡ℎ training sample and 𝑧𝑘 is the 𝑘
𝑡ℎ element 
in the output vector which represents the unnormalized log probability of the 𝑘𝑡ℎ class. 
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We can then define the gradient 𝑔 of the Error 𝐸 with respect to the network parameters 𝑊 as: 
 𝑔 =  ∇𝑊𝐸(𝑊) =  
1
𝑁
 ∇𝑊 ∑ 𝐸[𝑓(𝑥𝑖 , 𝑊),   𝑦𝑖]
𝑁
𝑖=1
 (15) 
 
 Optimization Algorithms with Accelerated Gradient & Adaptive Learning 
We use mini-batch Stochastic Gradient Descent (SDG) optimization for training our Gene 
eXpression Network. The motivation in using SDG is that it is very well suited for training our 
deep network given the high dimensionality of the gene expression data which includes a very 
large number of features representing the genes across the whole transcriptome. Performing 
gradient descent optimization using a mini batch of samples instead of the traditional batch 
training using the entire training data is more computationally efficient for large data sets. It 
has also been shown to perform a regularizing effect due to the noise it adds to the learning 
process [76]. We can obtain an unbiased estimate of the gradient by sampling a mini batch of 
tumor samples drawn i.i.d from the training data and calculating the average gradient on the 
mini batch. We then update the network parameters 𝑊 in the direction of the gradient 𝑔 to 
optimize the generalization error using the following update:  
 𝑊 =  𝑊 −  η𝑡 ∇𝑊𝐸(𝑊) (16) 
where η𝑡 is the learning rate at iteration 𝑡 which is also a parameter that can change across 
training iterations. The challenge with this update is that choosing the right learning rate is very 
difficult. If we choose a very small learning rate, then training well be very slow and if it is too 
large it will not guarantee convergence where the error function can fluctuate around the local 
minimum. Learning rate scheduling is one common approach to solve this problem by updating 
the learning rate at certain intervals based on specific criteria. But at the same time these 
updates have to be defined before the training and are not adaptive based on the tumor samples. 
Another big challenge that we faced in optimization for our network is the non-convex nature 
of the error function and the very high dimensional landscape of the network weight space 
which causes the optimization algorithm to suffer the presence of Local Min, Plateaus, Saddle 
points and other flat regions [75]. To over come all these challenges, we train our network by 
adopting and experimenting with a variety of different optimization algorithms which adopt 
accelerated gradient methods and adaptive learning rate methods which we describe in the 
following sections. 
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GeneXNet Optimization with Momentum  
 
We experiment with applying the Momentum update [77] to accelerate the learning process by 
accumulating an exponentially decaying moving average of past gradients and continually 
moving in that direction. We implement Momentum by introducing a new velocity term 𝑣 
which controls the direction and speed of the parameter updates. The velocity is calculated as 
an exponentially decaying average of the negative gradient as:  
 𝑣 =  α 𝑣 −  η ∇𝑊 [
1
𝑁
 ∑ 𝐸[𝑓(𝑥𝑖 , 𝑊),   𝑦𝑖]
𝑁
𝑖=1
] (17) 
 𝑊 =  𝑊 +  𝑣 (18) 
where α ∈ [0,1) is a parameter which determines how fast the contributions of the previous 
updates for the gradient will decay exponentially. Momentum helps in solving the poor 
conditioning of the Hessian matrix and variance in applying the standard SDG by accelerating 
in the correct direction of the local minimum. Figure 4.12 illustrates the acceleration effect of 
momentum on SDG optimization [75], where the contour lines represent a poorly conditioned 
Hessian matrix. The red path represents the direction followed by momentum, while the black 
path represents the standard SDG which has a slower learning since it oscillates heavily before 
finally converging. 
 
We also experiment with applying the Nesterov Momentum update [78] which is motivated by 
the accelerated optimization methods of Nesterov [79]. We apply a correction factor to the 
gradient calculation by performing it after the velocity update which is now defined as: 
 𝑣 =  α 𝑣 −  η ∇𝑊 [
1
𝑁
 ∑ 𝐸[𝑓(𝑥𝑖 , 𝑊 +  α 𝑣 ),   𝑦𝑖]
𝑁
𝑖=1
] (19) 
Figure 4.12 Accelerating Stochastic Gradient Descent Optimization with Momentum [72] 
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GeneXNet Optimization with AdaGrad  
 
Since choosing the learning rate is one of the most complex hyperparameters, we also 
experiment with optimization algorithms with an adaptive learning rate. We apply the AdaGrad  
algorithm [51] which adapts the learning rate of all model parameters individually by 
performing large updates for infrequent parameters and smaller updates for the frequent ones. 
This adaptive learning characteristic is very important for training our network since it has been 
shown to perform well on sparse data [80] which is one of the big challenges in our underlying 
gene expression dataset.  
We apply this adaptive learning to our Gene eXpression Network by updating the learning rate 
for each parameter and scaling it at a rate which is inversely proportional to the historical values 
of the gradient as follows:  
 𝑊𝑡+1 =  𝑊𝑡 −  
η
√𝐺𝑡 +
 ⊙ 𝑔𝑡 (20) 
where η is the learning rate for each parameter at each iteration 𝑡,  is a constant that avoids 
division by zero, 𝐺𝑡 is a matrix having each diagonal element as the sum of squares for the 
gradients with respect to each parameter for all previous iterations and ⊙ represents element 
wise matrix vector multiplication. The outline of the algorithm we implement is as follows: 
 
Algorithm 4.1 GeneXNet Optimization with AdaGrad  
1 Input:  𝑊0, η ,  initial network parameters, learning rate, const 
2 Output: 𝑊 GeneXNet optimized network parameters  
3 Init 𝐺0 = 0 
4 while (Convergence criteria is false): 
5 Read minibatch of N cancer tumor samples (𝑥𝑖  , 𝑦𝑖) 
6 Calculate gradient 𝑔𝑡 =   
1
𝑁
 ∇𝑊 ∑ 𝐸[𝑓(𝑥𝑖 , 𝑊),   𝑦𝑖]
𝑁
𝑖=1  
7 Calculate accumulated gradient 𝐺𝑡 =  𝐺𝑡 +  𝑔𝑡 ⊙ 𝑔𝑡 
8 Update network parameters 𝑊𝑡+1 =  𝑊𝑡 −  
η
√𝐺𝑡+
 ⊙ 𝑔𝑡 
9 end while 
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GeneXNet Optimization with RMSProp  
 
We also experiment with the RMSProp algorithm [62] which is a modified version of AdaGrad 
since it has been shown to perform better on non-convex loss functions. This is achieved by 
calculating the gradient across iterations as an exponentially decaying average of all past 
gradients which allows discarding the historical values and converge more rapidly. We add a 
new parameter 𝛿 to configure the moving average and calculate the accumulated gradient as: 
 𝐺𝑡 =   𝛿. 𝐺𝑡 + (1 −  𝛿)𝑔𝑡 ⊙ 𝑔𝑡 (21) 
We also combine the update with the Nesterov momentum as before to accelerate the learning 
process by adding an additional parameter α and calculating the velocity as: 
 𝑣 =  α 𝑣 −  
η
√𝐺𝑡
 ⊙ 𝑔𝑡 (22) 
The outline of the algorithm we implement is as follows: 
 
Algorithm 4.2 GeneXNet Optimization with RMSProp   
1 Input:  𝑊0, 𝑣0, η , 𝛿, α   
       initial network parameters, initial velocity,  
       learning rate, rate of decay, momentum  
2 Output: 𝑊 GeneXNet optimized network parameters  
3 Init 𝐺0 = 0 
4 while (Convergence criteria is false): 
5 Read minibatch of N cancer tumor samples (𝑥𝑖  , 𝑦𝑖) 
6 Calculate gradient 𝑔𝑡 =   
1
𝑁
 ∇𝑊 ∑ 𝐸[𝑓(𝑥𝑖 , 𝑊),   𝑦𝑖]
𝑁
𝑖=1  
7 Calculate accumulated gradient 𝐺𝑡 =   𝛿. 𝐺𝑡 + (1 −  𝛿)𝑔𝑡 ⊙ 𝑔𝑡 
8 Calculate velocity 𝑣 =  α 𝑣 −  
η
√𝐺𝑡
 ⊙ 𝑔𝑡 
9 Update network parameters 𝑊𝑡+1 =  𝑊𝑡 +  𝑣 
10 end while 
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GeneXNet Optimization with Adam  
 
The final optimization algorithm we experiment with is the Adaptive Moment Estimation 
(Adam) [50]. For this optimization method we combine the updates from both the previous 
optimizations methods of RMSProp and momentum by calculating two different averages of 
past gradients to be used in the update term. The first is calculating an estimate of the first order 
moment by calculating an exponentially decaying average of past gradients as in momentum. 
The second is calculating an estimate of the second order moment by calculating an 
exponentially decaying average of past squared gradients as in RMSProp: 
 
𝑚𝑡 =   𝛿1. 𝑚𝑡−1 + (1 − 𝛿1)𝑔𝑡  (23) 
 𝑣𝑡 =   𝛿2. 𝑣𝑡−1 + (1 − 𝛿2)𝑔𝑡
2 (24) 
where 𝑚𝑡, 𝑣𝑡 are the estimation of the first moment representing the mean and the second 
moment representing the uncentered variance of the gradients. In addition we also calculate 
bias corrections to the estimates of the first order moment and the uncentered second order 
moment as in [50] to remove the bias of these values towards zero. The outline of the algorithm 
we implement is as follows: 
Algorithm 4.3 GeneXNet Optimization with Adam 
1 Input:  𝑊0, η , , 𝛿1, 𝛿2    
       initial network parameters, learning rate, constant, 
       1st moment rate of decay, 2nd moment rate of decay 
2 Output: 𝑊 GeneXNet optimized network parameters  
3 Init 1st and 2nd moment variables  𝑚𝑡 = 0, 𝑣𝑡 = 0 
4 while (Convergence criteria is false): 
5 Read minibatch of N cancer tumor samples (𝑥𝑖  , 𝑦𝑖) 
6 Calculate gradient    𝑔𝑡 =   
1
𝑁
 ∇𝑊 ∑ 𝐸[𝑓(𝑥𝑖 , 𝑊),   𝑦𝑖]
𝑁
𝑖=1  
7 Calculate 1st moment  𝑚𝑡 =   𝛿1. 𝑚𝑡−1 + (1 − 𝛿1)𝑔𝑡  
8 Calculate 2nd moment  𝑣𝑡 =   𝛿2. 𝑣𝑡−1 + (1 − 𝛿2)𝑔𝑡
2  
9 Correct bias of 1st moment 𝑚?̃? =  
𝑚𝑡
1− 𝛿1
𝑡 
10 Correct bias of 2nd moment 𝑣?̃? =  
𝑣𝑡
1− 𝛿2
𝑡 
11 
Update network parameters 𝑊𝑡+1 =  𝑊𝑡 − η 
𝑚?̃?
√𝑣?̃?+
  
12 end while 
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 Deep Reinforcement Learning to Discover Optimal Gene eXpression 
Network Architecture 
Section 4.5 described the detailed architecture of our proposed Gene eXpression Network 
which we have designed to specifically target the complex nature of gene expression data and 
address the lack of training samples. We described how our network design incorporates 
multiple layers of GeneXNet blocks which combine both dense and residual learning layers in 
order to efficiently train our deep network despite the large number of genes. We also defined 
several configurable parameters in order to control the variation of the network architecture 
and size across different gene expression data sets. We defined the parameters 𝜃𝐷, 𝜃𝑅 which 
allow us to control the percentage of dense and residual sub-blocks in the network and the 
parameter 𝜃𝑘 which controls the number of filters used in the convolution layers. 
In this section we tackle another difficult deep learning problem: how do we search and find 
the optimal network architecture that would function as the optimal multi-tissue cancer 
classifier? Our deep network architecture can be constructed by configuring many different 
parameters such as: number of GeneXNet blocks, number and type of learning layers in each 
block, order of learning and convolutional layers, number and size of filters for convolutional 
operations, size of strides and zero padding for convolutional operations, size of pooling layers 
and many more. The development of deep neural network architectures to improve accuracy 
and performance continues to be an active research area such as InceptionNet [57], ResNet 
[46], [58], DenseNet [41], MobileNet [39], [43], SENet [42]. The drawback in using similar 
design approaches for building a comprehensive multi-tissue cancer classifier is that they rely 
on manually designing and configuring the network architecture [86], where the optimal design 
configuration is achieved by experimentation on benchmark  datasets such as ImageNet [48]. 
One of the great challenges in using deep networks is the absence of a systematic approach to 
search within the huge network architecture space which is exponential in size to discover the 
optimal architecture [87]. There has been extensive work which attempts to solve the problem 
of hyperparameter optimization for deep networks using approaches such as random or grid 
search [85], [86], [87] and Bayesian optimization [88]. These methods have a limitation in that 
they can only search for network architectures within a fixed length space and lack the 
capability of producing networks with variable length configurations [81]. Since our objective 
is to build a comprehensive multi-tissue cancer classifier based on molecular signatures of 
whole-transcriptome gene expressions, we would like to design our end-to-end deep learning 
framework without manually configuring the optimal network architecture. We have already 
demonstrated how our approach using deep learning provides an alternative solution to feature 
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engineering and eliminates the need for discovering a predefined subset of genes by combining 
the process of gene feature selection and classification into one end-to-end learning system. 
We would also like to eliminate the manual process of handcrafting the network architecture 
which typically depends on carefully engineering and fine-tuning the network design to achieve 
optimal performance on the target dataset.  
Our objective is to design an end-to-end learning framework that would enable us to 
automatically learn the optimal network architecture together with the associated optimal 
hyperparameters that would maximize the multi-tissue classification performance on our 
cancer tumor dataset. 
To solve this problem, we propose a different approach by designing an end-to-end Deep 
Reinforcement Learning (DRL) framework. The objective of the DRL framework is to discover 
and learn the optimal Gene eXpression Network architecture that would maximize the 
performance of our multi-tissue cancer classifier on any potential gene expression dataset.  
In our proposed DRL framework, we use a Recurrent Neural Network (RNN) to generate 
different GeneXNet architectures and we train the RNN using Reinforcement Learning to find 
an optimal GeneXNet architecture that would maximize the expected classification 
performance on our underlying multi-tissue cancer dataset. Our methods are motivated from 
the work done in the areas of Robotics and Optimal Control of Autonomous Vehicles using 
Deep Reinforcement Learning [89], [90], [91], [92], [93] and also the work done in Adversarial  
Game Playing using Reinforcement Learning and Deep Neural Networks [100], [101].  We 
build on the Policy Gradient optimization methods which use Reinforcement Learning and 
Trajectory optimization to learn complex nonlinear policies used in controlling high 
dimensional robotics systems using deep neural networks [94], [95], [96]. We also build on the 
gradient based optimization methods using Recurrent Neural Networks which have been used 
for image classification [40], [81]. The following sections describe our DRL framework and 
our proposed approach. We discuss how our task is formulated as a Reinforcement Learning 
problem and present our detailed design for finding a solution. 
 
 Deep Reinforcement Learning Framework for GeneXNet Model Generation   
Deep Reinforcement learning (DRL) and optimal control methods have allowed building 
robotic systems that can autonomously discover complex behaviors [93]. DRL algorithms 
based on policy gradients, actor-critic methods and Q-Learning have been used extensively to 
solve a wide range of complex problems with high dimensional state spaces including robotic 
locomotion, autonomous driving, flight simulators and game playing [89], [100], [101].  
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The general goal of reinforcement learning is to learn an optimal policy for making decisions 
on actions that maximize the total amount of rewards that a learning agent receives by 
interacting with the surrounding environment. A schematic diagram of our framework using 
model-based Deep Reinforcement Learning is shown in Figure 4.13. Our approach is based on 
formulating the Gene eXpression Network architecture as a variable length sequence of design 
elements which collectively describe the action of how to construct the full network. Each 
design element describes details about the network blocks in terms of the type of learning layers 
and all associated configuration parameters. By combining all the sequence of design elements, 
we are able to perform the action of constructing a full GeneXNet model whose architecture is 
fully described by the design elements. In order to generate the design elements of our target 
GeneXNet models, we use a Recurrent Neural Network (RNN) to function as a GeneXNet 
model generator, where the output of the RNN units represent each design element. The RNN 
in this framework represents the action policy and is responsible for performing the action of 
generating a GeneXNet model. Once the RNN generates an instance of a GeneXNet model, we 
then proceed to train the model on the multi-tissue cancer tumor dataset as described in the 
previous sections and evaluate the model’s classification performance by calculating the 
accuracy and ROC AUC on the validation dataset. We then use the classification performance 
achieved by the generated GeneXNet model as a reward signal which we feedback into the 
RNN model generator to repeat another iteration of generating a new improved GeneXNet 
model. We use Deep Reinforcement Learning and Policy Gradient optimization to improve the 
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Figure 4.13  Deep Reinforcement Learning Framework 
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action policy by updating the weight parameters of the RNN so that on the next iteration it will 
generate a GeneXNet model architecture with an improved classification performance and 
which can achieve a better accuracy. By repeating the reinforcement learning and optimization 
process over time, our end-to-end learning framework will allow the RNN to learn an optimal 
policy for generating a GeneXNet model that maximizes the total amount of reward signals 
and therefore maximizing the classification performance on the cancer tumor dataset.  
 
 Formulation as a Reinforcement Learning Problem  
In this section we provide the detailed formulation of our Reinforcement Learning task. The 
Reinforcement Learning problem is commonly formulated as a sequential decision problem 
using a Markov Decision Process (MDP) [97]. For each time step 𝑡, where the learner and 
decision maker (or agent) is in a state 𝑠𝑡 ∈ 𝑆, then executes some action 𝑎𝑡 based on a policy 
𝜋. As a result of this action and based on the dynamics of the surrounding environment, in the 
next time step 𝑡 + 1,  the learner transitions to the next state 𝑠𝑡+1 and receives a reward 𝑟𝑡.  
Through this interaction, the sequence of states, actions and rewards represent a trajectory of 
the agent learning. The objective at each time step is to decide on the action that maximizes the 
discounted sum of future rewards. Our approach is based on modelling the action policy πθ 
using a Recurrent Neural Network with weight parameters 𝜃, which is responsible for deciding 
on actions at each time step. The RNN modelling the policy can be represented using a non-
linear function denoted by 𝑓𝜃(𝑠𝑡, 𝜃) which is dependent on the parameters θ such that the 
function takes the current state 𝑠𝑡 and model parameters θ as input, and outputs an  action 𝑎𝑡. 
We formulate our learning problem as a finite Markov Decision Process (MDP) where the 
RNN in our design represents the action policy πθ and the environment is modelled as the 
multi-tissue cancer classifier represented by the GeneXNet. In every iteration, the RNN is 
considered to be in state 𝑠𝑡 and performs an action 𝑎𝑡 to generate a GeneXNet model which is 
trained on the underlying tumor dataset and evaluated on the validation dataset. The 
classification performance of the GeneXNet model is evaluated based on the resulting accuracy 
and ROC AUC which represent the reward. By feeding the reward signal to the RNN and using 
reinforcement learning optimization to update its weights, we transition the RNN into a new 
state which can then generate a new improved GeneXNet model and repeat the process. At 
every iteration, the current weights of the RNN provide a full representation of all previous 
states and therefore satisfying the properties of a Markov Decision Process.  
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By formulating our problem as a finite Markov Decision Process, we can describe the 
dynamics of the environment using the state transition probabilities where each state 𝑠𝑡+1 
depends only on the immediately preceding state 𝑠𝑡 and action 𝑎𝑡. We can then define the 
probability of transition to a certain state 𝑠′ and receiving a reward 𝑟 in terms of the preceding 
state 𝑠 and action 𝑎 as follows: 
 𝑝(𝑠′, 𝑟 | 𝑠, 𝑎) =  Pr{𝑆𝑡+1 =  𝑠
′,  𝑅𝑡 =  𝑟 |  𝑆𝑡 =  𝑠 ,  𝐴𝑡 =  𝑎 } (25) 
where 𝑆𝑡, 𝑅𝑡, 𝐴𝑡 are random variables representing the states, rewards and actions.  
We can also define the expected rewards for being in state 𝑠 and performing action 𝑎 as follows:  
 𝑟(𝑠, 𝑎) =  𝔼[𝑅𝑡 |  𝑆𝑡 =  𝑠 ,  𝐴𝑡 =  𝑎] =  ∑ 𝑟 ∑ 𝑝(𝑠
′, 𝑟 | 𝑠, 𝑎)
𝑠′ ∈ 𝑆𝑟 ∈ ℛ
 (26) 
where 𝔼 denotes the expected value and the double summation represents the expected rewards 
𝑟 ∈  ℛ for being in state 𝑠 and performing action 𝑎, across all the possible states 𝑠′  ∈  𝑆 which 
could result from performing the action 𝑎.  
On every iteration, the reward 𝑟𝑡 at time step 𝑡 can be calculated by evaluating the classification 
performance of the generated 𝐺𝑒𝑛𝑒𝑋𝑁𝑒𝑡𝑡(θ) model on the underlying cancer dataset. The 
classification performance can be evaluated using any of the performance measures such as the 
classification accuracy or ROC AUC or even a weighted combination of both. 
  𝑟𝑡 = 𝐶𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛_𝑃𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒[𝐺𝑒𝑛𝑒𝑋𝑁𝑒𝑡𝑡(θ)] (27) 
where 𝐺𝑒𝑛𝑒𝑋𝑁𝑒𝑡𝑡(θ) represents the GeneXNet model generated by the RNN with weight 
parameters θ at the time step 𝑡. 
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Figure 4.14  Formulation as Reinforcement Learning Problem 
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The actions taken at each time step are based on the action policy πθ which is modelled using 
the RNN with weight parameters 𝜃. We define 𝜋(a|s, 𝜃) as the probability of being in state s 
and performing action a by following the policy with parameters 𝜃:  
 𝜋(a|s, 𝜃)  =  Pr{ 𝐴𝑡 =  𝑎 |  𝑆𝑡 =  𝑠 ,  𝜃𝑡 =  𝜃 } (28) 
Since the policy πθ(𝜏) gives rise to a set of trajectories, we can then define the probability 
πθ(𝜏) = 𝑝θ as the joint probability of obtaining the trajectory of states, actions and rewards 
resulting from following the policy πθ across a time interval of 𝜏 iterations as follows:  
 πθ(𝜏) =  𝑝θ(𝑠1, 𝑎1, … , 𝑠𝜏, 𝑎𝜏) = 𝑝(𝑠1) ∏ πθ(𝑎𝑡|𝑠𝑡). 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
 (29) 
Since the policy πθ(𝜏) gives rise to trajectory probability distributions across states and actions, 
then in order to evaluate the performance of the policy, we can evaluate the rewards of these 
states and actions and sum them over time. We therefore also need to define a value function 
V𝜋(𝑠𝑡) which represents the expected return in rewards when starting in an initial state 𝑠𝑡 and 
following the policy πθ: 
 
V𝜋(𝑠𝑡)  =  𝔼πθ [∑ 𝛾
𝑡 .  𝑟(𝑠𝑡, 𝑎𝑡) | 𝑠𝑡
𝜏
𝑡=1
] (30) 
where 𝑟(𝑠𝑡, 𝑎𝑡) is the reward received at time step 𝑡 when being in state 𝑠 and performing action 
𝑎. The expectation 𝔼πθ denotes the expected value over the probability distribution πθ resulting 
from obtaining the trajectory of states, actions and rewards by following the action policy πθ 
which is represented using a model with parameters 𝜃. The parameter 𝛾𝑡 ∈ [0,1] is a reward 
discount factor which gives preference to current rewards over future rewards. 
We also define an action-value function Q𝜋(𝑠𝑡) which represents the expected return in rewards 
when starting in an initial state 𝑠𝑡 and taking action 𝑎𝑡 and then following the policy πθ: 
 
Q𝜋(𝑠𝑡, 𝑎𝑡)  =  𝔼πθ [∑ 𝛾
𝑡 .  𝑟(𝑠𝑡, 𝑎𝑡) |  𝑠𝑡 , 𝑎𝑡  
𝜏
𝑡=1
] (31) 
Since the only difference between the value function V𝜋(𝑠𝑡) and the action-value function 
Q𝜋(𝑠𝑡) is the action 𝑎𝑡, we can therefore also represent the value function as the expected 
action-value across all possible actions: 
 V𝜋(𝑠𝑡) = 𝔼πθ[Q𝜋(𝑠𝑡, 𝑎𝑡) ] (32) 
VALUE 
FUNCTION 
ACTION-VALUE 
FUNCTION 
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We now define the objective function 𝐽(𝜃) as the expected return in rewards when starting in 
the initial state 𝑠1 and following the action policy πθ as follows: 
 
𝐽(𝜃) = V𝜋(𝑠1) =  𝔼πθ(𝜏) [∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
] (33) 
where 𝔼πθ(𝜏) denotes the expected value with respect to the time period 𝜏, over the probability 
distribution πθ(𝜏), resulting from following the policy πθ and obtaining the trajectory 
distributions of states, actions and rewards. 
Finally, we can then define the objective of our Reinforcement Learning task: which is to 
find the optimal weight parameters 𝜃∗ of the RNN, that would achieve the optimal action policy 
πθ
∗ by maximizing the expected return in rewards resulting from the trajectory of states and 
actions across the time interval of 𝜏 iterations. We formulate our reinforcement learning 
objective as: 
 
     𝜃∗  =  arg 𝑚𝑎𝑥𝜃 𝐽(𝜃) =  arg 𝑚𝑎𝑥𝜃 𝔼πθ(𝜏) [∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
] (34) 
where the optimal parameters 𝜃∗ represent the optimal weight parameters of the RNN that 
would generate the optimal GeneXNet model which maximizes the total amount of reward 
signals and therefore maximizing the classification performance on the cancer tumor dataset. 
Now that we have formulated our Reinforcement Learning objective, we discuss in the next 
section our implementation to find a solution. 
 
 Deep Reinforcement Learning Algorithm 
In this section we provide the detailed formulation of our Deep Reinforcement Learning 
algorithm to find a solution to our learning objective. In our proposed framework, we use a 
RNN to generate different GeneXNet architectures and we train the RNN using RL to find an 
optimal GeneXNet architecture that would maximize the expected classification performance 
on our underlying multi-tissue cancer dataset. Since our approach is based on modelling the 
action policy πθ using the RNN weight parameters 𝜃, this implies that our optimization 
problem is required to learn a complex non-linear policy with a very high dimensional space 
of state/action pairs representing the possible decisions made by the RNN. Given this complex 
constraint, it is not practical to use an algorithm which depends on storing and evaluating value 
functions or policies. Our approach is therefore to formulate our RL algorithm by learning a 
OBJECTIVE 
FUNCTION 
RL 
OBJECTIVE 
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parametrized policy without the need to evaluate action values given the high dimensional 
space of states and actions. Our work is motivated by the Policy Gradient optimization methods 
used in controlling high dimensional robotics systems which use trajectory optimization and 
deep neural networks to learn complex nonlinear policies [94], [95], [96]. We also build on the 
REINFORCE algorithm [98], [99] by following the approach of Monte Carol Policy Gradient 
learning. We first present an outline of our RL algorithm and then we describe the detailed 
implementation. 
Our objective is to learn the optimal action policy πθ modelled by the RNN with weight 
parameters θ. The RNN is a non-linear function approximator whose output generates a 
conditional probability distribution of actions conditioned on input states. Our environment is 
modelled as the multi-tissue cancer classifier represented by the generated GeneXNet model. 
We have defined an objective function 𝐽(𝜃) in (33) as the expected return in rewards when 
starting in the initial state and following the action policy πθ. We also defined our 
reinforcement learning objective in (34) which is to find the optimal parameters 𝜃∗ that would 
achieve the optimal action policy πθ
∗ by maximizing the expected return in rewards. 
 
The outline of our algorithm using Policy Gradient optimization is shown in Figure 4.15 
and is based on the iteration over 3 main steps: Running the policy, Evaluating the policy and 
Improving the policy. 
  Since our environment is modelled as the GeneXNet multi-tissue cancer classifier, 
therefore the state transition distribution 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡) is unknown and the initial state 
distribution 𝑝(𝑠1) is also unknown. In the context of RL, this means that we do not have a 
complete knowledge of our environment. In order to solve this problem, we follow the 
approach of Monte Carlo sampling since it does not require prior knowledge of the 
environment and can learn by experience through interacting with the environment [99].  
Run the Policy 
Monte Carlo sampling 
Evaluate the Policy 
𝐽(𝜃) = 𝔼πθ(𝜏) [∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
] 
Improve the Policy 
𝜃𝑡+1 = 𝜃𝑡 + 𝛼  ∇𝜃𝐽(𝜃𝑡 ) 
Figure 4.15  Outline of GeneXNet Policy Gradient Optimization 
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Accordingly, in order to evaluate and improve our objective function, we use Monte Carlo 
sampling to generate samples of state/action pairs by running our policy πθ and interacting 
with our environment. We sample a set of trajectories of state/action pairs by running our policy 
πθ, where in every iteration, the RNN receives an input which is the current state 𝑠𝑡 of the 
environment and performs an action 𝑎𝑡 to generate a GeneXNet model based on the weight 
parameters representing the policy πθ. We then evaluate the policy by calculating our objective 
function. This is done by training the GeneXNet model on the underlying tumor dataset and 
evaluating the classification performance to produce a reward signal and transition our 
environment into the next state and therefore simulating the unknown state transition 
distribution 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡). The objective function is then calculated by estimating the total 
expected rewards as the average rewards across the generated samples of trajectories. The 
average rewards across our samples provides an unbiased estimate of the expected reward of 
our policy πθ. Now that we have evaluated our policy, our final step is then to improve the 
policy using stochastic gradient ascent. We improve the policy, by estimating the policy 
gradient using the generated samples and updating our model parameters 𝜃 by taking a step in 
the direction of the gradient.  
Now that we have described an outline of our algorithm, we derive the mathematical 
formulations for evaluating and improving the policy. We evaluate the objective function 𝐽(𝜃) 
as the estimate of total expected rewards by calculating the average rewards across the sampled 
trajectories as follows: 
       𝐽(𝜃) = 𝔼πθ(𝜏) [∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
]  ≈  
1
𝑁
∑ ∑ 𝛾𝑡 . 𝑟(𝑠𝑖,𝑡, 𝑎𝑖,𝑡)
𝜏
𝑡=1
𝑁
𝑖=1
 (35) 
where 𝑁 represents the number of samples generated by running our policy πθ and 𝑟(𝑠𝑖,𝑡, 𝑎𝑖,𝑡) 
is the reward of sample 𝑖 resulting for being in state 𝑠𝑖,𝑡 and performing action 𝑎𝑖,𝑡. The time 
interval 𝜏 represents the number of output design elements that the RNN needs to predict, in 
order to generate a full GeneXNet model. The reward is calculated by evaluating the 
classification performance of the generated GeneXNet model on the underlying cancer dataset. 
In order to maximize the objective function 𝐽(𝜃), we improve the policy by using stochastic 
gradient ascent. We update our RNN weight parameters 𝜃 in the direction of the gradient: 
 𝜃𝑡+1 = 𝜃𝑡 + 𝛼  ∇𝜃𝐽(𝜃𝑡 ) (36) 
where ∇𝜃𝐽(𝜃𝑡 ) is the gradient of the objective function 𝐽(𝜃) with respect to the RNN model 
parameters 𝜃.  
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Now, in order to update our model parameters using the above equation, we need to calculate 
the gradient of the objective function ∇𝜃𝐽(𝜃𝑡 ). We describe the derivation of the gradient 
calculation in the following steps. Starting with the objective function in (35), we expand the 
expectation 𝔼πθ(𝜏) as the summation with respect to the time period 𝜏 over the probability 
distribution πθ(𝜏) and then calculate the gradient as follows: 
∵ 𝐽(𝜃) = 𝔼πθ(𝜏) [∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
] 
                         = ∑ [ πθ(𝜏) ∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
]
𝜏
 (37) 
∴  ∇𝜃 𝐽(𝜃𝑡 )  =  ∇𝜃  ∑ [ πθ(𝜏) ∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
]
𝜏
 
                         = ∑ [ ∇𝜃 πθ(𝜏) ∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
]
𝜏
 (38) 
Now, we need to expand the probability distribution πθ(𝜏) so we can calculate the gradient. In 
order to do that, we can represent the term  ∇𝜃 πθ(𝜏) in an equivalent form by multiplying the 
numerator and denominator with πθ(𝜏): 
 ∵  ∇𝜃 πθ(𝜏) =  
 πθ(𝜏) .  ∇𝜃 πθ(𝜏)
πθ(𝜏)
  𝑎𝑛𝑑 ∵  ∇𝜃  log 𝑓(𝑥) =  
 ∇𝜃 𝑓(𝑥) 
𝑓(𝑥)
 
  ∴  ∇𝜃 πθ(𝜏) =   πθ(𝜏)  .  ∇𝜃 log πθ(𝜏) (39) 
By inserting (39) into (38) and then by collapsing the expectation 𝔼πθ(𝜏) once again: 
∴  ∇𝜃𝐽(𝜃𝑡 )  = ∑ [ πθ(𝜏) . ∇𝜃 log πθ(𝜏) ∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
]
𝜏
 
                    = 𝔼πθ(𝜏) [  ∇𝜃 log πθ(𝜏) ∑ 𝛾
𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
] (40) 
 
From (35) 
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From (29) we can expand the probability distribution πθ(𝜏) and then apply the log 
 ∵ πθ(𝜏) =  𝑝θ(𝑠1, 𝑎1, … , 𝑠𝜏, 𝑎𝜏) = 𝑝(𝑠1) ∏ πθ(𝑎𝑡|𝑠𝑡). 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
 (41) 
 ∴ log πθ(𝜏) = log 𝑝(𝑠1) +  ∑ log πθ(𝑎𝑡|𝑠𝑡) + log 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
 (42) 
 ∴ ∇𝜃 log πθ(𝜏) =  ∇𝜃 log 𝑝(𝑠1) +  ∑ ∇𝜃 log πθ(𝑎𝑡|𝑠𝑡) + ∇𝜃 log 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
 (43) 
But both the terms ∇𝜃 log 𝑝(𝑠1) and ∇𝜃 log 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡) are equal to zero as they do not rely 
on the policy parameters θ and therefore we get the simpler form: 
 ∴ ∇𝜃 log πθ(𝜏) =  ∑ ∇𝜃 log πθ(𝑎𝑡|𝑠𝑡)
𝜏
𝑡=1
 
 
(44) 
By inserting (44) into (40) , we can now express the gradient of the objective function as: 
 ∴  ∇𝜃𝐽(𝜃𝑡 )  = 𝔼πθ(𝜏) [ (∑ ∇𝜃 log πθ(𝑎𝑡|𝑠𝑡)
𝜏
𝑡=1
) (∑ 𝛾𝑡 . 𝑟(𝑠𝑡, 𝑎𝑡)
𝜏
𝑡=1
)] (45) 
We can then evaluate the gradient of the objective function ∇𝜃𝐽(𝜃𝑡 ) using the samples 
generated from our Monte Carlo sampling. We calculate the average across the sampled 
trajectories as follows: 
            ∴  ∇𝜃𝐽(𝜃𝑡 ) ≈  
1
𝑁
∑ [ (∑ ∇𝜃 log πθ(𝑎𝑖,𝑡|𝑠𝑖,𝑡)
𝜏
𝑡=1
) (∑ 𝛾𝑡 . 𝑟(𝑠𝑖,𝑡, 𝑎𝑖,𝑡)
𝜏
𝑡=1
)]
𝑁
𝑖=1
 (46) 
Now the formula in (46) is exactly what we need. It provides an expression for calculating the 
gradient of the objective function which does not depend on the unknown state transition 
distribution of the environment 𝑝(𝑠𝑡+1|𝑠𝑡, 𝑎𝑡). The formula only depends on two terms which 
are known and can be readily evaluated from our framework. The first term depends on the 
parametrized policy πθ(𝑎𝑡|𝑠𝑡) which is given by the RNN. The second term depends on the 
rewards which we can calculate by evaluating the classification performance of the generated 
GeneXNet model. 
GRADIENT  
OF 
OBJECTIVE 
FUNCTION 
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One problem with (46) which uses Monte Carlo sampling to estimate the policy gradient is 
that it can have a high variance resulting from the variation in reward values and their 
estimation [96]. We further improve on our policy gradient evaluation by adopting two 
methods to decrease the variance.  
The first approach we use to reduce the variance is by decreasing the overall number of 
reward terms. We make use of time causality as in [98] which implies that the policy at time 𝑡′ 
cannot affect any rewards in the past at time 𝑡 for all 𝑡 < 𝑡′. Therefore, at any time step 𝑡, we 
can ignore the earlier rewards and still evaluate an unbiased estimate for the policy gradient 
[98]. Since the sum of rewards will now be smaller, it will also reduce the variance in the policy 
gradient. By applying this to (46), the policy gradient can now be calculated as follows: 
 ∇𝜃𝐽(𝜃𝑡 ) ≈  
1
𝑁
∑  ∑ ∇𝜃 log πθ(𝑎𝑖,𝑡|𝑠𝑖,𝑡)
𝜏
𝑡=1
( ∑ 𝛾𝑡
′
 . 𝑟(𝑠𝑖,𝑡′ , 𝑎𝑖,𝑡′)
𝜏
𝑡′= 𝑡
)
𝑁
𝑖=1
 (47) 
The second approach to reduce the variance is by subtracting a baseline amount from the 
expected reward of the trajectory [99]. The baseline can be calculated as the average reward 
across the samples. This is equivalent to estimating how much the total reward of the trajectory 
is better over the average reward of the samples. Now we can express the final formula for 
evaluating the policy gradient as: 
 ∇𝜃𝐽(𝜃𝑡 ) ≈  
1
𝑁
∑  ∑ ∇𝜃 log πθ(𝑎𝑖,𝑡|𝑠𝑖,𝑡)
𝜏
𝑡=1
( ∑ 𝛾𝑡
′
 . 𝑟(𝑠𝑖,𝑡′ , 𝑎𝑖,𝑡′)
𝜏
𝑡′= 𝑡
− 𝑏)
𝑁
𝑖=1
 (48) 
where b is the average reward across the samples: 
 𝑏 =
1
𝑁
 ∑ 𝑟𝑖
𝑁
𝑖=1
 (49) 
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The outline for our full Policy Gradient Reinforcement Learning algorithm is as follows: 
 
Algorithm 4.4  GeneXNet Policy Gradient Reinforcement Learning 
1 Input: RNN Action Policy:   𝑅𝑁𝑁(𝜃) =  πθ(a|s, 𝜃),  
      Number of GeneXNet Design Elements: 𝜏, 
      Learning Rate: 𝛼 
2 Output: Optimal parameters 𝜃∗ for Optimal Action Policy  𝑅𝑁𝑁(𝜃∗)  
3 Init RNN weight parameters 𝜃 
 # (Run the policy 𝝅𝜽) 
4 Perform Monte Carlo sampling to generate a set of 𝑁  
trajectories across a time period 𝜏: (𝑠1, 𝑎1, 𝑟1, … , 𝑠𝜏, 𝑎𝜏, 𝑟𝜏)  
5 For (each sample 𝑖 = 1 𝑡𝑜 𝑁): 
6 For (each time step 𝑡 = 1 𝑡𝑜 𝜏): 
7 Generate a new GeneXNet model from 𝑅𝑁𝑁(𝜃) based on 
the action policy πθ  
 𝐺𝑒𝑛𝑒𝑋𝑁𝑒𝑡𝑡(θ) =  πθ(𝑎𝑖,𝑡|𝑠𝑖,𝑡) 
8 Train the GeneXNet model on the underlying Cancer 
tumor dataset and evaluate the classification 
performance to produce a reward 
                 𝑟𝑡 = 𝐶𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛_𝑃𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒[𝐺𝑒𝑛𝑒𝑋𝑁𝑒𝑡𝑡(θ)] 
           # (Evaluate the Policy 𝝅𝜽)  
9 Calculate the gradient of the objective function:   
∇𝜃𝐽(𝜃𝑡 ) ≈  
1
𝑁
∑  ∑ ∇𝜃 log πθ(𝑎𝑖,𝑡|𝑠𝑖,𝑡)
𝜏
𝑡=1
( ∑ 𝛾𝑡
′
 . 𝑟(𝑠𝑖,𝑡′ , 𝑎𝑖,𝑡′)
𝜏
𝑡′= 𝑡
− 𝑏)
𝑁
𝑖=1
 
 # (Improve the Policy 𝝅𝜽) 
10 Update RNN weight parameters 𝜃𝑡+1 = 𝜃𝑡 + 𝛼  ∇𝜃𝐽(𝜃𝑡 ) 
11 Next 𝑡 
12 Next 𝑖 
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 Recurrent Neural Network Architecture for GeneXNet Model Generation   
In our proposed DRL framework, we use a RNN to generate different GeneXNet 
architectures and we train the RNN using Reinforcement Learning to find an optimal 
GeneXNet architecture that would maximize the expected classification performance on our 
underlying multi-tissue cancer dataset. In the previous sections we described our Deep 
Reinforcement Learning framework and provided the detailed formulation of our RL 
algorithm. In this section we describe the detailed design of our Recurrent Neural Network 
(RNN) which is used to generate the different GeneXNet model architectures. The design of 
our proposed RNN is shown in Figure 4.16. We build on the methods used for constructing 
deep Recurrent Neural Networks with hidden-to-hidden recurrent connections [102]. The 
motivation in using a RNN as a generator for model architectures, is that it provides us the 
capability to generate architectures with variable length configurations in the form of a 
sequence of design elements that determine the structure and connectivity of our GeneXNet 
models. We use the RNN to generate a variable length sequence of design elements which 
collectively describe the full GeneXNet architecture. Each design element describes details 
about the network blocks in terms of the type of learning layers and all associated configuration 
parameters. By combining all the sequence of design elements, we are able to construct the 
GeneXNet model whose architecture is fully described by the design elements. The sequence 
of design elements generated by the RNN includes: 
(1) Number of Dense Layers; (2) Number of Residual Layers; (3) Number of Conv. Filters; 
(4) Filter Size; (5) Stride Size; (6) Padding Size; and (7) Pooling Size.    
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Figure 4.16  Recurrent Neural Network Architecture 
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Our proposed RNN represents a discrete time dynamical system which operates on a 
sequence with input 𝑥t, desired output 𝑦t and hidden state ℎt where 𝑡 represents the time step. 
The RNN can be formulated using the following recurrence equations: 
 
ℎt  =  𝑓ℎ(ℎt−1 , 𝑥t , 𝜃ℎ) (50) 
 𝑦ො𝑡  =  𝑓𝑜(ℎt , 𝑥t , 𝜃𝑜) (51) 
where 𝑦ො𝑡 is the network output,  𝑓ℎ is the hidden-to-hidden state transition function with 
parameters 𝜃ℎ and 𝑓𝑜 is the output function with parameters 𝜃𝑜. 
The RNN maps the input sequence of values 𝑥t to a corresponding sequence of output values 
using the softmax function. The design of our RNN includes four different types network of 
connections. The first are input-to-hidden connections which are parameterized by a weight 
matrix 𝑈. The second are hidden-to-hidden recurrent connections parameterized by a weight 
matrix 𝑊. The third are hidden-to-output connections parameterized by the weight matrix V. 
The fourth are output-to-input connections that do not have any weight parameters to be learned 
and feed the output at each time step to the input of the next step. The forward propagation of 
the RNN can therefore be formulated using the following recurrence equations: 
 
ℎt  =  𝑡𝑎𝑛ℎ( 𝑊. ℎt−1 + 𝑈. 𝑥t + 𝑏) (52) 
 𝑦ො𝑡  =  𝑠𝑜𝑓𝑡𝑚𝑎𝑥( 𝑉. ℎt + 𝑐) (53) 
where 𝑊, 𝑈, 𝑉 are the weight matrices and the parameters 𝑏 and 𝑐 are the bias vectors. 
We define the Error objective function 𝐸(𝑊) as the average over the training data given by: 
 𝐸(𝑊, 𝑈, 𝑉 ) =  
1
𝑁
∑  ∑ 𝐸𝑖[𝑦ො𝑡
𝑖 , 𝑦𝑡
𝑖]
𝑇𝑖
𝑡=1
𝑁
𝑖=1
 (54) 
where 𝑁 represents the number of training samples, 𝑇𝑖 represents the time interval for the 𝑖
𝑡ℎ 
training sample, 𝑦ො𝑡
𝑖, 𝑦𝑡
𝑖 are the predicted output and target output for the 𝑖𝑡ℎ training sample, 𝐸𝑖 
represents the cross entropy loss for the 𝑖𝑡ℎ training sample and 𝑊, 𝑈, 𝑉 represents the weight 
parameters to be learned. 
In order to train our RNN and learn the weight parameters, we implement stochastic gradient 
descent (SDG) and backpropagation through time (BPTT) as described in [102], [75]. We also 
experimented with using the LSTM recurrent cell architecture to avoid vanishing and 
exploding gradients [104]. 
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 Visualizing Genomic Relationships of Gene Expressions Across 
Multiple Cancer Tumors 
 
One of the challenges in using deep learning for disease diagnosis, is that deep networks are 
conceived as “black boxes” without much interpretation on how these complex models make 
their decisions [53]. Extensive work has been done to introduce novel visualization techniques 
for deep networks to help understand and interpret their record breaking performance in 
computer vision tasks [52], [53], [65]. The output from these techniques can be interpreted by 
non-experts when studied in conjunction with image or video datasets because they are visually 
comprehensible. Unfortunately, these methods are not directly applicable to genomic datasets 
such as gene expressions, since they cannot be visually rendered in a human-friendly form that 
allows easy interpretations. Our learning system architecture can contribute in solving this 
problem, since it is designed to take full potential of next generation sequencing technologies 
that produce datasets with detailed molecular characterizations of thousands of tumors using 
genome-wide platforms. 
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Figure 4.17  Visualizing genomic relationships of gene expressions 
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We introduce two visualization procedures for better understanding how our proposed deep 
network is performing cancer classification across multiple tumor types. Our methods are 
inspired from the work used to visualize intermediate feature activations for CNNs used in 
image classification [65]. We also build on the methods for Class Activation Maps (CAM) 
[52], [53] which visualize heatmaps of class activations for deep networks used in image 
classification and captioning. The outline of the procedures is shown in Figure 4.17 and 
described in the next sections. The results of applying these procedures to the underlying 
dataset is described in the experiments. 
 
 Visualizing Class-Discriminative Localization Maps of Gene Expressions 
We introduce a visualization method which uses the gradient information flowing into the 
last convolutional layer of the GeneXNet model to produce gene localization maps highlighting 
the important regions in the gene expressions which influenced the resulting tumor class 
prediction. The gene expression data used to train the network is sparse and very high in 
dimensionality since it represents a snapshot of the whole transcriptome rather than a 
predetermined subset of genes. By identifying a class-discriminative localization map in the 
gene expressions, we can identify the subset of genes driving cancer progression and resulted 
in the model’s tumor class prediction. We refer to this localization map as a Gene-Class-
Activation-Map (Gene-CAM). For each tumor type, the Gene-CAM is a representation of the 
discriminative genes used by the network to correctly classify the tumor. The procedure can be 
summarized as follows: 
We build a multi-tissue classifier by training our GeneXNet model with the genomic 
signatures of multiple tumor types across multiple sites using the underlying dataset. We group 
the data by tumor type and feed the trained network with each of the samples one by one to 
produce a prediction. For a GeneXNet with 𝐿 blocks, the network will produce a set of 
intermediate activation feature maps as the output of each block.  Let 𝐹𝑙 represent the output 
feature maps of the 𝑙𝑡ℎ block with dimensions (width: 𝑋𝑙, height: 𝑌𝑙, depth: 𝐷𝑙). This volume 
represents the molecular features learned by the network that will be activated when matched 
with similar patterns in the input gene expressions of a given tumor sample.  
Let 𝑓𝐿
𝑘(𝑖, 𝑗) represent the 𝑘𝑡ℎ feature map for the last block at special location (𝑖, 𝑗). Since 
the network uses Global Average Pooling (GAP) [54] before the final Softmax layer to 
calculate the spatial average of the feature maps, then the classification score 𝑠𝑐 for tumor type 
𝑐 which is used as input to the softmax can be written as: 
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 𝑠𝑐 = ∑ 𝑤𝑘
𝑐
𝐷𝐿
𝑘
 ∑ ∑ 𝑓𝐿
𝑘(𝑖, 𝑗)
𝑌𝐿
𝑗
𝑋𝐿
𝑖
 (55) 
where  𝑐 is the tumor class, 𝑤𝑘
𝑐 represents the weights for class 𝑐 with respective to feature map 
𝑘 and 𝐷𝐿 is the number of feature maps in the last block before the GAP layer each with width 
𝑋𝐿 and height 𝑌𝐿. 
To generate the Gene-Class Activation Map, we redefine the weights of each feature map 
with respect to a class as 𝛼𝑘
𝑐  by computing the gradient of the score of each class with respect 
to each feature map as follows: 
 𝛼𝑘
𝑐 =  
1
𝑋𝐿 . 𝑌𝐿
  ∑ ∑  
𝜕𝑠𝑐
𝜕𝑓𝑖𝑗
𝑘
𝑌𝐿
𝑗
𝑋𝐿
𝑖
 (56) 
where the new weights 𝛼𝑘
𝑐  represent the importance of each feature map for class 
discrimination. The Gene-Class-Activation-Map (Gene-CAM) is then calculated as: 
 𝐺𝑒𝑛𝑒_𝐶𝐴𝑀𝑐(𝑖, 𝑗) =  𝑅𝑒𝐿𝑈 [∑ 𝛼𝑘
𝑐  .
𝐷𝐿
𝑘
𝑓 
𝑘(𝑖, 𝑗)] (57) 
The resulting map with dimensions (𝑋𝐿, 𝑌𝐿) represents a gene localization for the given tumor 
sample that captures the discriminative regions in the gene expression input matrix which 
influenced the prediction of the tumor class. The ReLU [49] is applied to obtain only the 
features that have a positive contribution to the correct class [53].  
Finally, to visualize the Gene-CAM we resize it using up-sampling and overlay it against 
the input gene expression matrix. The resulting heatmap highlights the important regions in the 
gene expression input matrix which in turn helps identify the subset of genes that are possibly 
influencing the Cancer tumor and resulted in the model’s prediction.  
 
 Visualizing Molecular Clusters of Intermediate Feature Maps 
We introduce a visualization procedure for observing the evolution of molecular clusters 
formed by intermediate gene expression feature maps learned by the network. The genetic 
signatures learned by the feature maps in the deep layers make the network capable of 
representing complex genetic alterations shared by tumors across different tissue types. 
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Visualizing the molecular clusters of gene expressions provides more insight on how the 
network is learning small meaningful relationships between the genes which in turn describe 
the characteristic influencing the Cancer tumor. We demonstrate how this visualization 
provides the opportunity to study the genomic relationships of gene expressions across multiple 
cancer tissue types. This is motivated by recent studies which have performed an integrated 
multiplatform analysis across multiple cancer types that have revealed molecular classification 
within and across tissues of origin [5], [7]. The procedure can be summarized as follows: 
 
As in the previous section, for a GeneXNet with 𝐿 blocks, let 𝐹𝑙 represent the output feature 
maps of the 𝑙𝑡ℎ block. Let 𝑓𝑙
𝑘(𝑖, 𝑗) represent the 𝑘𝑡ℎ feature map for the 𝑙𝑡ℎ block at special 
location (𝑖, 𝑗). We apply Global Average Pooling (GAP) [54] to each of the intermediate 
feature maps after each block to convert the volume 𝐹𝑙 into a 1-dimensional feature vector 𝐹𝑙
′  
with dimensions (1, 1, 𝐷𝑙) as follows: 
 𝑓𝑙
′ 𝑘(𝑖, 𝑗) =
1
𝑋𝑙. 𝑌𝑙
 ∑ ∑ 𝑓𝑙
𝑘(𝑖, 𝑗)
𝑌𝑙
𝑗
𝑋𝑙
𝑖
 (58) 
 𝐹𝑙
′ = [ 𝑓𝑙
′ 𝑘(𝑖, 𝑗) ]  ∀ 𝑘 ∈ {1, . . , 𝐷𝑙} (59) 
where 𝐷𝑙 is the number of feature maps in the  𝑙
𝑡ℎ block each with width 𝑋𝑙 and height 𝑌𝑙. 
The feature vector 𝐹𝑙
′  represents the spatial average of the feature maps produced by each filter 
in the convolutional layer. The intuition behind using GAP is due to its ability to produce a 
generic localizable deep representation of the features which can be used for class 
discrimination [53]. 
We stack together all the feature vectors at the 𝑙𝑡ℎ block across all 𝑁 tumor samples to 
produce what we refer to as a Gene Feature Map (𝐺𝑒𝑛𝑒_𝑀𝑎𝑝𝑙
 ) of dimensions (𝐷𝑙  , 𝑁):  
 𝐺𝑒𝑛𝑒_𝑀𝑎𝑝𝑙
 = [𝐹𝑙
′ (𝑛)𝑇]  ∀ 𝑛 ∈ {1, . . , 𝑁} (60) 
The resulting matrix stores the collective class-discriminative localization maps for the gene 
expressions at the 𝑙𝑡ℎ block across all the tumor types. It also represents the collective genetic 
signatures learned by the feature maps shared by tumors across different organ sites. 
Finally, we perform a consensus hierarchical clustering [70] of the gene feature map 
𝐺𝑒𝑛𝑒_𝑀𝑎𝑝𝑙
  to generate a 𝐺𝑒𝑛𝑒_𝐶𝑙𝑢𝑠𝑡𝑒𝑟_𝑀𝑎𝑝𝑙
  which is a molecular clustering that groups 
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each of the tumor types together based on the class discriminative gene localizations extracted 
from the gene expressions. Consensus clustering is specifically tailored for gene expression 
data and is based on resampling to reach a consensus across multiple runs of a clustering 
algorithm and assess the stability of the discovered clusters [69].  
By visualizing a heatmap of the resulting clusters, we can observe the evolution of molecular 
clusters formed by intermediate gene expression feature maps learned by the network. 
Visualizing the molecular clustering helps in revealing the genomic relationships and high-
level structures of gene expressions across multiple cancer tumor types that appeared 
influential in the cancer tumor progression beyond the standard grouping by anatomical organ 
site. The results of applying the visualization procedures to the underlying dataset are described 
in the experiments. 
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CHAPTER 5   
 EXPERIMENTS 
 
 Datasets 
Our objective was to design a comprehensive multi-tissue Cancer classifier capable of 
detecting complex types of genetic alterations by learning the genomic signatures of whole-
transcriptome wide gene expressions across multiple cancer tissue types. To achieve this 
objective, the datasets we selected for our experiments included a total of 11,093 human 
samples for mRNA gene expression quantification, which were collected from 26 different 
human anatomical sites of origin and covering 33 different Cancer tumor types. The datasets 
were obtained from “The Cancer Genome Atlas” (TCGA) [38] and generated by means of 
Total RNA sequencing using Illumina based systems [5]. Each individual human sample 
represents the whole transcriptome and includes a total of 60,483 genes annotated against a 
reference genome. The patients included both males and females and the biospecimens were 
collected from tumor tissue, adjacent normal tissue and normal whole blood samples. Table 
5.1 shows a listing of the 33 cancer tumor types we used in our experiments together with the 
associated human sites of origin and the number of human samples available for each tumor 
type. One of the biggest challenges in using this dataset is the very small number of human 
samples in each of the tumor types, compared to the very large number of genes. Most of the 
tumor types only have several hundred samples and some even have less than a hundred 
samples while we have a total of 60,483 genes for each sample. 
TCGA is a comprehensive atlas of cancer genomic profiles which includes the molecular 
characterization of over 20,000 primary cancer and matched normal samples [38]. TCGA uses 
next generation sequencing (NGS) methods such as DNA and RNA sequencing to generate 
cancer profiles in multiple various genome-wide platforms including DNA (DNA methylation, 
exome sequencing and copy number), RNA (mRNA and microRNA sequencing) and other 
forms of relevant cancer sets of proteins [5]. The RNA-Sequencing experiment consists of 
isolating RNA, converting it to complementary DNA (cDNA), then preparing the sequencing 
library and sequencing it on a NGS platform [22]. The expression of genes are quantified by 
generating the FASTQ-format files which contain reads sequenced from the NGS platform and 
then aligning these reads to an annotated reference genome [38].   
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The gene expression values we used to generate our datasets are based on the read counts 
measured on a gene level and then normalized using the Fragments Per Kilobase of transcript 
per Million mapped reads (FPKM) [38]. The formula for FPKM normalization is defined in 
(13) where 𝑅𝐶𝑔 are the number of genes mapped to the gene, 𝑅𝐶𝑝𝑐 are the number of reads 
mapped to all protein coding genes and 𝐿 is the length of the gene in base pairs. 
 𝐺𝑒𝑛𝑒 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 =  𝐹𝑃𝐾𝑀 =  
𝑅𝐶𝑔 ∗  10
9
𝑅𝐶𝑝𝑐 ∗ 𝐿
 (61) 
We transform the gene expression data in a format that makes it suitable as input to our model. 
We represent the gene expressions in an equivalent 2D matrix of dimensions (60,483, 11,093) 
as in Figure 4.2. Each column represents a human sample and each row represents a single 
gene. We convert each human sample into an equivalent 3D volume of genes with dimensions 
(142, 142, 3). The full dataset for all the 11,093 samples is represented by the 4D input matrix 
with dimensions (11,903, 142, 142, 3) to make it suitable as input to our GeneXNet model. 
Organ Site  Cancer Tumor Type(s) Total 
Samples 
Adrenal 
Gland 
Adrenocortical carcinoma 
(ACC), Pheochromocytoma 
and Paraganglioma (PCPG) 
265 
Bile Duct Cholangiocarcinoma 
(CHOL) 
45 
Bladder Bladder Urothelial 
Carcinoma (BLCA) 
433 
Bone 
Marrow 
Acute Myeloid Leukemia 
(LAML) 
151 
Brain Glioblastoma multiforme 
(GBM), Brain Lower Grade 
Glioma (LGG) 
703 
Breast Breast invasive carcinoma 
(BRCA) 
1222 
Cervix Cervical squamous cell 
carcinoma and endocervical 
adenocarcinoma (CESC) 
309 
Colorectal Colon adenocarcinoma 
(COAD), Rectum 
adenocarcinoma (READ) 
698 
Esophagus Esophageal carcinoma 
(ESCA) 
173 
Eye Uveal Melanoma (UVM) 80 
Head and 
Neck 
Head and Neck squamous 
cell carcinoma (HNSC) 
546 
Kidney Kidney Chromophobe 
(KICH), Kidney renal clear 
cell carcinoma (KIRC), 
Kidney renal papillary cell 
carcinoma (KIRP), 
1021 
 
Organ Site  Cancer Tumor Type(s) Total 
Samples 
Liver Liver hepatocellular 
carcinoma (LIHC) 
424 
Lung Lung adenocarcinoma 
(LUAD), Lung squamous 
cell carcinoma (LUSC) 
1145 
Lymph 
Nodes 
Lymphoid Neoplasm 
Diffuse Large B-cell 
Lymphoma (DLBC) 
48 
Ovary Ovarian serous 
cystadenocarcinoma (OV) 
379 
Pancreas Pancreatic 
adenocarcinoma (PAAD) 
182 
Pleura Mesothelioma (MESO) 86 
Prostate Prostate adenocarcinoma 
(PRAD) 
551 
Skin Skin Cutaneous 
Melanoma (SKCM) 
472 
Soft Tissue Sarcoma (SARC) 265 
Stomach Stomach adenocarcinoma 
(STAD) 
407 
Testis Testicular Germ Cell 
Tumors (TGCT) 
156 
Thymus Thymoma (THYM) 121 
Thyroid Thyroid carcinoma 
(THCA) 
568 
Uterus Uterine Corpus 
Endometrial Carcinoma 
(UCEC), Uterine 
Carcinosarcoma (UCS) 
 
 
643 
(ALL Sites) (All Tumors) 11,093 
 
Table 5.1  Multi-tissue Cancer Tumor Dataset used in our experiments. The dataset includes 33 different 
cancer tumor types across 26 different anatomical organ sites. 
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 Classification Experiments 
Our experiments demonstrate how the design of our Gene eXpression Network (GeneXNet) 
can be used as a general end-to-end learning system for classification across multiple cancer 
tissue types without performing the prerequisite process of gene feature selection. We also 
demonstrate how our model can specifically target the complex nature of the whole-
transcriptome gene expression data and addresses the lack of training samples, without 
suffering from severe overfitting in comparison to using the current state-of-the-art deep CNN 
models which have been designed specifically for computer vision tasks. 
We perform several different multi-class and binary classification tasks. For binary 
classification we predict whether the given sample represents a tumor versus a normal tissue. 
For multi-class classification we predict for a given sample the type of Cancer tumor within 
each anatomical site of origin. The following are details of the classification experiments: 
 Experiment 1 - Multi-tissue Multi-class classification 
We build a multi-tissue multi-class classifier by training our model using ALL the data which 
includes the genomic signatures from 26 organ sites covering 33 tumor types. 
 Experiment 2 - Multi-Tumor Binary classification 
We build a multi-tumor binary classifier for each individual organ site. We group the data by 
each individual site and train each model separately. For this task we selected the organ sites 
that relatively had the greatest number of samples compared to the other sites (at least 400 
samples per site). These included 11 sites as shown in Table 5.2. 
 Experiment 3 - Comparison between Transfer Learning and Full Training 
We repeat the second experiment, but this time we perform performing transfer learning using 
the weights of the pre-trained model from the first experiment. The objective was to compare 
the performance between transfer learning using a pre-trained model and full training. We 
evaluate whether finetuning the pre-trained model was able to achieve a comparable 
performance in comparison to models which were fully trained. 
 Experiment 4 – Transfer Learning for Tumors Lacking Sufficient Training Data 
We use transfer learning to build binary classifiers for the organ sites with the least number of 
samples which did not have sufficient data to be trained independently. We start with the pre-
trained model from the first task and use the data from each site separately to finetune the pre-
trained model. These included Bile Duct and Esophagus which only had 45 and 147 samples 
respectively.  
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 Experiment 5 – Comparison between GeneXNet & State-of-the-art models 
We evaluate the multi-tissue classification performance of our GeneXNet model in 
comparison with some of the current state-of-the-art deep CNN models specifically designed 
for computer vision tasks. We perform the same multi-class classification in experiment 1 using 
all the data but replacing our model with the publicly available implementations of ResNet 
[46],[58], DenseNet [41], NasNet [40] and MobileNet [39],[43].   
 
 Experiment 6 – Comparison between different GeneXNet Architectures 
We evaluate the multi-tissue classification performance of our GeneXNet model with 
different architectures and sizes by tuning the parameters 𝜃𝐷, 𝜃𝑅 with values (0, 0.25, 0.5 and 
1) and 𝜃𝑘 with values (32, 64). These parameters define the percentage of dense and residual 
sub-blocks in the network and the number of filters used in the convolution layers as described 
in section 4.5. 
 
Organ Site 
 
Cancer Tumor Type(s) Total Samples 
Bladder Bladder Urothelial Carcinoma (BLCA) 433 
Breast Breast invasive carcinoma (BRCA) 1222 
Colorectal Colon adenocarcinoma (COAD),  
Rectum adenocarcinoma (READ) 
698 
Head & Neck Head and Neck squamous cell carcinoma (HNSC) 546 
Kidney Kidney Chromophobe (KICH),  
Kidney renal clear cell carcinoma (KIRC),  
Kidney renal papillary cell carcinoma (KIRP) 
1021 
Liver Liver hepatocellular carcinoma (LIHC) 424 
Lung Lung adenocarcinoma (LUAD),  
Lung squamous cell carcinoma (LUSC) 
1145 
Prostate Prostate adenocarcinoma (PRAD) 551 
Stomach Stomach adenocarcinoma (STAD) 407 
Thyroid Thyroid carcinoma (THCA) 568 
Uterus Uterine Corpus Endometrial Carcinoma (UCEC),  
Uterine Carcinosarcoma (UCS) 
643 
 
Table 5.2  Multi-Tumor Binary Classification Dataset used in our experiments. The dataset includes 11 
Individual Organ Sites that relatively had the greatest number of samples 
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 Training, Optimization and Evaluation 
We treat our dataset as a very scarce and valuable resource since the biggest challenge in 
using the underlying dataset to train our deep models is the very small number of available 
tumor samples compared to the very large number of genes. We use stratified random sampling 
to divide our dataset into 85% for training/validation and 15% for final testing. We train all our 
models using stratified k-fold cross-validation experimenting with different fold sizes. We use 
the validation data to optimize the hyperparameters of our models while the test data is strictly 
used only once to evaluate the final performance of each model.  
Training a deep multi-layer CNN architecture like GeneXNet is a very complex 
optimization problem as it involves non-convex loss functions [67]. Adjusting the weights of 
the network to reduce the classification error requires an optimization algorithm capable of 
adapting the learning rate and leveraging information in the Hessian matrix of the loss function 
[62]. Among the challenges we faced in model optimization is the very high dimensional 
landscape of the network weight space resulting from training the network with the whole-
transcriptome wide gene expressions for every tumor sample. To overcome these problems, we 
train our model using mini-batch Stochastic Gradient Descent (SDG) with an adaptive learning 
rate optimization algorithm  [62]. We experiment with Adam [50], AdaGrad [51] and RMSprop 
[62]. We start with a learning rate of 1e-4 and divide it by half when the validation loss plateaus 
for more than 50 epochs.  
We evaluate the classification performance of our GeneXNet models using the receiver 
operating characteristics (ROC) curves [68]. For all our experiments across each of the cancer 
tumor types, we report the average classification accuracy and ROC Area Under the Curve 
(AUC) on the Test dataset. The ROC AUC has an advantage of being less sensitive to changes 
in class distribution as it summarizes the performance over a range of tradeoffs between the 
true positive and false positive rates [68]. To overcome any potential impact on the 
classification performance due to class imbalance, we experimented with two different 
methods for addressing class imbalance. We used Synthetic Minority Over-sampling [109] and 
Adaptive Synthetic Sampling [110]. 
VAL (17%)
SPLIT 1 TRAIN TRAIN TRAIN TRAIN VAL
SPLIT 2 TRAIN TRAIN TRAIN VAL TRAIN
SPLIT 3 TRAIN TRAIN VAL TRAIN TRAIN
SPLIT 4 TRAIN VAL TRAIN TRAIN TRAIN
SPLIT 5 VAL TRAIN TRAIN TRAIN TRAIN
TRAINING (68%)
TRAINING & VALIDATION (85 %)
ALL DATA       (26 ORGAN SITES, 33 TUMOR TYPES)
TEST (15 %)
 
Figure 5.1  Training with K-Fold Cross Validation 
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 Deep Reinforcement Learning to Discover the Optimal GeneXNet 
Architecture 
For all our experiments, the objective was to discover and automatically learn the optimal 
Gene eXpression Network architecture together with the associated optimal hyperparameters 
that would maximize the multi-tissue classification performance on our cancer tumor dataset. 
We build our proposed end-to-end Deep Reinforcement Learning framework and we execute 
our GeneXNet Policy Gradient Reinforcement Learning algorithm as described in section 4.9. 
 
 We use our proposed RNN as a GeneXNet model generator. In each iteration we use the 
RNN to generate a different GeneXNet architecture by generating a variable length sequence 
of design elements which collectively describe the full network architecture. Each design 
element describes details about the network blocks in terms of the type of learning layers and 
all associated configuration parameters as described in section 4.5. Once the RNN generates 
an instance of a GeneXNet model, we then proceed to perform our classification experiments 
by training the model on the underlying multi-tissue cancer tumor dataset for 100 epochs. Once 
training is completed, we evaluate the model’s classification performance by calculating the 
accuracy and ROC AUC on the validation dataset. We then use the classification performance 
achieved by the generated GeneXNet model as a reward signal which we feedback into the 
RNN model generator to repeat another iteration of generating a new improved GeneXNet 
model. We use our Policy Gradient Reinforcement Learning algorithm as described in section 
4.9 to improve the action policy by updating the weight parameters of the RNN so that on the 
next iteration it will generate a GeneXNet model architecture with an improved classification 
performance and which can achieve a better accuracy.  
Generated 
GeneXNet Model 
Tumor 
Class 
Prediction 
Tumor 
Classification 
Model  
Training 
GeneXNet Model 
Generator 
ACTION 
Generate 
Model 
Classification 
Performance 
REWARD 
State 𝑆𝑡+1 
State 𝑆𝑡 
Reward 𝑅𝑡+1 
𝑅𝑡+1 𝑅𝑡 
ACTION POLICY 
RNN GeneXNet 
Trained 
GeneXNet 
Model 
Input 
Gene Expressions 
Reward 𝑅𝑡 
𝐴𝑡 
Figure 5.2  Deep Reinforcement Learning Experiments to Search for the Optimal GeneXNet Architecture 
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By repeating the reinforcement learning and optimization process over time, our end-to-end 
Deep Reinforcement Learning framework will allow the RNN to learn an optimal policy for 
generating a GeneXNet model that maximizes the total amount of reward signals and therefore 
maximizing the classification performance on the cancer tumor dataset. 
For all our classification experiments, we used our Deep Reinforcement Learning framework 
to generate and train a total of 128 different GeneXNet architectures by generating the different 
network design elements and constructing the networks. The design elements generated by the 
RNN include: (1) Number of Dense Layers; (2) Number of Residual Layers; (3) Number of 
Conv. Filters; (4) Filter Size; (5) Stride Size; (6) Padding Size; and (7) Pooling Size.  
Table 5.3 shows an example of some of the GeneXNet configurations generated by our RL 
algorithm. Some examples of the detailed GeneXNet architectures for the generated models 
based on the design elements are shown in Tables 5.4 - 5.10. Although it was possible to expand 
the search domain and generate much more model architectures, but we only sampled this 
reasonable amount, since training the networks was time consuming. For each experiment, we 
selected one model out of all the 128 GeneXNet architectures which achieved the best 
classification performance on the validation dataset. Finally, we used these selected models to 
evaluate and report our final classification accuracy and ROC AUC on the Test dataset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GeneXNet 
Model 
 
No. of 
Dense 
Layers 
No. of 
Residual 
Layers 
Dense  
Layer 
Flags 
Residual 
Layer 
Flags 
Number of Filters Total 
Parameters 
Total 
Number of 
Layers 
GenexNet-8 - 1 Residual (0,0,0,0) (1,0,0,0) [64,128,256,512] 156,928 8 
GenexNet-14 - 2 Residual (0,0,0,0) (1,1,0,0) [64,128,256,512] 819,968 14 
GenexNet-20 - 3 Residual (0,0,0,0) (1,1,1,0) [64,128,256,512] 3,456,768 20 
GenexNet-26 - 4 Residual (0,0,0,0) (1,1,1,1) [64,128,256,512] 13,973,248 26 
GenexNet-14 1 Dense - (1,0,0,0) (0,0,0,0) [64,128,256,512] 348,800 14 
GenexNet-38 2 Dense - (1,1,0,0) (0,0,0,0) [64,128,256,512] 1,483,136 38 
GenexNet-86 3 Dense - (1,1,1,0) (0,0,0,0) [64,128,256,512] 5,576,575 86 
GenexNet-118 4 Dense - (1,1,1,1) (0,0,0,0) [64,128,256,512] 9,657,216 118 
GenexNet-70 2 Dense 2 Residual (1,0,1,0) (0,1,0,1) [64,128,256,512] 7,361,536 70 
GenexNet-74 2 Dense 2 Residual (0,1,0,1) (1,0,1,0) [64,128,256,512] 15,871,616 74 
GenexNet-20 1 Dense 1 Residual (1,0,0,0) (1,0,0,0) [64,128,256,512] 557,440 20 
GenexNet-50 2 Dense 2 Residual (1,1,0,0) (1,1,0,0) [64,128,256,512] 2,600,576 50 
GenexNet-104 3 Dense 3 Residual (1,1,1,0) (1,1,1,0) [64,128,256,512] 9,908,352 104 
GenexNet-142 4 Dense 4 Residual (1,1,1,1) (1,1,1,1) [64,128,256,512] 25,005,184 142 
 
Table 5.3  Examples of  GeneXNet Architectures Generated by our Reinforcement Learning Algorithm 
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Table 5.4  GeneXNet-142 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
  
GeneXNet-142 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(36,36,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
[
𝐶𝑜𝑛𝑣(1𝑥1 , 64 )
𝐶𝑜𝑛𝑣(3𝑥3 , 64 )
   𝐶𝑜𝑛𝑣(1𝑥1 , 256 )
 ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 2 
 
 
(18,18,512) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 12 
 
 
4𝜃𝑘 
𝜃𝑘  
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128)
   𝐶𝑜𝑛𝑣(3𝑥3 , 128)
   𝐶𝑜𝑛𝑣(1𝑥1 , 512)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 3 
 
 
(9,9,1024) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 24 
 
 
4𝜃𝑘 
𝜃𝑘  
[
 𝐶𝑜𝑛𝑣(1𝑥1 , 256)
 𝐶𝑜𝑛𝑣(3𝑥3 , 256)
    𝐶𝑜𝑛𝑣(1𝑥1 , 1024)
] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 4 
 
 
(5,5,2048) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 16 
 
 
4𝜃𝑘 
𝜃𝑘  
[
 𝐶𝑜𝑛𝑣(1𝑥1 , 512)
 𝐶𝑜𝑛𝑣(3𝑥3 , 512)
   𝐶𝑜𝑛𝑣(1𝑥1 ,2048)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,2048) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
GeneXNet-104 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(36,36,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
[
𝐶𝑜𝑛𝑣(1𝑥1 , 64 )
𝐶𝑜𝑛𝑣(3𝑥3 , 64 )
   𝐶𝑜𝑛𝑣(1𝑥1 , 256 )
 ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 2 
 
 
(18,18,512) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 12 
 
 
4𝜃𝑘 
𝜃𝑘  
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128)
   𝐶𝑜𝑛𝑣(3𝑥3 , 128)
   𝐶𝑜𝑛𝑣(1𝑥1 , 512)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 3 
 
 
(9,9,1024) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 24 
 
 
4𝜃𝑘 
𝜃𝑘  
[
 𝐶𝑜𝑛𝑣(1𝑥1 , 256)
 𝐶𝑜𝑛𝑣(3𝑥3 , 256)
    𝐶𝑜𝑛𝑣(1𝑥1 , 1024)
] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,1024) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
Table 5.5  GeneXNet-104 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
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GeneXNet-74 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(71,71,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
 
 
 
GeneXNet 
Block 2 
 
 
(36,36,512) 
  [
   𝐶𝑜𝑛𝑣(1𝑥1 , 128)
   𝐶𝑜𝑛𝑣(3𝑥3 , 128)
   𝐶𝑜𝑛𝑣(1𝑥1 , 512)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 3 
 
(36,36,1280) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 24 
 
 
4𝜃𝑘 
𝜃𝑘  
 
 
 
GeneXNet 
Block 4 
 
 
(18,18,2048) 
  [
 𝐶𝑜𝑛𝑣(1𝑥1 , 512)
 𝐶𝑜𝑛𝑣(3𝑥3 , 512)
   𝐶𝑜𝑛𝑣(1𝑥1 ,2048)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,2048) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
GeneXNet-70 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(36,36,256) 
 
 
 
4𝜃𝑘 
𝜃𝑘  
[
𝐶𝑜𝑛𝑣(1𝑥1 , 64 )
𝐶𝑜𝑛𝑣(3𝑥3 , 64 )
   𝐶𝑜𝑛𝑣(1𝑥1 , 256 )
 ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 2 
 
 
(36,36,640) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 12 
 
 
4𝜃𝑘 
𝜃𝑘  
 
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 3 
 
 
(18,18,1024) 
 
 
 
4𝜃𝑘 
𝜃𝑘  
[
 𝐶𝑜𝑛𝑣(1𝑥1 , 256)
 𝐶𝑜𝑛𝑣(3𝑥3 , 256)
    𝐶𝑜𝑛𝑣(1𝑥1 , 1024)
] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 4 
 
 
(18,18,1536) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 16 
 
 
4𝜃𝑘 
𝜃𝑘  
 
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,1536) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
Table 5.7  GeneXNet-74 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
Table 5.6  GeneXNet-70 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
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GeneXNet-50 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(36,36,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
[
𝐶𝑜𝑛𝑣(1𝑥1 , 64 )
𝐶𝑜𝑛𝑣(3𝑥3 , 64 )
   𝐶𝑜𝑛𝑣(1𝑥1 , 256 )
 ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 2 
 
 
(18,18,512) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 12 
 
 
4𝜃𝑘 
𝜃𝑘  
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128)
   𝐶𝑜𝑛𝑣(3𝑥3 , 128)
   𝐶𝑜𝑛𝑣(1𝑥1 , 512)
  ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,512) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
GeneXNet-20 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(36,36,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
[
𝐶𝑜𝑛𝑣(1𝑥1 , 64 )
𝐶𝑜𝑛𝑣(3𝑥3 , 64 )
   𝐶𝑜𝑛𝑣(1𝑥1 , 256 )
 ] ∗ 2   
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,256) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
GeneXNet-38 
GeneXNet 
Block 
 
Output Size 
Dense Sub-block Residual Sub-block 
Dense Layers 
 
No. of 
Filters 
𝜃𝑘 
Residual Layers 
 
No. of 
Filters 
𝜃𝑘 
Input (142,142,3)  
Pre-layers (71,71,64) 𝐶𝑜𝑛𝑣(7𝑥7 , 64) 
 
GeneXNet 
Block 1 
 
 
(71,71,256) 
 
[
  𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32  )
] ∗ 6   
 
 
4𝜃𝑘 
𝜃𝑘  
 
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
GeneXNet 
Block 2 
 
 
(71,71,640) 
 
[
   𝐶𝑜𝑛𝑣(1𝑥1 , 128  )
𝐶𝑜𝑛𝑣(3𝑥3 , 32 )
] ∗ 12 
 
 
4𝜃𝑘 
𝜃𝑘  
 
 
2𝑙𝜃𝑘 
2𝑙𝜃𝑘 
2𝑙+2𝜃𝑘  
 
Classification 
(1,1,640) Global Average Pooling 
(C-Classes) Fully connected (C-Tumor Types) – Softmax 
 
Table 5.8  GeneXNet-50 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
Table 5.10  GeneXNet-38 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
Table 5.9  GeneXNet-20 Detailed Architectures Generated by our Reinforcement Learning Algorithm 
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 Results 
Experiment 1 - Multi-tissue Multi-class classification 
The results of the first experiment which performed multi-class classification using ALL 
the data including 26 organ sites covering 33 tumor types are shown in Table 5.11. Our 
GeneXNet model was able to achieve excellent results with an overall classification accuracy 
of 98.93% and a ROC AUC of 0.99 on the test dataset.  The results show that our model 
achieved 100% accuracy on 14 different tumor types, even for some tumor types which had 
very little human samples such as: Bile Duct Cholangiocarcinoma (CHOL), Eye Uveal 
Melanoma (UVM) and Pleura Mesothelioma (MESO) which only had 45, 80 and 86 samples 
respectively. 
Anatomical Site 
of Origin 
Cancer Tumor Type(s) Total 
Samples 
Classification 
Accuracy (%) 
Adrenal Gland Adrenocortical carcinoma (ACC), 
Pheochromocytoma and Paraganglioma (PCPG) 
265 100 
Bile Duct Cholangiocarcinoma (CHOL) 45 100 
Bladder Bladder Urothelial Carcinoma (BLCA) 433 98.46 
Bone Marrow Acute Myeloid Leukemia (LAML) 151 91.3 
Brain Glioblastoma multiforme (GBM),  
Brain Lower Grade Glioma (LGG) 
703 100 
Breast Breast invasive carcinoma (BRCA) 1222 99.46 
Cervix Cervical squamous cell carcinoma and endocervical 
adenocarcinoma (CESC) 
309 100 
Colorectal Colon adenocarcinoma (COAD),  
Rectum adenocarcinoma (READ) 
698 99.05 
Esophagus Esophageal carcinoma (ESCA) 173 96.15 
Eye Uveal Melanoma (UVM) 80 100 
Head and Neck Head and Neck squamous cell carcinoma (HNSC) 546 100 
Kidney Kidney Chromophobe (KICH), 
Kidney renal clear cell carcinoma (KIRC), 
Kidney renal papillary cell carcinoma (KIRP), 
1021 99.35 
Liver Liver hepatocellular carcinoma (LIHC) 424 98.44 
Lung Lung adenocarcinoma (LUAD),  
Lung squamous cell carcinoma (LUSC) 
1145 99.42 
Lymph Nodes Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma (DLBC) 
48 87.5 
Ovary Ovarian serous cystadenocarcinoma (OV) 379 98.25 
Pancreas Pancreatic adenocarcinoma (PAAD) 182 96.43 
Pleura Mesothelioma (MESO) 86 100 
Prostate Prostate adenocarcinoma (PRAD) 551 97.59 
Skin Skin Cutaneous Melanoma (SKCM) 472 98.59 
Soft Tissue Sarcoma (SARC) 265 100 
Stomach Stomach adenocarcinoma (STAD) 407 98.39 
Testis Testicular Germ Cell Tumors (TGCT) 156 100 
Thymus Thymoma (THYM) 121 100 
Thyroid Thyroid carcinoma (THCA) 568 97.67 
Uterus Uterine Corpus Endometrial Carcinoma (UCEC), 
Uterine Carcinosarcoma (UCS) 
643 100 
(ALL Sites) (All Tumors) 11,093 98.93 
 
Table 5.11  Results Of Multi-Tissue Classification Using 26 Organ Sites Covering 33 Tumor Types 
111   
  
 
AUC SID:  800-09-0336                                                                       Name: Tarek Khorshed 
Experiment 2 - Multi-Tumor Binary classification 
The results of the second experiment which performed binary classification for the 11 
selected individual organ sites are shown in Table 5.12. Our GeneXNet model was able to 
achieve 100% accuracy for 8 different tumor types and between 95.35% to 99.42% accuracy 
for the remaining tumors.  
 
Experiment 3 - Comparison between Transfer Learning and Full Training 
The results of the third experiment which performed transfer learning are shown in Table 
5.12. The results show that transfer learning managed to achieve excellent results which are 
comparable to the results achieved using full training.  
 
Experiment 4 – Transfer Learning for Tumors with very little data 
The results of the fourth experiment which performed transfer learning to build binary 
classifiers for organ sites which did not have sufficient data to be trained independently are 
shown in the last two rows of Table 5.12. Transfer learning was able to solve the problem for 
tumor sites such as Bile Duct and Esophagus which did not have sufficient data to be trained 
independently. By finetuning the pre-trained model, we were able to achieve 92.31% accuracy 
for Esophageal carcinoma (ESCA) and 85.71% accuracy for Bile Duct Cholangiocarcinoma 
(CHOL) despite that these sites only had 147 and 45 samples respectively. 
 
 
Anatomical Site of 
Origin 
(Human Organ) 
Total 
Samples 
Full Training Transfer Learning & 
Finetuning 
Accuracy (%) ROC 
AUC 
Accuracy (%) ROC 
AUC 
Bladder 433 96.92 1.0 95.38 0.99 
Breast 1222 98.37 0.998 98.37 1.0 
Colorectal 698 100 1.0 100 1.0 
Head and Neck 546 98.78 0.985 92.68 1.0 
Kidney 1021 100 1.0 100 0.97 
Liver 424 100 1.0 98.44 1.0 
Lung 1145 99.42 1.0 99.42 0.94 
Prostate 551 97.59 0.961 97.59 0.94 
Stomach 407 96.77 0.979 96.77 0.88 
Thyroid 568 95.35 0.981 93.02 1.0 
Uterus 643 100 1.0 100 0.89 
Bile Duct* 45 - - 85.71 0.89 
Esophagus* 173 - - 92.31 0.99 
 
Table 5.12  Results Of Multi-Tumor Binary Classification For 11 Individual Organ Sites 
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Experiment 5 – Comparison between GeneXNet and State-of-the-art CNN models 
The results of the fifth experiment for evaluating the performance of our GeneXNet model 
in comparison with state-of-the-art CNN models is shown in Table 5.13. A comparison 
between the ROC curves for the different models is shown in Figure 5.3. These results 
demonstrate that our GeneXNet model consistently outperformed other CNN models by a large 
margin. The classification accuracy achieved by our model is 98.93% which is significantly 
higher than the other models which achieve an accuracy below 37%. Figure 5.3 shows that our 
model produced a much higher ROC curve in comparison to the other models.  
 
 
Network Model Accuracy (%) ROC AUC Cross Entropy 
Loss 
GeneXNet 98.93 0.99 0.06 
ResNet-50 v2  [46]    36.96 0.86 4.9 
DenseNet-121 [41]  22.33 0.79 6.09 
NasNetMobile [40]  21.61 0.84 2.58 
MobileNet v2  [39]  24.96 0.8 5.99 
 
Table 5.13 Classification Performance Of GeneXNet In Comparison With State-Of-The-Art CNN Models 
Figure 5.3  Comparison of ROC curves for Multi-Tissue classification between our GeneXNet 
model and state-of-the-art CNN models. Our model produced a much higher ROC curve and 
outperformed other models by a large margin. 
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To provide more insight on this degradation in performance for state-of-the-art models, 
Figure 5.4 shows a comparison between the training and validation curves for each model by 
plotting the cross-entropy loss across the training epochs. Figure 5.4 demonstrates that training 
these state-of-the-art models which were specifically designed for computer vision tasks, 
suffered from severe overfitting when presented with the underlying dataset that includes 
whole transcriptome gene expressions from multiple tumors types.  
On the other hand, our GeneXNet model was able to achieve high accuracy in multi-tumor 
classification while avoiding overfitting. This ability is attributed to the architecture of our 
model that is designed specifically to target the complex nature of gene expressions and which 
incorporates both dense and residual learning layers that perform a regularizing effect which 
allows the network to overcome overfitting.  
 
 
 
Figure 5.4  Comparison of training and validation Cross-Entropy Loss for Multi-Tissue classification, 
between GeneXNet and other models. Our model achieved minimum loss while other models suffered 
severe overfitting. Dashed curves are training and solid are validation. 
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 Results of Deep Reinforcement Learning 
In this section we show a comparison of the cancer classification performance of different 
selected GeneXNet architectures, which were generated by executing our proposed Deep 
Reinforcement Learning (DRL) framework as described in sections 4.9 and 5.4. 
Figure 5.5 shows a comparison between the ROC curves for multi-tissue cancer 
classification of 6 different GeneXNet models generated by DRL. Figure 5.6 shows a zoomed-
in version of the same comparison. The results show that our deepest model GeneXNet-142 
achieved the best classification performance in comparison to other models.  
  
Figure 5.5  Comparison between ROC curves for multi-tissue cancer classification of 6 different 
GeneXNet models generated by our Deep Reinforcement Learning Framework 
Figure 5.6  Zoomed-In Comparison between ROC curves for multi-tissue cancer classification of 6 different 
GeneXNet models generated by our Deep Reinforcement Learning Framework 
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Figure 5.7 shows a comparison between the cancer classification accuracy of 6 different 
GeneXNet models generated by DRL.  Figure 5.8 shows a comparison between the cross-
entropy loss across the training epochs of the 6 GeneXNet models.  The results also show that 
our deepest model GeneXNet-142 achieved the best classification performance. These results 
demonstrate how our model design has allowed training deeper network architectures with 
complex data like whole-transcriptome gene expressions, despite the large number of genes.  
  
Figure 5.8  Comparison between Cross-Entropy Loss of 6 GeneXNet models 
generated by our Deep Reinforcement Learning Framework 
Figure 5.7  Comparison between cancer classification Accuracy of 6 different 
GeneXNet models generated by our Deep Reinforcement Learning Framework 
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Figure 5.9 shows a comparison between the ROC curves across 5 cross-validation folds, for 
multi-tissue classification of our deepest and best performing model GeneXNet-142. Figure 
5.10 shows the same comparison but with highlighting the Mean and Variance of the ROC 
curves across the 5 folds which we report in our results. This helps visualize the difference in 
classification performance resulting from applying training using k-fold cross-validation.  
  
Figure 5.10  Mean and Variance of ROC curves for GeneXNet-142 across 5 Cross-Validation Folds 
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Figure 5.11 shows a comparison between the cancer classification accuracy across 5 cross-
validation folds, for multi-tissue classification of our deepest and best performing model 
GeneXNet-142.  Figure 5.12 shows a comparison between the cross-entropy loss across the 
training epochs for the 5 folds.  Figure 5.13 shows a comparison between the training and 
validation accuracy of the best performing fold for GeneXNet-142 Model. Figure 5.14 shows 
the same comparison but for the cross-entropy loss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GeneXNet-142  CLASSIFICATION ACCURACY 
GeneXNet-142  CROSS-ENTROPY-LOSS 
Figure 5.11  Comparison between the classification accuracy across 5 cross-validation folds for GeneXNet-142 
Figure 5.12  Comparison between Cross-Entropy Loss across 5 cross-validation folds for GeneXNet-142 
Figure 5.13  Training & Validation Accuracy of 
best performing fold for GeneXNet-142 
Figure 5.14  Training &Validation Cross-Entropy 
Loss of best performing fold for GeneXNet-142 
GeneXNet-142  CLASSIFICATION ACCURACY CROSS-ENTROPY-LOSS 
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 Analysis of Classification Results 
The results of our classification experiments have demonstrated how the design of our 
proposed Gene eXpression Network (GeneXNet) can be used as a general end-to-end learning 
system for classification across multiple cancer tissue types without performing the prerequisite 
process of gene feature selection. We demonstrated how our model can specifically target the 
complex nature of the whole-transcriptome gene expression data and addresses the lack of 
training samples, without suffering from severe overfitting in comparison to using the current 
state-of-the-art deep CNN models which have been designed specifically for computer vision 
tasks. Our model has allowed training deeper network architectures with complex data like 
whole-transcriptome gene expressions, despite the large number of genes. The experiments 
demonstrated that our model design which combines both dense and residual learning layers, 
performs a regularizing effect which helps avoid overfitting and degradation in performance as 
the network depth increases. This is achieved by means of re-using the gene expression feature 
maps learned by different layers, which increases the variation of input signals fed to 
subsequent layers since it represents the collective knowledge of the network. The connectivity 
of the dense layers provide each layer with more direct access to the gradients from the loss 
function and the original input signal, while the residual layers with identity mappings provide 
a direct path for information propagation in the forward and backward passes. 
The results of our Transfer Learning experiments have demonstrated that the comprehensive 
genomic signatures learned by training our model using all the data allowed us to perform 
efficient transfer learning by using the pre-trained model as a generic feature extractor to build 
additional classifiers for any of the individual tumor sites, especially for the organ sites which 
were lacking sufficient patient samples to be trained independently. These results have 
demonstrated how transfer learning was able to solve one of the biggest challenges in cancer 
classification which is lack of patient samples. The experiment demonstrated that by reusing 
the weights of the pretrained GeneXNet model, we were able to use the same network for 
feature extraction on a different cancer tumor type. The experiments have also demonstrated 
that the discriminative molecular features for one cancer classifier were also relevant for other 
cancer types. The results demonstrated that our pretrained model was able to learn the complex 
types of genomic signatures collected from multiple cancer tissue types and that it was able to 
effectively function as a generic model for cancer classification. 
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 Visualizing Class-Discriminative Localization Maps 
We introduced a visualization method in section 4.10 to identify a class discriminative 
Gene-Class Activation Map (Gene-CAM) which is a localization map extracted from the gene 
expression input samples. We apply the visualization procedure to the underlying dataset to 
produce a Gene-CAM for each of the 33 individual tumor types and visualize them using 
heatmaps. Figure 5.15 shows the resulting heatmaps of four selected tumor types (Breast, Liver, 
Stomach and Uterus). We used a GeneXNet with 4 blocks which produces feature activation 
maps of dimensions (5, 5, 2048) after the 4th block. By mapping the resulting Gene-CAM to 
each input sample, the network was able to identify a subset of 75 discriminative genes. For 
visualization, we apply a threshold where each heatmap shows the top 20 genes influencing the 
underlying tumor across 20 randomly selected samples. The rows represent the genes and the 
columns represent the samples and the values are the normalized gene expression levels. The 
gene symbols are displayed on the right side of each row together with the percentage of 
samples which have also identified this gene in their Gene-CAM. Each map is a visual 
representation of the discriminative genes used by the network to correctly classify the tumor. 
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Figure 5.15  Visualizing class-discriminative localization maps highlighting the important regions in the gene expressions 
which influenced the tumor class prediction. Each map shows the top 20 genes across 20 random samples and is a visual 
representation of the discriminative genes used by our network to correctly classify the tumor. The rows represent genes, 
columns represent samples and the values are the gene expression levels. 
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 Biological Significance of Visualizing Class-Discriminative Maps 
The strength of our method is that the network was able to automatically identify a small 
subset of class-discriminative genes out of the total 60,483 genes originally included in each 
individual sample. What was also very interesting about these results is that the network 
automatically identified the TP53 gene as one of the top features common across all tumor 
types. This result implicitly validates our procedure since the TP53 is considered the most 
commonly mutated gene in all cancers which produces a protein that suppresses the growth of 
tumors [4].  
We also observed from our experiments that some of the identified discriminative genes 
were also common in at least 30% of samples across different tumor types even though the 
tissues belonged to different organ sites. This subset includes: TP53, TTN, MUC16, LRP1B, 
CSMD3, PIK3CA, MUC4, RYR2, USH2A, FLG, PTPRD, CSMD1. These discriminative 
genes identified by the network have great biological significance for early cancer diagnosis. 
For example, the mutations of PIK3CA gene are one of the most common in Breast cancer and 
are reported in over one third of cases [112]. Mutations in TTN gene are associated with one 
of the most common inherited cardiac disorders known as Hypertrophic Cardiomyopathy 
(HCM) [111]. MUC16 has a biological role in the progression of Ovarian tumors and there has 
been substantial work to develop therapeutic approaches to eradicate Ovarian tumors by 
targeting MUC16 [113]. LRP1B is frequently mutated in Melanoma, Non-small Cell Lung 
cancer (NSCLC) and other types of tumors. LRP1B is also a potential contributor to the 
emergence of chemotherapy resistance while treating cancer patients [114]. CSMD3 was 
identified as the second most frequently mutated gene in Lung cancer after TP53 [4]. MUC4 
is a membrane bound mucin gene responsible for progression of several cancers due to its anti-
adhesive properties including Bile Duct, Breast, Colon, Esophagus, Ovary, Lung, Prostate, 
Stomach and Pancreas [111]. Mutations of RYR2 gene are a common cause of abnormal heart 
failures such as Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [111]. 
PTPRD is frequently mutated in various types of cancer, including Glioblastoma, Melanoma, 
Breast and Colon [4]. CSMD1 has been found as a tumor suppressor in the development of 
Breast cancer [111]. To validate our visualization results, we compared the subset of 
discriminative genes identified by our network with the top mutated genes reported in the 
underlying dataset based on percentage of cases with simple somatic mutations [38]. We 
observed from this comparison that the set of discriminative genes identified by our network 
were also identified among the top mutated genes in 92% of the samples. 
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 Visualizing Molecular Clusters of Intermediate Feature Maps 
We introduced a visualization method in section 4.10 for observing the molecular clusters 
formed by intermediate gene expression feature maps learned by the network. We apply the 
method using all the underlying dataset which includes 11,093 samples for 26 organ sites across 
33 tumor types. We used a GeneXNet with four blocks to produce a molecular clustering of 
the gene feature maps (𝐺𝑒𝑛𝑒_𝐶𝑙𝑢𝑠𝑡𝑒𝑟_𝑀𝑎𝑝𝑠) 
 after each block. Each individual 
𝐺𝑒𝑛𝑒_𝐶𝑙𝑢𝑠𝑡𝑒𝑟_𝑀𝑎𝑝 represents a molecular clustering that groups the tumors by organ site 
based on the class discriminative gene localizations extracted from the gene expressions and 
learned by the network after each block. As outlined in Table 4.2, the output depth after each 
block is 256, 512, 1024 and 2048 respectively. Figure 5.16 shows a heatmap of the 
𝑮𝒆𝒏𝒆_𝑪𝒍𝒖𝒔𝒕𝒆𝒓_𝑴𝒂𝒑 for the last block filtered for clusters with at least 200 samples per 
cluster, which resulted in a total of 17 cluster groups comprising the 26 organ sites. The rows 
represent the gene localization feature maps, the columns represent the samples and the values 
are the normalized activations from the feature maps. The heatmap visually illustrates the 
genomic relationships and high-level structures of the cancer tumor types across the different 
sites of origin.  
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Figure 5.16  Visualizing molecular clusters of intermediate feature maps to reveal genomic relationships across multiple 
tumors that appeared influential in cancer progression. The heatmap shows a Gene Cluster Map of 17 cluster groups 
comprising 33 tumors across 26 organ sites. Rows represent gene feature maps, columns represent samples and the values 
are activations of feature maps. The heatmap visually illustrates the genomic relationships and high-level structures of the 
cancer tumor types across the different organ sites. 
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 Biological Significance of Visualizing Molecular Clusters of 
Intermediate Feature Maps 
We observed from our experiments that the number of cluster groups learned by the network 
in the 𝐺𝑒𝑛𝑒_𝐶𝑙𝑢𝑠𝑡𝑒𝑟_𝑀𝑎𝑝s decreases as we move towards the deep layers in the network. The 
feature maps generated after the first block seem to have little in common across the different 
tumor types which is evident by the very large number of resulting cluster groups. As we reach 
the final network block, we observed that the 𝐺𝑒𝑛𝑒_𝐶𝑙𝑢𝑠𝑡𝑒𝑟_𝑀𝑎𝑝 has less number of clusters 
where more clusters have merged together to finally reach only 17 cluster groups. These results 
have great significance since they demonstrate that as we go deeper in the network, the gene 
feature maps become more abstract in the sense that they are less representative of the 
individual tumor samples and more representative of the tumor classes.  
We further analyzed the resulting cluster groups in-terms of membership of tumor organ 
sites among the groups. We observed that although tissue site of origin was mostly a dominant 
factor for cluster formation, but some clusters also included tumor types across multiple 
different organs. We also observed that clusters were formed for tumor types which appeared 
to have similar organs or tissue characteristics. For example, Bile Duct and Liver tumors 
clustered together including Cholangiocarcinoma (CHOL) and Liver hepatocellular Carcinoma 
(LIHC). Brain and Nervous system tumors clustered together including Brain Lower Grade 
Glioma (LGG) and Glioblastoma multiforme (GBM). Kidney and Adrenal Gland tumors 
formed multiple clusters including Chromophobe (KICH), Renal Clear Cell (KIRC), Renal 
Papillary cell (KIRP) and Adrenocortical Carcinoma (ACC). Lymph Nodes and Bone Marrow 
tumors clustered together including Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 
(DLBC) and Acute Myeloid Leukemia (LAML). Many small overlapping clusters formed 
together for Stomach, Colorectal, Esophagus and Pancreas tumors including STAD, COAD, 
READ, ESCA and PAAD. Finally, the remaining clusters were dominated by mostly tumors 
of a single organ site but also included less than 5% of other tumors types.  
Visualizing the evolution of molecular clusters formed by intermediate gene feature maps, 
has demonstrated how our proposed GeneXNet is functioning as a comprehensive multi-tumor 
Cancer classifier. The network was capable of learning the complex molecular signatures and 
genetic alterations shared by tumors across different tissue types and organ sites. This also 
demonstrates how the network was able to perform efficient transfer learning by using the pre-
trained models as a generic multi-tumor feature extractor to build additional classifiers for any 
individual tumor types especially for organ sites which were lacking sufficient patient samples 
to be trained independently. 
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CHAPTER 6  
 CONCLUSIONS 
 Motivation 
The objective of our research has been to contribute in saving the lives of cancer patients 
through early cancer diagnosis and detection. Our work in cancer classification helps in directly 
solving one of the major challenges in cancer treatment, since patients are diagnosed at very 
late stages when appropriate medical interventions become less effective and full curative 
treatment is no longer achievable. To our knowledge, this is the first effort to develop a Multi-
Tissue cancer classifier based on a full set of whole-transcriptome wide gene expressions 
collected from tumors across different tissue types without requiring a prerequisite process of 
gene feature selection. We have contributed in providing medical professionals with more 
confidence in using deep learning for medical diagnosis by providing some biological insights 
on how complex deep learning models are performing cancer classification and making 
predictions across multiple cancer tissues using gene expressions. 
 Contributions 
Our work has contributed to developing cancer classifiers with the capabilities of detecting 
more complex types of genetic alterations driving cancer progression, by learning the genomic 
signatures shared across multiple cancer tissue types. This was achieved by introducing a Deep 
Learning framework for early cancer diagnosis and designing a comprehensive Multi-Tissue 
cancer classifier based on molecular signatures of whole-transcriptome wide gene expressions. 
Our cancer classifier is based gene expressions collected from human samples representing 
multiple cancer tissue types and covering multiple organ sites.  
We have contributed to eliminating the dependency on the prerequisite process of gene 
feature selection which is performed by current state-of-the-art cancer classification methods 
for discovering a predefined subset of informative genes to be used in the learning process. 
This was achieved by designing our Deep Learning framework as an end-to-end learning 
system for early cancer diagnosis which combines the process of gene feature selection and 
classification into one integrated learning system. 
We have contributed in developing cancer classifiers with the capabilities of taking full 
advantage of genome-wide Next Generation Sequencing technologies to discover the 
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correlated patterns of genes across the full set of DNAs in the human genome and across 
multiple cancer tissue types. This was achieved by designing a new Deep Neural Network 
architecture called Gene eXpression Network (GeneXNet), which is specifically designed to 
address the complex nature of whole-transcriptome gene expressions. We demonstrated how 
our model architecture can learn the sequence of DNA and RNA in cancer cells and identify 
genetic changes that alter cell behavior and cause uncontrollable growth and malignancy. We 
also demonstrated how our  new model architecture has the capabilities for learning the 
genomic signatures across multiple tissue types without requiring the prerequisite of gene 
feature selection. 
We have contributed to eliminating the dependency on huge amounts of patient data and 
helped in solving one of the biggest challenges in cancer classification which is lack of patient 
samples. This was achieved by designing a Deep Transfer Learning model that effectively 
functions as a generic Multi-Tissue cancer classifier by learning genomic signatures collected 
from multiple cancer tissue types. We demonstrated how our model can be used for Transfer 
Learning to build classifiers for tumor types that are lacking sufficient patient samples to be 
trained independently.  
We have contributed to eliminating the manual process of handcrafting the design of deep 
network architectures and contributed to eliminating the manual process of hyperparameter 
optimization and fine-tuning on the target dataset. This was achieved by designing an end-to-
end Deep Reinforcement Learning framework that automatically learns the optimal Deep 
Neural Network architecture together with the associated optimal hyperparameters that 
maximizes the performance of our multi-tissue cancer classifier.  
We have contributed in providing medical professionals with more confidence in using deep 
learning for medical diagnosis by providing some biological interpretation on how complex 
deep learning models are performing cancer classification and making predictions on cancer 
tumors. This was achieved by designing visualization procedures to provide more biological 
insight on how the proposed network model is learning genomic signatures of whole-
transcriptome gene expressions and accurately performing classification across multiple cancer 
tumors. We have demonstrated how our network design provides the capability to visualize 
gene localization maps highlighting the important regions in the gene expressions influencing 
the tumor class prediction. We have also demonstrated how our network design provides the 
capability to visualize the molecular clusters formed by intermediate gene expression feature 
maps learned by the network which helps in revealing the genomic relationships of gene 
expressions that are influential in the tumor progression.  
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 Analysis 
Our classification experiments have demonstrated how the design of our proposed Gene 
eXpression Network (GeneXNet) can be used as a general end-to-end learning system for 
classification across multiple cancer tissue types without performing the prerequisite process 
of gene feature selection. We demonstrated how our model can specifically target the complex 
nature of the whole-transcriptome gene expression data and addresses the lack of training 
samples, without suffering from severe overfitting in comparison to using the current state-of-
the-art deep CNN models which have been designed specifically for computer vision tasks. 
Our model has allowed training deeper network architectures with complex data like whole-
transcriptome gene expressions, despite the large number of genes. The experiments 
demonstrated that our model design which combines both dense and residual learning layers, 
performs a regularizing effect which helps avoid overfitting and degradation in performance as 
the network depth increases. This is achieved by means of re-using the gene expression feature 
maps learned by different layers, which increases the variation of input signals fed to 
subsequent layers since it represents the collective knowledge of the network. The connectivity 
of the dense layers provide each layer with more direct access to the gradients from the loss 
function and the original input signal, while the residual layers with identity mappings provide 
a direct path for information propagation in the forward and backward passes. 
Our Transfer Learning experiments have demonstrated that the comprehensive genomic 
signatures learned by training our model using all the data allowed us to perform efficient 
transfer learning by using the pre-trained model as a generic feature extractor to build additional 
classifiers for any of the individual tumor sites, especially for the organ sites which were 
lacking sufficient patient samples to be trained independently. These results have demonstrated 
how transfer learning was able to solve one of the biggest challenges in cancer classification 
which is lack of patient samples. The experiment demonstrated that by reusing the weights of 
the pretrained GeneXNet model, we were able to use the same network for feature extraction 
on a different cancer tumor type. The experiments have also demonstrated that the 
discriminative molecular features for one cancer classifier were also relevant for other cancer 
types. The results demonstrated that our pretrained model was able to learn the complex types 
of genomic signatures collected from multiple cancer tissue types and that it was able to 
effectively function as a generic model for cancer classification. 
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 Biological Significance 
Our work in cancer classification helps in directly solving one of the major challenges in cancer 
treatment, since patients are diagnosed at very late stages when appropriate medical 
interventions become less effective and full curative treatment is no longer achievable. To our 
knowledge, this is the first effort to develop a Multi-Tissue cancer classifier based on a full set 
of whole-transcriptome wide gene expressions collected from tumors across different tissue 
types without requiring a prerequisite process of gene feature selection. We have contributed 
in providing medical professionals with more confidence in using deep learning for medical 
diagnosis by providing some biological insights on how complex deep learning models are 
performing cancer classification and making predictions across cancer tumors. 
We introduced a visualization method which uses the gradient information flowing in our 
proposed Gene eXpression Network (GeneXNet) model to produce gene localization maps 
highlighting the important regions in the gene expressions which influenced the resulting tumor 
class prediction. The gene expression data is sparse and very high in dimensionality since it 
represents a snapshot of the whole transcriptome rather than a predetermined subset of genes. 
By identifying class-discriminative localization map in the gene expressions, we were able to 
identify the subset of genes driving cancer progression and resulted in the model’s tumor class 
prediction. Our experiments have demonstrated the strength of our method as our GeneXNet 
model was able to automatically identify a small subset of class-discriminative genes out of the 
total 60,483 genes originally included in each individual sample of our cancer tumor dataset. 
The network automatically identified the TP53 gene as one of the top features common across 
all tumor types which implicitly validates our procedure since the TP53 is considered the most 
commonly mutated gene in all cancers. Our experiments also demonstrated that some of the 
identified discriminative genes were also common in other samples across different tumor 
types even though the tissues belonged to different organ sites. This subset includes: TP53, 
TTN, MUC16, LRP1B, CSMD3, PIK3CA, MUC4, RYR2, USH2A, FLG, PTPRD, CSMD1. 
These discriminative genes identified by the network have great biological significance for 
early cancer diagnosis. For example, the mutations of PIK3CA gene are one of the most 
common in Breast cancer and are reported in over one third of cases [112]. Mutations in TTN 
gene are associated with one of the most common inherited cardiac disorders known as 
Hypertrophic Cardiomyopathy (HCM) [111]. MUC16 has a biological role in the progression 
of Ovarian tumors and there has been substantial work to develop therapeutic approaches to 
eradicate Ovarian tumors by targeting MUC16 [113]. LRP1B is frequently mutated in 
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Melanoma, Non-small Cell Lung cancer (NSCLC) and other types of tumors. LRP1B is also a 
potential contributor to the emergence of chemotherapy resistance while treating cancer 
patients [114]. CSMD3 was identified as the second most frequently mutated gene in Lung 
cancer after TP53 [4]. MUC4 is a membrane bound mucin gene responsible for progression of 
several cancers due to its anti-adhesive properties including Bile Duct, Breast, Colon, 
Esophagus, Ovary, Lung, Prostate, Stomach and Pancreas [111]. Mutations of RYR2 gene are 
a common cause of abnormal heart failures such as Catecholaminergic Polymorphic 
Ventricular Tachycardia (CPVT) [111]. PTPRD is frequently mutated in various types of 
cancer, including Glioblastoma, Melanoma, Breast and Colon [4].  
We introduced a visualization procedure for observing the evolution of molecular clusters 
formed by intermediate gene expression feature maps learned by our GeneXNet model. The 
genetic signatures learned by the feature maps in the deep layers make the network capable of 
representing complex genetic alterations shared by tumors across different tissue types. 
Visualizing the molecular clusters of gene expressions provides more insight on how the 
network is learning small meaningful relationships between the genes which in turn describe 
the characteristic influencing the Cancer tumor. Our experiments have demonstrated how this 
visualization provides the opportunity to study the genomic relationships of gene expressions 
across multiple cancer tissue types. We observed from our experiments that the number of 
cluster groups learned by the network decreases as we move towards the deep layers. We 
observed that the final network block has less number of clusters where more clusters have 
merged together. These results have great significance since they demonstrate that as we go 
deeper in the network, the gene feature maps become more abstract in the sense that they are 
less representative of the individual tumor samples and more representative of the tumor 
classes. We also observed from our experiments that although tissue site of origin was mostly 
a dominant factor for cluster formation, but some clusters also included tumor types across 
multiple different organs. We observed that clusters were formed for tumor types which 
appeared to have similar organs or tissue characteristics. For example, Bile Duct and Liver 
tumors clustered together. Brain and Nervous system tumors also clustered together. Kidney 
and Adrenal Gland tumors formed multiple clusters, Lymph Nodes and Bone Marrow tumors 
clustered together. Many small overlapping clusters formed together for Stomach, Colorectal, 
Esophagus and Pancreas tumors. Visualizing the evolution of molecular clusters formed by 
intermediate gene feature maps, has demonstrated how our proposed GeneXNet is functioning 
as a comprehensive multi-tumor Cancer classifier.  
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 Future work 
We believe there is great potential for further research to expand on our work for cancer 
diagnosis. Our work focused on designing a multi-tissue cancer classifier based on Total RNA 
Sequencing using gene expressions from coding mRNA. Future work can explore learning 
more complex genomic signatures by including Omics data using other multiple forms of NGS 
platforms and experimental strategies such as DNA hypermethylation, aneuploidy, non-coding 
microRNA, DNA Copy Number Variants (CNV) and Reverse Phase Protein Arrays (RPPA). 
This will provide the opportunity to create a more comprehensive repository of pretrained 
models readily available for cancer classification using transfer learning.  
One of the common approaches in classification is to use an Ensemble of multiple classifiers 
(mixture of experts) to improve the classification accuracy. Future work can target cancer 
diagnosis and improving classifier performance by designing Ensemble Models which could 
integrate multiple genome-wide platforms by learning molecular signatures across multiple 
forms of Omics data. Future work can also target using different Gene eXpression Network 
models in addition to other network architectures and combine their classification decisions.  
Future work can further expand on our visualization methods to provide more in-depth 
biological insights to medical professionals and provide them with more confidence in using 
deep learning for medical diagnosis. Our experiments have demonstrated how are proposed 
network was able to automatically identify discriminative genes that were common across the 
cancer tumor types even though the tissues belonged to different organ sites. We have provided 
some biological significance for these identified genes for early cancer diagnosis. Future work 
needs to expand further on these results and provide more in-depth biological interpretation on 
the discriminative genes and their influence on early cancer diagnosis. Our experiments have 
demonstrated how our proposed network is functioning as a comprehensive multi-tumor cancer 
classifier by visualizing the evolution of molecular clusters formed by intermediate gene 
feature maps. Future work could target to perform a more in-depth analysis and biological 
evaluation of the clusters formed for different tumor types. This requires the research 
collaboration with medical experts as it requires more in-depth knowledge of the medical 
characteristics of the underlying human organs and their tissue characteristics.  
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 COVID-19 
COVID-19 has shown a dramatic and devastating impact across the world. Predicting virus 
diseases such as COVID-19 is extremely challenging, but there is great potential for the 
application of deep machine learning for early detection and diagnosis. Although our work was 
focused on cancer classification, but we believe that our proposed methods are applicable to 
other diseases and Omics data in particular for COVID-19. Next generation sequencing 
provides a great opportunity to investigate the mechanisms that underpin COVID-19 infections 
and transmission. Future work should target the use of deep machine learning and Omics data 
in the development of novel screening methods, drug molecules, vaccines, and potential 
antibiotics. Future work should also explore the use of genomics and transcriptomics data to 
predict the effects of new vaccines and drugs on patients. 
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